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Abstract of Dissertation 
PLATELET ENDOCYTOSIS: ROLES IN HEMOSTASIS AND INNATE IMMUNITY 
 
Endocytosis is key to fibrinogen (Fg) uptake, receptor trafficking of integrins 
(αIIbβ3, αvβ3) and purinergic receptors (P2Y1, P2Y12), and thereby for normal platelet 
function. However, platelet endocytosis could potentially be critical for actively sensing 
changes in vascular microenvironments and responding accordingly to what is being 
taken up. This is a more dynamic view of platelets as active surveyors of the vasculature; 
extending the importance of platelet endocytosis beyond granule biogenesis and 
perhaps even hemostasis. The mechanistic underpinnings of endocytosis, its importance 
in platelets, and the molecular machinery required and possible trafficking routes are 
however understudied, in part due to a lack of experimental tools. The work presented 
here, puts forth new players that regulate platelet endocytosis and mediate cargo 
loading and hemostasis as well as provides a novel mechanistic understanding of how 
endocytosis allows platelets to act as immune cells and become the first responders to 
pathogens in the vasculature. 
Previously we showed the importance of ADP-ribosylation factor 6 (Arf6), which 
regulates αIIbβ3-mediated Fg uptake/storage and affects acute platelet functions e.g., 
clot retraction and spreading. To further identify elements of this endocytic machinery, 
we examined the role of a vesicle-residing Soluble N-ethylmaleimide Factor Attachment 
Protein Receptor (v-SNARE) called Cellubrevin/Vesicle-Associated Membrane Protein-3 
(VAMP-3) in platelet function. VAMP-3 KO mice had less platelet-associated Fg, 
indicating a defect in Fg uptake/storage. Loss of VAMP-3 led to a defective uptake of 
fluorescently-tagged Fg and low molecular dextran in platelets though it had a greater 
negative effect on receptor-mediated Fg uptake than on the fluid-phase marker uptake. 
Additionally, we followed the time-dependent trafficking of Fg and dextran into 
platelets using 3D-Structured Illumination Microscopy. Wild-type platelets endocytosed 
both cargoes but quickly sorted them into distinct compartments with partial overlap 
occurring only at early time points. Sorting was unaffected in VAMP-3 KO platelets. The 
VAMP-3 loss did affect some acute platelet functions leading to enhanced spreading on 
 
 
Fg and faster clot retraction compared to wild-type. Additionally, the rate of JAK2 
phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl) activation, 
was affected in VAMP-3 KO platelets. 
The idea that platelets can act as immune cells and contribute to innate 
immunity has been increasingly gaining ground. Groups have correlated 
thrombocytopenia with clinical outcomes of viremia and bacteremia. Chronic viral 
infections, e.g., HIV-1, severely increase the risk of acute myocardial infarction (MI), 
possibly via some level of platelet activation, contributing to increased thrombotic 
potential. Platelets do endocytose viruses and bacteria, but the molecular machinery is 
ill-defined. In nucleated cells, responses to HIV-1 are mediated by virus 
phagocytosis/endocytosis, degradation to release Toll-like Receptor ligands, and 
subsequent receptor activation. Is this process recapitulated in platelets? Here we show 
that platelets indeed use VAMP-3 and Arf6-dependent pathways to endocytose HIV-1 
virions, degrade retroviral particles to release TLR ligands, which initiate platelet 
activation and secretion. HIV-1 uptake and subsequent activation is abolished in VAMP-
3 and Arf6 KO mice.  
Collectively, our studies shed light on how platelets act at the early stage of 
pathogen recognition and are able to process them to initiate an immune response.  
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Chapter One: Introduction 
Subsection One: Platelets and their roles 
Platelet biology overview  
While Max Schultze, in 1865, and William Osler, in 1874, were the first to discover 
platelets as a “normal constituent of blood”, it was Giulio Bizzozero in 1882, who 
first coined the term “blood plates” to describe platelets as “morphological elements 
of blood” important for their roles in coagulation and thrombosis [1]. Mammalian 
platelets are small (~2-3 µM in diameter), anucleate, circulatory cell fragments that 
are derived from the cytoplasm of megakaryocytes, the only polyploid 
hematopoietic cell within the bone marrow. They are the smallest blood cells and 
are second only to erythrocytes in number, ranging from 150,000-450,000 
platelets/µL of blood, making them the most abundant “responsive” cell type in the 
bloodstream due to their ability to respond to various kinds of damage in the 
circulation. The primary physiological role of platelets is to sense vascular damage 
and seal the breach in the vessel endothelium to prevent blood leaks by initiating 
hemostasis. Upon vascular injury, circulating platelets get exposed to collagen or 
other extracellular matrix (ECM) proteins and become activated upon binding via 
their myriad surface receptors and adhere to the site of injury. This resulting 
activation leads to increases in cytosolic [Ca2+] levels followed by shape change 
culminating into secretion from the intracellular granule stores, leading to further 
platelet recruitment and activation, eventually forming the so-called “platelet plug” 
at the site of injury. This, in conjunction with the activation of the coagulation 
cascade and thrombin generation which converts fibrinogen to fibrin, allows 
platelets to form a fibrinous thrombus which arrests blood loss. As such, platelets, 
their activation and secretion, are essential for thrombosis and hemostasis. A 
growing body of evidence now suggests that platelet functions extend beyond 
hemostasis and thrombosis including promoting inflammatory and immune 
responses [2], maintaining vascular integrity [3] and contributing to wound healing 
[4].  Additionally, platelets have also been shown to contribute to pathophysiological 
conditions such as atherosclerosis [5, 6], ischemic cerebrovascular diseases [7], and 
angiogenesis [8-10] as well as cancer and tumor metastasis [11-13]. Platelets have a 
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diverse array of granule cargo as well as several unique receptors that enable them 
to oversee the aforementioned functions in health and disease. While exocytosis of 
vesicular (from granules and compartments) cargo is central to a majority of platelet 
functions, endocytosis of circulating exogenous cargo also occurs in platelets and is 
vital to at least some functions.  As vascular sentries, platelets constantly sample the 
bloodstream contents and this surveillance mechanism could be mediated by 
endocytosis. Uptake of small particles and solutes by human platelets was first 
reported by Zucker-Franklin in 1981 [14] into a unique membrane structure called 
the open canalicular system (OCS) by a phagocytosis-like process. Further studies 
using electron microscopy and cytochemistry provide evidence for endocytosis of 
circulating proteins such as plasma fibrinogen [15, 16] into platelets. Platelet 
endocytosis is important for granule cargo loading (such as fibrinogen and VEGF) [9, 
17] and contributes to thrombus formation by controlling the surface expression of 
several key proteins such as the integrins, chiefly αIIbβ3, the major platelet 
glycoprotein receptor [18]. Integrin trafficking modulates platelet spreading on 
endothelial surfaces and clot retraction [19]. Endocytosis of purinergic receptors 
such as P2Y1 and P2Y12 mediates their resensitization and response to ADP [20]. 
CLEC-2 and Thrombopoietin receptor (Mpl/TPOR) endocytosis regulates their surface 
levels and downstream signaling responses [21, 22].  
Clearly, platelets are far more multi-functional than we give them credit for. For 
normal physiological responses, it is imperative for both arms of membrane 
trafficking, exocytosis, and endocytosis, to occur under tight regulation. Disruption in 
any of these processes leads to severe platelet dysfunction. Hyperactive platelets 
cause spurious thrombosis which precipitates occlusive events such as heart attack 
and stroke, which collectively accounts for 1 in 3 deaths from non-communicable 
diseases, worldwide (World Health Organization, 2012 statistics). Hypoactive 
platelets or platelets from patients suffering from granule biogenesis disorders have 
a bleeding diathesis [23]. Thus, regulating platelet functions is crucial to developing 
therapeutics to prevent cardiovascular diseases (CVD). While targeting platelet 
activation and exocytosis remains the cornerstone for developing anti-platelet drugs, 
understanding the mechanisms of platelet endocytosis enables us with an 
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alternative approach to load platelets with therapeutics that can then modulate 
platelet responses paving the way to effectively treat cardiovascular diseases. 
Platelet structures  
Platelets are formed from the cytoplasm of megakaryocytes (MKs), their large 
precursor cells, in the bone marrow [24]. MKs release platelets through a multi-step 
and tightly regulated process involving the complex interplay of transcription factors, 
signaling regulators, extensive cytoskeletal rearrangements and the bone marrow 
microenvironment [25]. MKs become polyploid by endomitosis and undergoes 
maturation wherein their cytoplasm gets packaged into long pseudopodial 
projections, termed proplatelets [26]. Platelets form selectively at the tip of the 
proplatelets and derive granule and organelle content from the MK cell body [27]. 
Once the proplatelets extend into sinusoidal blood vessels, they undergo fission to 
release platelets into the circulation. Each megakaryocyte produces 5000-10,000 
platelets. While the process of platelet production appears to be similar in mice and 
humans, human platelets have a lifespan of 10 days while mouse platelets survive 
for 4-5 days [28]. Mouse platelets are similar to human platelets, but they are 
smaller in size (mean platelet volume ~4.7 vs. ~7.5-10 fl) and more numerous (~1.1 X 
106/µL of blood) [28, 29].  
In the quiescent state (see adjoining figure), platelets are a discoid shape with 
smooth surfaces. Microtubules, located beneath the cell membrane of resting 
platelets, together with the actin cytoskeleton, help in maintaining this discoid shape 
[30, 31]. Anucleate platelets chiefly contain three major kinds of granules; dense 
core granules, alpha granules, and lysosomes. These granule stores contain a 
multitude of different kinds of cargo molecules that form the bulk of the platelet 
secretome, upon release. Alpha granules are the largest and most abundant 
secretory granule in platelets and based on electron microscopy of platelet thin 
sections; there are 50-80 of these per platelet with a diameter of 200-500 nm [32-
35]. Alpha granules contain bioactive molecules such as growth factors (e.g. Platelet-
Derived Growth Factor (PDGF), Transforming Growth Factor β (TGFβ), 
Thrombopoietin (TPO) etc.), chemokines (e.g. Platelet Factor 4(PF4), Regulated on 
activation, normal T cell expressed and secreted (RANTES) etc.), various pro- (e.g. 
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Vascular Endothelial Growth Factor (VEGF)) and anti-angiogenic molecules (e.g. 
Endostatin), adhesion molecules (e.g. von Willebrand factor (vWF), P-Selectin) and 
coagulation factors (e.g. fibrinogen). Some of these cargo molecules such as vWF, 
PF4, and P-Selectin, a granule membrane protein, are synthesized in the 
megakaryocytes while cargo molecules such as fibrinogen are endocytosed via the 
αIIbβ3 integrins [17]. Some alpha granules and their precursor multivesicular bodies 
(MVBs), which are present in platelets [41, 42], contain small vesicles called 
exosomes, that are about 40-200 nm in range and are released upon exocytosis [36]. 
Dense core granules number around 5-8 per platelet [37] and contain small 
molecules such as calcium, serotonin, ADP, and ATP, etc. Lysosomes are another 
type of secretory granule in platelets. Though largely considered as degradative 
compartments, yet there exists strong evidence suggesting the release of cargo upon 
platelet activation both in vitro and in vivo [38, 39]. Platelets contain only a few 
lysosomes (~2-3) [40] which contain degradative enzymes, including β-
hexosaminidase, cathepsins D and E, and acid hydrolases [43-45]. Platelets also 
contain the lysosomal membrane proteins LAMP1, LAMP-2, and CD63 (LAMP-3) [46]. 
Additionally, platelets contain mitochondria as well as other organelles such as 
Endoplasmic Reticulum (ER), an ER-derivative dense tubular system (DTS) and Golgi 
Apparatus [48] and recent evidence suggests that cargo contained in these 
organelles may also be released upon activation [49, 50].  
Upon activation, rapid re-organization of the actin cytoskeleton allows platelets to 
extend protrusions called filopodia to finally generate lamellipodia, resulting in a 
dramatic increase in the platelet surface area [51]. It is thought that this generous 
amount of extra membrane comes from a membrane reservoir, called the open 
canalicular system (OCS), unique to platelets.  The OCS, which is an extension and 
invagination of the platelet plasma membrane, serves as the pathway for transport 
of substances into the cells as well as channels for the release of granule cargo upon 
activation-induced exocytosis [52, 53]. However, the exact roles of the OCS remain 
controversial. While it is widely thought that alpha granules dump their cargo into 
the OCS upon activation [54], recent evidence suggests otherwise. Tomographic 
analysis from scanning transmission electron microscopic images of quiescent 
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platelets shows alpha granules and the closed canalicular system to be discrete 
membrane-bound structures. In the early stages of platelet activation, the closed 
canalicular system fuses with the plasma membrane and becomes open, while the 
alpha granules fuse with the plasma membrane forming long tubular connections 
[55]. It could be speculated that these OCS, are in fact, some sort of endosomal 
compartments, that could get fused with the plasma membrane during platelet 
activation. Recent data from our lab provides evidence for the presence of two 
distinct populations of endosomes, Rab4-positive early endosomes and Rab11-
positive recycling endosomes in platelets [19]. These new findings suggest that 
platelets are in fact more complex with what could be an extensive endomembrane 
system that allows greater capacity for intracellular trafficking than previously 
thought to exist, an avenue that will definitely warrant future studies. 
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Figure 1 Resting and activated platelet structures. Mature quiescent platelets are 
discoid shaped and contain various cargo molecules within the different secretory 
granules and ER-derived and intracellular membrane compartments as depicted in 
the legends. Upon activation, platelets undergo a dramatic shape change and 
become stellate, followed by granule/compartment-plasma membrane fusion drives 
surface mobilization and release of luminal cargo into the extracellular space.  
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Platelet surface receptors and their downstream signaling pathways: roles in 
hemostasis and thrombosis 
Platelets detect and respond to their external environment via a multitude of surface 
receptors on their plasma membrane. The majority of the platelet surface receptors 
contribute to the primary function of hemostasis; by either platelet activation or 
adhesion to the damaged endothelium and in facilitating thrombus formation. 
Platelets also express several other receptors that have seemingly non-hemostatic 
functions namely in pathogen recognition and immunological defense. Several 
transmembrane receptors span the platelet surface, including many integrins (αIIbβ3, 
α2β1, α5β1, α6β1, αvβ3), leucine-rich repeats (LRR) receptors (Glycoprotein [GP] Ib-IX-V, 
Toll-like Receptors), G-protein coupled receptors (GPCRs) (PAR-1 and PAR-4 
thrombin receptors, P2Y1 and P2Y12 purinergic receptors, TPα and TPβ thromboxane 
A2 (TxA2) receptors), proteins belonging to the immunoglobulin superfamily (GP VI, 
FcγRIIA), C-type lectin receptors (CLEC-2), tyrosine kinase receptors (thrombopoietin 
receptor TPOR/Mpl) and other miscellaneous receptors [56].  While platelets do 
share certain receptors with other cells present in the vasculature, there are some 
that are unique to platelets only, e.g., αIIbβ3. As such, they have become the hotspots 
for therapeutic intervention. Most of the surface receptors, whether they are 
engaged in hemostasis or non-hemostatic functions, give rise to downstream 
signaling cascades that crosstalk significantly in platelets.  
Platelet adhesion, recruitment and activation leading to thrombus formation at the 
sites of vascular damage is dynamic and requires a series of time-dependent 
concerted events that can be broadly classified as: (i) “initiation phase” when the 
first layer of platelets descend on the exposed endothelium and get activated; (ii) 
“extension phase” when the first activated platelets release ADP, TxA2, which act as 
autocrine and paracrine agonists and help in the recruitment and activation of 
additional platelets; (iii) “stabilization phase” when the forming platelet plug is 
maintained to arrest blood loss and prevent its premature dislodgement until wound 
healing commences [58]. Different platelet receptors come into play at each of these 
phases, in an order, leading to a complex but coordinated interplay of receptor-
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ligand interactions and downstream signaling that is tightly regulated to prevent 
uncontrolled thrombosis at the site of injury. 
 In this section, the major platelet receptors will be discussed in order of their 
engagement in forming the growing thrombus. 
GPIb-IX-V complex (GPIb complex) 
At the vascular site of injury, the first contacts between surveilling platelets and the 
damaged endothelium, underflow, is made through the interaction between the 
glycoprotein (GP) Ib-IX-V complex and collagen receptors, GP VI and α2β1 integrin, 
on the platelet surface, and by von Willebrand Factor (vWF) and fibrillary collagen in 
the exposed endothelium [57]. This initial tethering and firm adhesion of platelets 
allows further platelet recruitment and drives activation. Platelet adhesion to the 
vessel wall components that are exposed to damage largely depends on the shear 
rates [57]. In the microvasculature (small arteries), where platelets encounter high 
shear conditions (>1000 s-1), GPIb-IX-V-mediated adhesion to the vessel wall is 
chiefly vWF-dependent [59]. In the veins and larger arteries, where platelets 
encounter low shear rates (~500 s-1) adhesion to the vessel wall primarily involves 
binding to fibrillar collagen, fibronectin, and laminin [60]. The GPIb-IX-V complex 
contains four distinct subunits that each span the lipid bilayer once: the two 
disulfide-linked subunits of GPIb (GPIbα[CD42b] and GPIbβ[CD42c]), GPIX (CD42a) 
and GPV (CD42d), expressed in the ration of 2:2:2:1 respectively [61]. Each subunit of 
this complex has one or more leucine-rich repeats of about 24 amino acids: GPIbα 
has 7 repeats, GPIbβ and GPIX have 1 each, and GPV has 15 repeats [61]. Aside from 
the hydrophobic membrane-spanning segments of this complex, GPIbβ and GPIX are 
palmitoylated at cysteine residues to further anchor them in the plasma membrane 
[62].  
In addition to vWF, GPIb-IX-V complex can also bind to P-Selectin, expressed on 
activated platelets and activated endothelial cells [63], and to the integrin αMβ2 
(Mac-1) expressed on leukocytes [64]. GPIbα also binds to coagulation factors from 
the intrinsic pathway such as high molecular weight kininogen, FXII and FXI and 
thrombin generated from the activation of the extrinsic or intrinsic coagulation 
cascades [65-67]. The cytoplasmic tail of GPIbα interacts with filamin, calmodulin, 
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14-3-3ζ which in turn allows it to interact with signaling proteins such as 
phosphatidylinositol 3-kinase (PI-3K), focal adhesion kinase (FAK), Src-related 
tyrosine kinases, GTPase-activating protein and tyrosine phosphatases (PTP1b and 
SHPTP10) [68, 69]. The GPIbα-vWF interaction drives the initial platelet activation by 
causing intracellular calcium transients followed by PLCγ2, ERK-1/2 and Syk 
phosphorylation, TxA2 generation and ADP release from dense granules, ultimately 
leading to the activation of the integrin αIIbβ3 [69]. 
Deficiency of functional GPIbα on human platelets causes a rare autosomal recessive 
disease, called Bernard-Soulier syndrome, characterized by thrombocytopenia, large 
platelets and mild to severe bleeding phenotype [70], stressing the importance of 
this receptor complex in mediating hemostasis and thrombosis.  
Glycoprotein VI (GPVI) 
At the site of damaged endothelium, collagen is present, which facilitates the initial 
platelet adhesion. Fibrillar collagen is better suited to bind to platelets than 
monomeric collagen [71]. Platelets utilize GPVI, a member of the immunoglobulin 
superfamily, and an integrin, α2β1, to bind directly to collagen. 
Glycoprotein VI (GP VI) is a platelet and megakaryocyte-specific, a transmembrane 
protein, consisting of two immunoglobulins (Ig)-like domains in the extracellular 
region connected to a highly glycosylated linker, a transmembrane domain, and a 
cytoplasmic tail [72, 73]. This cytoplasmic tail can bind to Fyn and Lyn Src kinases 
[74]. GP VI exists as a complex with the homodimeric Fc receptor γ chain (FcRγ with a 
possible stoichiometry of 2 GP VI molecules and 1 FcRγ dimer) on the platelet 
surface, which bears an immunoreceptor tyrosine-based activation motif (ITAM) 
acting as a signal-transducing subunit of the receptor [75]. Studies deciphering the 
role of GP VI in activating platelets have often used agonist surrogates such as 
Collagen-related peptide (CRP) consisting of (Gly-Pro-X)n or (Gly-X-Hyp)n sequences 
organized in triple helices [76] or the snake venom C-type lectin, convulxin, [77, 78] 
that are thought to work by clustering GP VI molecules on the platelet surface. When 
the GP VI receptor is cross-linked by binding to collagen or CRP or convulxin, the 
constitutively bound Src kinases (Fyn and Lyn) phosphorylate the ITAM sequence in 
the FcR γ-chain allowing the assembly and activation of Syk and initiating activation 
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of a downstream signaling pathway that has many similarities with that employed by 
immune cell receptors, mainly T-cell receptors. Activation of this signaling cascade 
leads to the formation of the signalosome, composed of various adaptors and 
effector proteins, such as LAT (Linker for Activation of T-cells), SLP-76 (SH2 domain-
containing leukocyte protein of 76 kDa), which associates to and activates PLCγ2, 
PI3K, and small molecular weight G proteins, leading to full platelet activation [79-
81]. 
GP VI blockade, or its depletion, has been shown in mice to result in complete 
protection against arterial thrombosis, without significant prolongation of bleeding 
time. Blockade of GP VI results in impaired platelet response to collagen and may, 
therefore, present a useful antithrombotic target [82-84]. 
Integrin α2β1  
Integrin α2β1 also called GP Ia/IIa, VLA-2 or CD49b/CD29, plays a role in the adhesion 
of platelets to collagen and subsequent platelet activation [75]. Loss of α2 subunit or 
β1 subunit in mice does not cause bleeding defects, although these platelets show 
minor defects in platelet adhesion and aggregation to collagen [85-86]. Studies on 
these knockout mice showed variable phenotypes in in vivo models of arterial 
thrombosis ranging from normal thrombus formation [87] to mildly delayed, reduced 
and unstable thrombi [88, 85]. Similar to other integrins, conformational activation 
of α2β1 increases its affinity for collagen and requires GP VI and collagen-dependent 
inside-out signaling [89]. However, combined deficiency of α2β1 and GPVI in mice 
causes complete inhibition of thrombus formation while isolated deficiency of each 
receptor leads to a partial defect in thrombus formation [90]. Thus, it is widely 
accepted that α2β1 and GPVI function synergistically for optimal platelet adhesion 
and activation by collagen. 
After the initial platelet adhesion and deposition on vWF and collagen exposed 
surfaces, the next step in thrombus formation is the recruitment of additional 
platelets from the flowing blood to form the platelet plug, called the “extension 
phase”. This process requires the localized accumulation of soluble agonists that are 
secreted by adherent-activated platelets, including ADP, TxA2, epinephrine, and 
thrombin. The final step is activation of αIIbβ3, causing a conformational change that 
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enables it to bind fibrinogen and vWF, allowing stable bridges between platelets that 
form large aggregate at the site of vascular damage. GPCRs or G-protein coupled 
receptors are important seven-transmembrane spanning receptors that play crucial 
roles in this extension phase. 
Platelet ADP receptors: P2Y1, P2Y12, P2X1 
When the adherent platelets get activated and release their cargo content, the 
dense granules which are pre-docked on the plasma membrane, are the first ones to 
be exocytosed [91]. ADP is stored in platelet dense granules and gets released upon 
activation at the site of injury. Red blood cells also release some ADP. ADP, though 
being a weak agonist, still causes the full range of platelet activation events including 
intra-platelet Ca2+ influx, thromboxane A2 synthesis, protein phosphorylation, shape 
change, granule secretion, and activation of αIIbβ3, and aggregation. These events are 
driven by ADP interacting with two types of purinergic GPCRs namely P2Y1 and P2Y12 
coupled to Gqα and Giα, respectively [92]. 
P2Y1 receptor 
P2Y1 receptor couples with Gqα to mobilize calcium and is responsible for initiation 
of platelet aggregation and shape change when ADP binds to it [93]. P2Y1 can also 
couple to G12/13 and can activate platelets via Rho Kinase and Calcium [94].  A3P5PS, 
a P2Y1-specific inhibitor, blocks shape change and calcium signaling in response to 
2MeSADP, a stable ADP analog, without affecting cAMP downregulation 
[95].Platelets from P2Y1-deficient mice are unable to aggregate in response to usual 
concentrations of ADP and display defective aggregation to other agonists, while 
high concentrations of ADP (together with serotonin) induce platelet aggregation 
without shape change. These mutant mice do not present a bleeding diathesis but 
are resistant to thromboembolic mortality induced by injecting ADP or collagen and 
adrenaline [96]. 
P2Y12 receptor 
ADP activation of P2Y12 results in amplification and sustenance of aggregation, and 
secretion but plays no role in ADP-induced shape change [98]. In addition to 
amplification of P2Y1-mediated platelet responses, P2Y12 plays an essential role in 
potentiating platelet responses initiated by other important platelet activators such 
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as thromboxane A2 and thrombin and therefore, is a critical regulator of hemostasis 
and thrombosis [92]. This second ADP receptor couples to Gi to inhibit adenylate 
cyclase and cause platelet aggregation [97]. Activation-based signaling downstream 
of the P2Y12 receptor potentiates agonist-induced dense granule release as well as 
alpha granule release of P-selectin [99, 100]. P2Y12 coupling to Gi also leads to 
activation of PI3K, Akt, Rap1b and potassium channels [99]. Both Rap1b and Akt are 
signaling mediators that contribute to platelet aggregation and are activated in a 
PI3K-dependent manner. Inhibiting P2Y12 receptor reduces thrombus formation 
without affecting its stability [101, 102]. In P2Y12-deficient mice, ADP does not induce 
aggregation and platelet responses to other agonists are dramatically reduced; these 
mice have a bleeding phenotype as well as reduced thrombus formation and 
resistance to thromboembolism [102, 104]. While congenital P2Y12 receptor 
deficiency is a rare autosomal recessive disorder, it presents with a bleeding 
diathesis, though the severity of it varies from patient to patient [103].  
Given its well-established importance in hemostasis and thrombosis, the P2Y12 
receptor is the target of a host of anti-platelet drugs such as the thienopyridine class 
of drugs (ticagrelor, clopidogrel, cangrelor, elinogrel, and prasugrel) [105]. These 
antagonists bind to the receptor irreversibly and reduce platelet function. Some of 
these are already in use as antithrombotic while others are in development. These 
drugs are routinely used together with aspirin which inhibits TxA2 synthesis in 
platelets and thus provides additional benefits of reducing platelet function. Of these, 
clopidogrel, marketed as Plavix, remains the most widely used anti-thrombotic to 
prevent vascular events in patients with cardiovascular diseases, especially in the 
case of coronary stent insertion.  
An important aspect of both the P2Y1 and P2Y12 receptors is their ability to become 
desensitized to ADP. This serves to regulate platelet reactivity and control thrombus 
formation. Once initially activated by ADP, there is a transient loss of platelet 
responsiveness to a second stimulation by ADP by selective desensitization of the 
P2Y1 receptor [106]. The P2Y12 receptor remains functional and conserves its ability 
to amplify the platelet aggregation induced by other agonists, suggesting that the 
two receptors are regulated differently [107]. Platelets, at the site of vascular injury, 
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use receptor desensitization as means to regulate responses when ADP, released 
from red blood cells, is the sole agonist in the medium, a situation when P2Y1 comes 
to play. Then, when platelets become refractory to ADP, P2Y12 still remains viable 
and can respond to other agonists thus ensuring platelets’ responsiveness and 
preserves the hemostatic function of the platelets [92]. Furthermore, surface levels 
of P2Y receptors and consequently ADP responsiveness is regulated through 
endocytic trafficking [148]. Endocytic trafficking of P2Y receptors allows platelets to 
be desensitized and resensitized to ADP. It has been shown that P2Y1 and P2Y12, 
upon ADP stimulation, rapidly desensitize in a kinase-dependent manner [149]. 
Endocytosis of P2Y1 is dependent on protein kinase C (PKC) activity, whereas P2Y12 
requires G protein-coupled receptor kinase (GSK). After removal of agonist, P2Y 
receptors recycle back to the cell surface, a process that is called resensitization. 
ADP-ribosylation factor 6 (Arf6), a small GTPase that is present in platelets and is key 
for integrin recycling [19], has been suggested to be important for P2Y12 
internalization by regulating Nm23-H1, an NDP (nucleoside diphosphate) kinase 
which facilitates dynamin-dependent fission of clathrin-coated vesicles [150]. 
P2X1 receptor 
In addition to P2Y1 and P2Y12 receptors, platelets express a third purinergic receptor 
P2X1. This receptor is actually an ATP-gated cation channel [108] that is unable to 
trigger platelet aggregation by itself, but under high shear conditions acts as a 
positive regulator of platelet responses to collagen and thus plays a significant role in 
thrombus formation [109]. P2X1-deficient mice have normal bleeding times but are 
resistant to thromboembolism upon collagen-epinephrine injection as well as to 
localized laser-induced injury of the vessel walls of mesenteric arteries [109]. 
Conversely, mice overexpressing the human P2X1 receptor are more prone to 
increased systemic thrombosis [110].  The P2X1 antagonist NF449 [111] inhibits 
platelet function ex vivo and in vivo thrombus formation [112]. Together, these data 
strongly suggest the effectiveness of P2X1 antagonists as potent anti-thrombotic 
drugs especially in patients with severe stenosis where shear forces are high.  
Amongst the soluble agonists secreted at the site of injury, thromboxane A2, is one 
of the key prostanoids secreted by activated platelets through the sequential 
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activities of cyclooxygenase (COX) and TxA2 synthase enzymes [117]. TxA2, an 
unstable arachidonic acid metabolite, is a vasoconstrictor and a potent platelet 
activator causing shape change, phosphoinositide hydrolysis, calcium mobilization, 
protein phosphorylation, secretion and aggregation [113]. Once synthesized, it 
diffuses through the plasma membrane and activates other recruited platelets, thus 
allowing the platelet plug formation. The receptor that TxA2 binds to on platelets is 
the thromboxane A2 receptor TP [114]. 
Thromboxane A2 (TP) receptor 
TP exists in two splice variants (TPα and TPβ) which differ mostly in their C-terminal 
cytoplasmic domains though their ligand-binding properties are the same. TPα was 
cloned from the placenta [115] while TPβ was cloned from endothelial cells [116]. 
Platelets contain both these isoforms [118]. TPs in platelets couple to Gqα and G12α 
activating pathways, but not to Giα, activating the phosphoinositide hydrolysis 
(leading to IP3 formation), mobilization of calcium and activation of Rho GTPases 
when activated by the thromboxane A2 analog, U46619 [119, 120]. Mice deficient in 
TP are unable to respond to TxA2 analogs, have reduced response to collagen and 
have prolonged bleeding times as well as altered vascular responses to arachidonic 
acid a TxA2 [121]. Blocking TxA2 synthesis using antagonists/inhibitors especially 
those that inhibit cyclooxygenase enzymes and thromboxane A2 synthase, such as 
aspirin (irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2) 
have been used for decades to manage high cardiovascular risk [122]. Aspirin still 
remains one of the most widely used drugs for preventing and managing 
cardiovascular diseases. Aspirin’s importance was honored when John Robert Vane, 
a British pharmacologist, won the Nobel Prize in Physiology or Medicine in 1982, for 
his landmark discovery in showing the inhibitory effects of aspirin on thromboxane 
and prostaglandin production, essentially being one of the most important anti-
platelet drugs to be discovered. 
The next major and a most important agonist that comes into play at promoting and 
stabilizing the growing thrombus at the site of damage under all shear conditions is 
thrombin [58]. Thrombin is a multifunctional serine protease that has both 
anticoagulant and procoagulant properties, being the only one of all the coagulation 
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cascade proteins to have the ability to regulate normal hemostasis and spurious 
uncontrolled thrombosis [147]. Thrombin is generated by the action of several 
members of the coagulation cascade on the surface of the platelets, namely tenase 
complex (FIXa in complex with FVIIa, which activate FX) and by the prothrombinase 
complex (FXa in complex with FVa, which activate FII) [123]. These coagulation 
factors together with the activated platelet surface which provides exposed 
phosphatidylserine, creates a procoagulant surface that allows thrombin generation 
to occur [124].  
Thrombin is the most potent platelet activator and generates full blown platelet 
activation in terms of platelet shape change, secretion, TxA2 generation, Ca2+ 
mobilization, protein phosphorylation and aggregation [58, 56]. Even low 
concentrations of thrombin (0.1 nM) can activate platelets [56]. Thrombin can 
efficiently couple to PLCβ activation, leading to rapid increase in cytosolic Ca2+ levels, 
triggering downstream events such as activation of PLA2 [125]. The thrombin-
induced platelet responses are mediated partially by the GPIb-IX-V complex [126, 
127, 68-69]. However, thrombin acts on platelets mainly through the action of two 
protease-activated receptors (PARs), PAR-1 and PAR-4 in humans and PAR-3 and 
PAR-4 in mice [128].  
Protease-activated receptors (PARs) 
PARs belong to the seven transmembrane domain containing G-protein coupled 
receptors that are present on the surface of platelets and are sufficient to activate 
platelets by themselves in the presence of thrombin. To date, four PAR receptors 
have been identified and characterized, three of which PAR-1, PAR-3, and PAR-4 are 
substrates for thrombin while PAR-2 is activated by mast cell tryptase, trypsin and 
factor Xa but not by thrombin [134-140]. There are four PAR members on platelets, 
PAR-1 and PAR-4 in human platelets while PAR-4 is the major mouse platelet PAR 
receptor with PAR-3 acting as a co-receptor [129]. Since thrombin generation 
requires some level of platelet activation (usually ADP, TxA2-mediated), PAR-
mediated activation occurs after platelet adhesion and activation.  
PAR-mediated activation requires irreversible proteolytic cleavage within the first N-
terminal extracellular loop of the seven transmembrane domain receptors that 
17 
 
contain a putative thrombin cleavage site LDPR/S [130]. Upon cleavage by thrombin, 
a new N-terminus is exposed that now serves as a tethered ligand. Studies were 
done on PAR-4 knockout mice, PAR-4 being the major thrombin receptor in mouse 
platelets, showed prolonged bleeding times and were protected in the FeCl3 injury 
model of arterial thrombosis; the platelets from these mice were unresponsive to 
thrombin, even at higher concentrations, with no observed shape change, ATP 
release from dense granules or aggregation [131]. In PAR-3 knockout mice, thrombin 
responses were abnormal as in low levels of thrombin did not elicit any response in 
terms of ATP release and aggregation, while higher concentrations elicited markedly 
delayed responses; bleeding times were normal in these mice [132]. Interestingly, 
platelets from PAR-3 knockout mice responded normally to a PAR-4 activating 
peptide mimetic, suggesting that while PAR-3 is necessary for normal responses, it is 
not the major thrombin receptor in mouse platelets. Furthermore, it leads to a dual-
receptor model for platelet activation by thrombin that has important implications 
for developing anti-thrombotic drugs.  
Understanding the role of the thrombin receptors on human platelets becomes key 
to developing therapeutic strategies against myocardial infarction and stroke. Similar 
to mice, a dual-receptor system for thrombin-induced platelet activation is also 
present in humans, mainly through the actions of PAR-1 and PAR-4. PAR-1 is the 
major thrombin receptor in human platelets [134]. The PAR-4 activating peptide can 
also activate human platelets suggesting that PAR-4 also plays a secondary but 
important function. Blockade of PAR-1 with antibodies or specific antagonists ablates 
platelet function even at low concentrations of thrombin, whereas similar blockade 
of PAR-4 at low thrombin concentrations has no inhibitory effect [133].  Blocking or 
inhibiting both PAR-1 and PAR-4 receptors results in complete ablation of platelet 
response to even very high concentrations of thrombin [133]. Further support for 
this dual receptor model in human platelets can be gleaned from studies on 
intracellular cytosolic calcium transients using PAR agonists and antagonists. Human 
platelets have a biphasic calcium response, the first phase being a rapid phase where 
intracellular cytosolic calcium levels spike in response to PAR-1 activation (by 
thrombin) and the second more sustained phase of calcium transient is maintained 
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by PAR-4 activation [141]. Studies using PAR-1 knockout mice revealed that 
disruption of the murine PAR-1 gene causes 50% embryonic lethality at E9-10 days, 
while the other half of mice developed normally with no hemorrhagic diatheses. 
PAR-1 knockout platelets normally respond to thrombin and have normal hemostasis, 
mainly because PAR-3 and PAR-4 thrombin responses are unaffected. However, 
these mice have defective vasculogenesis in their yolk sac and cardiovascular 
collapse leading to early embryonic lethality [142]. While PAR-3 and PAR-4 knockout 
mice are protected against thrombosis and demonstrate defective thrombus 
formation, direct PAR-1 inhibition in primate models also abolishes arterial 
thrombosis [131, 143-144].  PARs provide an important link between hemostasis and 
inflammatory pathways [145] due to the pro-inflammatory nature of thrombin. PARs 
have been implicated in thrombin-mediated activation of endothelial cells by 
triggering release of vWF from the Weibel-Palade bodies (granules that store vWF 
within the endothelial cells) and surface expression of P-selectin that facilitates 
rolling and adhesion of platelets and leukocytes on the endothelial surface as well as 
release of interleukins-6 and 8, thereby mediating inflammation [128, 145-146]. 
PARs have also been implicated in atherothrombosis [128].  
After thrombin-mediated PAR activation and engagement in the formation of the 
growing thrombus, the last phase that finally leads to a stable thrombus at the site of 
injury to arrest blood loss, is called the “stabilization phase”. In this phase, activated 
platelets within the developing platelet plug come into close contact with each other, 
aided by fibrin fibers that form bridges closing the gap between nearby platelets and 
facilitating the formation of the thrombus. Once aggregation has started, a series of 
late signaling events sets in to consolidate the stable thrombus and prevent its 
embolization. These contact-dependent signaling events that drive this late phase of 
thrombus formation is mainly mediated by the outside-in signaling through the 
platelet integrins, particularly αIIbβ3.  
Integrins 
The integrins are a major class of adhesive and signaling receptors that are present 
on most cell types consisting of two subunits, α subunit and β subunit [151]. 
Vertebrates have 18 α subunits and 8 β subunits, generating 24 heterodimers that 
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are non-covalently associated [152]. Integrins have a large extracellular domain, a 
single transmembrane domain from each subunit, and small cytoplasmic tail, 
although α and β subunits have distinct domain structures. Both subunits contribute 
to the ligand-binding site in their extracellular domain, with specific binding ligand 
for individual integrin. Integrins exist in two affinity states, low and high, which are 
altered by cytoplasmic signaling and phosphorylation of their cytoplasmic domains 
[153].   
Platelets express integrins from three families (β1, β2 and β3) and in total six different 
integrins:  α2β1, α5β1, α6β1, αLβ2, αIIbβ3, and αvβ3 [154].  
β3 family (αIIbβ3 and αvβ3) 
Integrin αIIbβ3 
αIIbβ3, or the GPIIb-IIIa complex, is the only integrin that is exclusively expressed on 
platelets and megakaryocytes [155]. There are about 80,000 copies of αIIbβ3 on the 
surface of quiescent platelets and additional heterodimers in the membranes of 
platelet granules are translocated to the surface during platelet activation [156-157]. 
αIIbβ3 is the major receptor for fibrinogen, vWF, fibronectin and vitronectin and is 
essential for platelet aggregation [158]. As a result, absence or deficiency of αIIbβ3 
prevent platelet aggregation and leads to sever bleeding disorder called Glanzmann’s 
thrombasthenia [159]. Conversely, the thrombi formed during arterial circulation 
result from αIIbβ3-mediated formation of platelet aggregates [160].  Given the 
importance of αIIbβ3 in mediating hemostasis and thrombosis, it is one of the most 
studied integrins and most targeted receptor for anti-thrombotic therapies.  
Integrin αvβ3 
This integrin is present in platelets in small amounts (several hundred copies per 
platelet) and is known to mediate platelet adhesion to osteopontin and vitronectin in 
vitro [161-162]. Integrin αvβ3 supports adhesion on fibronectin and promotes the 
formation of filopodia but not lamellipodia or downstream focal adhesion kinase 
(FAK) phosphorylation [163]. However, the in vivo role of integrin αvβ3 is unknown.  
β1 family (α2β1, α5β1 and α6β1) 
Integrin α2β1 
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Also known as GPIa-IIa and on lymphocytes as VLA-2, it is the second most important 
integrin after GPIIb-IIIa on platelets [164]. There are 2000-4000 copies per platelet 
and is the major collagen receptor on platelets as well as other cell types.  
Integrin α5β1 
The extracellular matrix protein, fibronectin, is the major ligand for the integrin α5β1 
and supports static platelet adhesion on fibronectin [163, 165]. Soluble fibronectin 
binds to integrin αIIbβ3 on thrombin-activated platelets and this binding is not 
observed with platelets from Glanzmann’s thrombasthenia patients that lack αIIbβ3. 
However, these platelets can still retain the ability to bind to fibronectin-coated 
surfaces as adhesion to fibronectin does not require platelet activation and is in fact 
inhibited by soluble fibronectin [166]. Another hallmark of platelet-fibronectin 
interactions is that it is shear stress-dependent and as a result platelet adhesion to 
fibronectin is thought to occur in large arterioles where the shear stress is 
considerably less [167].   
Integrin α6β1 
α6β1 is thought to be the principal laminin receptor on platelets and has a 
supplementary role in platelet adhesion at injury sites [170, 174]. Platelet adhesion 
to laminin strongly depends on the presence of divalent cations like Ca2+ and Mg2+ 
and low shear rates (about 800/s) but does not lead to aggregation although 
filopodia and lamellipodia formation does occur [168-169]. Laminin stimulates 
platelet spreading through α6β1-dependent activation of the collagen receptor, GPVI 
[174]. Lamellipodia formation on laminin is completely inhibited in the absence of 
GPVI, while filopodia formation remains viable and is thought to be mediated via 
α6β1 [174]. 
β2 family (αLβ2) 
Integrin αLβ2 
Quiescent platelets express low to variable expression levels of the integrin αLβ2, also 
known as CD11a/CD18 (LFA-1). However, activation of platelets leads to a marked 
increase in the levels of this integrin, suggesting that this integrin is expressed on 
granule membranes, which upon granule fusion with the plasma membrane gets 
exteriorized, in a manner similar to the alpha granule marker, P-selectin [171]. 
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Studies done on mice further revealed that stimulation of thrombocytopoiesis 
(production of new platelets) leads to loss of β2, but not β1 or β3 integrins, from the 
newly released platelets and there appears to be a selective loss of β2 integrin from 
platelets in circulation [172]. Further studies using the β2 integrin knockout mice, 
demonstrated that β2 modulates caspase activation and consequently platelet life 
span and response to inflammatory cytokines such as Tumor Necrosis Factor (TNF) 
[173].  
Platelet outside-in signaling, mainly mediated through fibrinogen binding to αIIbβ3, 
triggers key events for thrombus growth and stabilization, such as cytoskeletal 
reorganization, formation and stabilization of large platelet aggregates, development 
of a procoagulant surface and clot retraction that helps in bridging the gaps between 
platelets and increase the local concentration of soluble platelet agonists [175]. At 
the heart of this growing thrombus, where the concentrations of the soluble agonists 
(mainly thrombin) is highest is called the core and consists of fully activated platelets, 
while the surrounding region is overlaid by what is called the shell comprising of 
minimally activated platelets [176-178]. While the integrins are the main players in 
promoting the continued growth and stability of the hemostatic thrombus, other 
participants include cell adhesion molecules (junctional adhesion molecules, JAM-A 
and JAM-C) that provide cohesive and signaling interactions between adjacent 
platelets and leukocytes favoring thrombus stabilization [179]; receptor tyrosine 
kinases such as the Ephrin family of kinases (EphA4, EphB1, and ephrinB are present 
in human platelets) that cluster to cause platelet adhesion on fibrinogen [180]; 
secreted agonists and protein fragments that are shed from the surface of activated 
platelets such as CD40 ligand (CD40L, CD154). CD40L is shed from activated platelets 
to produce a soluble form, sCD40L that can bind to αIIbβ3 through the Arg-Gly-Asp 
motif and favors outside-in signaling that drives thrombus growth and stability [181]. 
Receptors involved in the negative regulation of platelet activation and thrombus 
growth 
To prevent uncontrolled thrombus growth at the site of injury that grows into an 
occlusion that covers the entire blood vessel, several negative regulators or 
passivators of platelet activation exists. Chief among them are nitric oxide (NO) and 
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prostacyclin (PGI2). PGI2, produced by the vascular endothelium, is a labile 
metabolite of arachidonic acid and acts as a potent vasodilator in coronary 
circulation as well as dampens platelet activation by inhibiting platelet adenylyl 
cyclase and preventing formation of cAMP [182]. Endogenous nitric oxide has been 
shown to inhibit platelet adhesion to the vascular endothelium and protects against 
platelet aggregation in stenosis and endothelium-injured arteries [183-184]. Platelet 
activation can also be blocked by the adhesion molecule, platelet endothelial cell 
adhesion molecule, PECAM-1 or CD31, a member of the Ig superfamily that contains 
an immunoreceptor tyrosine-based inhibitory motif (ITIM) that gets phosphorylated 
upon platelet activation. PECAM-1 plays a vital role in attenuating thrombus 
formation involving GP VI, GP Ib, thrombin-mediated activation of platelets as well as 
αIIbβ3-mediated platelet activation [185-187]. Another mechanism to arrest 
unregulated thrombus growth is by the action of the matrix metalloprotease 
ADAMTS13, which cleaves highly adhesive large vWF multimers that are formed on 
the surface of the growing thrombus. ADAMTS13 works as an anti-thrombotic by 
down-regulating both platelet adhesion to damaged endothelium and thrombus 
formation in injured arterioles [188]. 
Platelet exocytosis 
Activation-dependent platelet exocytosis, also called the “platelet release reaction”, 
is at the core of several physiological and pathophysiological processes such as 
thrombosis, wound healing, angiogenesis, and inflammation among others [245].  
Activated platelets release their granule contents that consist of ADP from dense 
granules (activates other platelets in the immediate vicinity in a paracrine manner), 
fibrinogen and vWF from alpha granules that modulates thrombus formation and 
stability, various cytokines, chemokines and growth factors that allows 
communication with other cell types (endothelial cells, leukocytes etc.) as well as 
several lytic enzymes from lysosomes that are thought to modulate clot remodeling. 
Platelet secretion, its kinetics, extent, and release composition, appears to have no 
functionally thematic pattern, with only agonist potency driving these parameters 
for the release reaction [91]. However, there are distinct kinetic patterns or waves in 
cargo release with dense granule cargo being the fastest and most important in 
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mediating hemostasis, followed by the secondary wave of alpha granule release and 
then by lysosomal release being the slowest. Distinct kinetic patterns of the granule 
releasates allow platelets to control their microenvironment. Platelet granule 
secretion provides a concentrated release of key effector molecules at the site of 
injury that allows platelets to carry out their functions. Secretion of more than 300 
proteins and bioactive small molecules [189-190] from activated platelets requires a 
cascade of complex protein-protein interactions that are tightly regulated and 
govern this release reaction. The Soluble N-ethylmaleimide Sensitive Fusion Protein 
Attachment Protein Receptor (SNARE) proteins are the core machinery [194] that 
drives the process of granule-plasma membrane fusion in platelets, using 
mechanisms similar to those found in other secretory cells such as neurons, 
chromaffin cells, mast cells, neutrophils etc. Platelet exocytosis involves the 
movement of granules to juxtapose with the plasma membrane, leading to granule-
plasma membrane fusion, and release of intracellular contents. Within the platelet 
itself, granule-granule fusion may occur in a process called compound fusion which 
may or may not precedes fusion with the plasma membrane [191-192]. SNAREs can 
be classified into two groups based on their location, v-SNAREs for the ones residing 
on the granules and vesicles, t-SNAREs for target-membrane localization. Extensive 
sequence analysis led to a further classification of the SNAREs based on amino acids 
present within their SNARE motifs, called the QabcR system [193]. All SNAREs 
contain 1-2 amphipathic, heptad-repeat-containing cytosolic domain called the 
SNARE motif consisting of 60-70 amino acids. Cognate v- and t-SNAREs interact with 
each other by binding to these SNARE domains. Specificity of binding is conferred by 
a highly conserved 16 amino acids stretch which lay up- and down-stream of an ionic 
“zero” layer. This zero layer invariably consists of three glutamines (Q) and an 
arginine (R) residue. The v-SNAREs also called Vesicle-Associated Membrane Proteins 
(VAMPs) make up the majority of the R-SNAREs while the t-SNAREs are mostly Q-
SNAREs. The t-SNAREs can be subdivided into two classes of proteins; the Syntaxins 
(Qa-SNAREs) and the Synaptosome Associated Proteins (SNAP-25/23 proteins) (Qbc 
SNAREs) [195-196]. SNARE-driven exocytosis in platelets proceeds in conformation 
to the SNARE hypothesis which states that members of the v- and t-SNAREs form 
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cognate pairs on the basis of binding specificity and should be essential and 
sufficient for vesicle docking in vivo [197]. Accordingly, four SNARE motifs, one each 
from Qa and R and two from Qbc families form a functional four-helical complex that 
undergoes a cis to trans conformational change that brings the granule membrane 
and plasma membrane in close physical apposition and drives fusion [197].  
Previous studies done by our lab and others have established the importance and 
contribution of several of these platelet SNARE proteins and their contributions to 
hemostasis and thrombosis.  
Platelet v-SNAREs 
SNAREs were first reported by our group when NSF, SNAP and Syntaxin-2 and 
Syntaxin-4 were detected in platelet lysates [198]. Platelets contain multiple 
isoforms of the VAMPs (VAMP-2,-3,-4,-5,-7,-8), based on data gleaned from 
proteomic analyses and quantitative Western blotting [199-200]. In terms of a 
number of copies per platelet, VAMP-8 and VAMP-7 are the most abundant in 
human platelets while VAMP-8, VAMP-2, and VAMP-3 are the major ones in mouse 
platelets. VAMP-8 which is the most abundant in both mouse and human platelets is 
the primary v-SNARE to mediate secretion. Loss of VAMP-8 attenuates secretion 
from all three granules, causes defective thrombosis (thrombus growth is slower and 
lessened in comparison to WT) with no bleeding diathesis [199, 201]. Loss of VAMP-3 
by itself had no defect in secretion and hemostasis proceeded normally as measured 
by tail bleeding assay [202]. Loss of VAMP-2 is embryonic lethal [201]. Treatment of 
tetanus toxin which specifically cleaves VAMP-2 and VAMP-3 showed that platelet 
secretion is unaffected as long as VAMP-8 and VAMP-7 are present [201]. Loss of 
VAMP-7 does not lead to a bleeding diathesis or defects in platelet accumulation at 
sites of injury in the laser injury model of arterial thrombosis, although alpha granule 
secretion is attenuated in these platelets [203]. Collectively, these data implies there 
appears to be an order of ranking amongst the isoforms in mediating secretion with 
some amount of redundancy. VAMP-8 is primary with VAMP-2 and VAMP-3 playing 
secondary roles. VAMP-7 on the other hand may be less involved in secretion but 
mainly play a part in platelet spreading due to its interactions with the actin 
cytoskeleton via VPS9-domain Ankyrin-repeat containing protein (VARP) and Arp2/3 
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[203]. Immunofluorescence studies have shown VAMP-7-dotted structures to be 
localized to the platelet periphery while VAMP-8 and VAMP-3 have been shown to 
be more centrally localized within the granulomere in spread platelets [204]. The 
central localization of VAMP-3 concurs with studies done in our lab where we 
reported the intracellular punctate staining of VAMP-3 containing structures that 
resist being targeted to the plasma membrane during thrombin activation [205]. 
These could very easily be VAMP-3 positive endosomes in platelets. Additionally, 
VAMP-8 and VAMP-7 could potentially mediate differential cargo release or may be 
differentially responsive to various kinds of agonists. However, future studies need 
to be done to parse this distinction.  
Platelet t-SNAREs 
While SNAP-25 is the major Qbc SNARE in neuronal cells, most hematopoietic cells 
including platelets rely on SNAP-23 as the functionally relevant t-SNARE [206-207]. 
Platelets also contain SNAP-25 [200] and SNAP-29 [208] but to lesser amounts. 
Platelets contain Syntaxins 2, 4, 6, 7, 8, 11, 12, 16, 17 and 18 based on proteomic 
analyses and functional studies [200]. Of the Syntaxins or Qa-SNAREs, Syntaxin 11, is 
the most important for platelet secretion. Platelets isolated from Familial 
Hemophagocytic Lymphohistiocytosis type 4 (FHL4) patients, which lack Syntaxin 11, 
were deficient in secretion from all three granules [209]. Co-immunoprecipitation 
analyses showed that upon stimulation, Syntaxin 11, complexed with SNAP-23 and 
VAMP-8 to form the fusogenic SNARE complexes. While previous secretion studies in 
permeabilized platelets using inhibitory antibodies and peptides showed the 
importance of Syntaxin 2 and 4 in platelet secretion [206-207, 210-212], both 
Syntaxin 4 single knockout mice and Syntaxin 2/4 double knockout showed no 
secretion defect [209, Ye unpublished data]. The previously reported incorrect 
results were due to the original Syntaxin 2 antibodies cross-reacting with Syntaxin 11 
to inhibit secretion [209]. As mentioned before, Syntaxin 8 is present in platelets and 
has been shown to regulate dense core granule release, platelet aggregation and 
thrombus stability [213].  
SNARE regulatory proteins 
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Several regulatory proteins affect the functions of the SNAREs by controlling their 
fusogenicity either temporally or spatially. Some of these SNARE regulators either 
function as chaperones or tethering/docking factors or modulate the SNAREs via 
post-translational modifications. 
SNARE chaperones 
Munc18b: Members of the Sec1/Munc 18 (SM) gene family regulate interactions 
between the various SNAREs. The Sec1/Munc 18 proteins bind to the Syntaxins and 
form a Syntaxin-Munc18 complex that regulates vesicle priming and potentially 
modulates the conformation of the SNARE proteins [214-215]. Platelets contain 
Munc18a, Munc18b, Munc18c (STXBP1, 2, 3) with Munc18b being the most 
abundant of these three [216]. Platelets isolated from Familial Hemophagocytic 
Lymphohistiocytosis type 5 (FHL 5) patients, which have defective Munc18b, had 
severe secretion deficits showing the importance of Munc18b in mediating secretion 
from all three different granules [216].  In platelets, Munc18c has been shown to 
interact with Syntaxin 4 and thereby contribute to platelet secretion [217]; however, 
platelets from heterozygous Munc18c mice showed normal secretion indicating that 
Munc18c loss does not affect secretion to a great extent [218]. Munc18s have also 
been reported to be phosphorylated in platelets and this is thought to affect their 
interactions with Syntaxins [219-220]. Platelets also contain Vacuolar Protein 
Sorting-associated protein 33A and B, VPS33A and VPS33B, which are members of 
the SM family and are important for dense and alpha-granule biogenesis respectively 
[221-222]. VPS33B has been recently shown to bind to the integrin β subunit and can 
modulate αIIbβ3-mediated fibrinogen endocytosis, platelet activation, aggregation, 
spreading, clot retraction and in vivo thrombosis and hemostasis [223].  
STXBP5/Tomosyn 1: Syntaxin Binding Protein 5 or Tomosyn 1 is a t-SNARE regulator 
that interacts with the t-SNARE heterodimers (e.g., Syntaxin 11/SNAP-23) through its 
v-SNARE-like domain, and is thought to be a “place-holder” for the t-SNAREs [224-
225]. In platelets, STXBP5 binds only to t-SNAREs and loss of this protein causes 
platelet secretion in mostly alpha granules and lysosomes, with a little defect in 
dense granule secretion. STXBP5 knockout mice also have a severe bleeding defect 
[226].  
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Tethering/docking factors 
Rab27: Platelets contain both the isoforms of Rab27, Rab27a, and Rab27b, which are 
small GTPases that mediate granule docking and tethering in secretory cells [227]. 
Loss of Rab27a in mouse platelets does not cause any bleeding defects. When these 
mice were crossed with a Rab27b knockout, both the double knockout and the 
Rab27b single knockout mice had a robust bleeding phenotype as well as a reduced 
secretion from dense granules. Additionally, the number of dense granules per 
platelet and the serotonin content within the dense granules was reduced in these 
Rab27b and Rab27a/b double KO strains suggesting a role for Rab27 in dense granule 
packaging at the megakaryocyte level [228]. Rab27a could partially compensate for 
the secretion deficit but not the reduced granule number, indicating there exists 
some level of compensation between these two homologs within platelets. 
Munc13-4:  Protein unc-13 homolog D, commonly known as Munc13-4, belongs to a 
family of multi-domain proteins that contain the Munc Homology Domain (MUN) 
domain and two calcium/lipid-binding C2 domains and act as “priming or docking 
factors” in driving SNARE-mediated fusion. Munc13-4 is highly expressed in cells of 
the immune system and platelets where it acts as a Rab27a-binding protein that 
regulates dense-core granule release [229]. Munc13-4 was the first identified 
priming factor that promotes Ca2+-dependent SNARE complex formation and SNARE-
mediated liposome fusion [230]. Cytotoxic T lymphocytes deficient in Munc13-4 
from familial hemophagocytic lymphohistiocytosis type 3 (FHL3) patients fail to 
exocytose docked cytotoxic granules, suggesting a role for Munc13-4 in granule 
priming [231]. Munc13-4 knockout platelets have a robust secretion defect as well as 
severe bleeding phenotype and acts as a limiting factor in driving fusion of docked 
granules [232]. Loss of Munc13-4 has a more pronounced effect on dense granule 
release than on alpha granules and lysosomes. Furthermore, the addition of ADP has 
shown to override the apparent alpha granule secretion deficiency in Munc13-4 
knockout platelets [233], implicating the role of ADP as an autocrine factor that 
modulates alpha granule and lysosome release.  
NSF and SNAPs: N-ethylmaleimide-sensitive factor (NSF), an AAA+ ATPase, and its 
adaptor proteins, Soluble NSF attachment proteins (SNAPs), are proteins that 
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disassemble spent SNARE complexes for recycling [234-237]. NSF and SNAPs are 
present in platelets [198]. Inhibitory peptides and antibodies that block alpha-SNAP-
stimulated ATPase activity of NSF impede secretion from permeabilized platelets 
[238]. Nitric oxide inhibits platelet secretion partly by the reversible S-nitrosylation 
of NSF [239]. Since platelet secretion is a terminal event with no discernible need to 
recycle exhausted SNARE complexes, the role of platelet NSF is unclear. However, in 
light of new studies that depict platelets to be more proficient at intracellular 
trafficking and membrane fusion, especially in the context of autophagy and 
endocytic trafficking, NSF and SNAPs may certainly become more relevant and 
functional than previously thought [240, 19].  
Post-translational modifications of SNAREs: Of the platelet SNAREs, SNAP-23 has 
been shown to be phosphorylated by both Protein Kinase C in vitro [241] and by IκB 
Kinase β (IKKβ or IKK2) [242]. Our group has shown that IKKβ, but not PKC, is the 
proximal kinase that drives SNAP-23 phosphorylation in platelets both in vivo and in-
vitro. IKKβ-mediated phosphorylation affects SNARE complex formation and 
platelets from either IKKβ knockout mice or those treated with IKKβ inhibitors shown 
severe secretion deficiency from all three granule types and robust bleeding 
phenotype [242]. Agonist-induced activation causes SNAP-23 to get phosphorylated 
at serine 95 and serine 120 by IKKβ in platelets. Data generated in this thesis shows 
that this phosphorylation event holds true for most platelet agonists (thrombin, 
convulxin, ADP, etc as well as immune agonists such as Toll-like Receptor ligands) 
implicating that this is an essential step that precedes granule secretion. Phospho-
SNAP-23 can thus be used as readout for activation-induced secretion in platelets.  
Acylation is another common post-translational modification of SNARE proteins. 
Thioester-linked fatty acids attached to cysteines present within several platelet 
proteins have been reported in proteomic analyses [243] and this active acylation 
appears to be agonist-induced and important for platelet function and in vivo 
thrombus formation [244]. Two potential SNAREs that could be acylated in platelets 
are Syntaxin 11 and SNAP-23. Both are membrane-anchored and yet lack classical 
transmembrane domains. The presence of a cysteine-rich domain at their C-terminus 
that can get readily acylated, allows them to be appropriate candidates for using 
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acylation to tether to the plasma membrane and disruptions in acylation leads to 
defects in platelet secretion and aggregation [Zhang J, in prep, 2017].  
Signaling events during activation-exocytosis coupling 
Platelets exocytosis is uniquely coupled to signaling events triggered by activation. 
Resting platelets contain cis-SNARE complexes that prevent the non-specific release 
of cargo in the absence of any activating stimulus. However, when platelets are 
activated by agonists such as thrombin, collagen, ADP, thromboxane A2, 
phosphatidylinositol-4, 5-bisphosphate (PIP2) present in the platelet membranes gets 
cleaved to form diacylglycerol and inositol-1, 4, 5-trisphosphate (IP3). Diacylglycerol 
(DAG) activates several forms of Protein Kinase C while IP3 increases the intracellular 
Ca2+ concentration, triggering platelet secretion [246-249]. Increases in intracellular 
Ca2+ are sufficient to induce platelet secretion but PKC also plays a key role, both 
being critical second messengers in this process and use of PKC inhibitors has been 
shown to block secretion [250]. How calcium regulates platelet secretion still 
remains a mystery, simply because no definite calcium sensors (Synaptotagmins) 
haven been detected in platelets. Although several proteins containing calcium-
binding C2 domains (synaptotagmin-like domains) are present and can potentially 
work as calcium sensors, yet definitive studies are yet to be done.  
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Subsection Two: Intracellular trafficking in platelets  
Eukaryotic cells are surrounded by a plasma membrane that serves as a partition 
between the inside of the cell and its outside. Membrane-bound compartments 
within the cells can transport cargo molecules (proteins and lipids) both into and out 
of the cell at the plasma membrane interface in order to communicate with their 
external environment. This process of cargo trafficking is key to the normal function, 
growth, and survival of cells. These membrane-bound compartments or vesicles 
traffic cargo via two major pathways: the outwards or the exocytic pathway that 
carries intracellular contents to the outside, and the inwards or endocytic pathway, 
that allows uptake/internalization of cargo from the external environment to the 
inside of the cell. Vesicular transport, thus, is a major process by which 
compartments within the cell, communicate with each other and connect the cell 
with its external environment. Cargo-loaded vesicles can form at a donor 
compartment with the help of specific coat and adaptor proteins (e.g., COPI, COPII 
and clathrin), and then targeted to their appropriate acceptor compartments, 
followed by tethering and vesicle fusion to said compartments, using an expansive 
array of proteins including the SNAREs that oversee this highly regulated process. As 
proposed by the SNARE hypothesis [197], intracellular membrane fusion reactions 
require a specific set of SNARE proteins from one membrane (donor) to bind to their 
cognate SNARE proteins associated with the other acceptor membrane, to drive this 
process. Although there are several regulatory proteins that participate in this 
collaborative process, it is widely accepted that the membrane-bridging SNARE 
complexes are the main drivers of the cellular fusion machinery [251].  
Platelets are secretory cells that release their cargo contents, upon activation, to 
oversee their primary functions of hemostasis and thrombosis. In light of this, 
platelet exocytosis has been extensively studied, with the SNAREs being the major 
players executing the platelet release reactions. Platelet endocytosis, on the other 
hand, has been largely recognized in the context of cargo loading into granules, and 
receptor-mediated uptake of fibrinogen and it's biological ramifications in the 
context of platelet cell biology and function. The role of SNAREs in mediating platelet 
endocytosis, though implicitly acknowledged given its necessity, remains largely 
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understudied. My thesis project aims to make important inroads into this facet of 
SNARE-mediated endocytic trafficking in platelets.  
General overview of endocytosis  
The routes that carry cargo inside a cell from the cell surface start with the process 
of endocytosis, by which cells internalize macromolecules, particulates and in some 
cases even dead cells and pathogens. Small portions of the cell membrane invaginate 
and engulf the material to be endocytosed, pinching off to form endocytic vesicles 
that allow internalization of said material. Two main types of endocytosis are 
distinguished on the basis of the size of the endocytic vesicle formed. Phagocytosis 
or “cell eating”, involves the ingestion of large particles such as microbes or dead 
cells via large vesicles called phagosomes (generally >250nm in diameter) [252]. The 
other process is called pinocytosis or “cell drinking” and involves ingestion of fluid 
and solutes via small pinocytic vesicles (about 100nm in diameter) [253]. Pinocytosis 
is generally thought to be a constitutive process with cells ingesting small solutes and 
fluids continually. The third kind of endocytosis, which allows uptake of specific 
macromolecules from the extracellular fluid, is called receptor-mediated endocytosis. 
In this process, specific macromolecules bind to their complementary 
transmembrane receptor proteins, accumulate in coated pits, and then enter the cell 
as receptor-macromolecule complexes in coated vesicles [254]. 
The pathways of endocytosis 
Phagocytosis 
Phagocytosis involves ingestion of large particles such as invading microbes or dead 
cells and is a critical mode of response of the innate immune system. Phagocytosis in 
eukaryotic cells serves to provide nutrition and is required for clearing apoptotic 
bodies, which is key for maintaining cell turnover, tissue homoeostasis and 
remodeling [255]. Phagocytosis of foreign bodies and microbes such as bacteria, 
fungi, and viruses can be cleared from infection sites by professional phagocytes-
macrophages, neutrophils, and dendritic cells, thus forming the first line of defense 
against infection. Phagocytosis is central to innate immunity; however, professional 
phagocytes can present processed/degraded phagocytosed antigens to the lymphoid 
32 
 
cells and initiate an adaptive immune response [256-258]. While the immune 
phagocytes can engulf microbes and initiate a pro-inflammatory response, 
phagocytosis by other non-professional phagocytes such as fibroblasts, epithelial 
cells, and endothelial cells mount an anti-inflammatory response. These cells, 
however, cannot ingest microbes, but they contribute in clearance of apoptotic 
bodies and help in clearance of dead cells and thereby serve to contain tissue 
damage [259]. Phagocytosis is a receptor-mediated event and as such numerous 
receptors are present on the cell surface that can engage with foreign bodies and 
mediate uptake. Some of the key receptors are the pattern recognition receptors 
that detect unique pathogen-associated molecular patterns (PAMPs) on microbes 
that are never found in higher eukaryotes (e.g., mannose receptor CD206, dectin-1, 
CD114, scavenger receptor CD204, CD36 etc.), opsonic receptors that allow 
opsonization of microbes (e.g., FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa receptors that bind to 
the different IgGs), apoptotic corpse receptors that bind to apoptotic bodies and 
help clear them (e.g., TIM-1 and TIM-4, CD36 receptors etc.) amongst others [255].  
The presence of FcγRIIa on platelet surface enables platelets to be uniquely capable 
of doing phagocytosis. This receptor is crucial for immune complex clearance and 
platelets have been shown to phagocytose immune complexes in a FcγRIIa-
dependent manner [260-261]. Platelets can phagocytose bacteria such as P. 
gingivalis [262] and S. aureus [263-264] and it is usually thought to be inside a 
membrane-bound compartment or the OCS. Platelets respond to phagocytosed 
bacteria by generating antimicrobial peptides (defensins) that could potentially kill 
the bacteria. Nevertheless, what happens to phagocytosed bacteria remains far from 
clear. Theories have been put forth suggesting that the bacteria remain trapped 
within these membrane-bound compartments but remain viable [265]. This is could 
be a potential mechanism to evade the immune system and may play a role in 
disease pathogenesis.  
Platelets can also phagocytose inert molecules such as latex beads that cause 
platelet aggregation due to the release of ADP [266]. Interestingly, longer 
incubations of platelets with latex beads led to the loss of granule integrity [266], 
though the mechanism of this is not clear. 
33 
 
Macropinocytosis 
Another regulated form of endocytosis that mediates the non-selective uptake of 
solutes, nutrients and antigens. It is one of the clathrin-independent endocytosis 
processes and is an actin-dependent process initiated from surface membrane 
ruffles that give rise to distinct heterogeneous endocytic vesicles called 
macropinosomes that are much larger than clathrin-coated vesicles [253]. 
Macropinocytosis is important for cell motility which becomes key in the case of 
tumor metastasis due to its role in Actin-dependent membrane ruffling [267]. In the 
immune system, micropinocytosis becomes a way for dendritic cells and 
macrophages to sample their microenvironment and endocytose antigens that are 
then processed and presented with major histocompatibility complex (MHC) class II 
or class I molecules to T cells to mount an adaptive immune response [268-270].  
Data generated in this thesis and others [271] have shown that platelets present 
antigen in the context of MHC class I. Though there are no definite reports of 
micropinocytosis occurring in platelets, platelets acting as antigen presenting cells 
could potentially utilize an endocytic mechanism similar to micropinocytosis to 
engulf pathogens and respond accordingly.  
Clathrin-mediated endocytosis 
Clathrin-mediated endocytosis also called receptor-mediated endocytosis is the most 
ubiquitous endocytic pathway and it requires the use of clathrin, a coat protein, 
which plays a major role in the formation of coated vesicles [272]. Clathrin forms a 
triskelion-shaped structure composed of three heavy chains and three light chains. 
The three heavy chains form the structural backbone of the clathrin lattice while the 
three light chains are thought to regulate the formation and disassembly of the 
polyhedral clathrin lattice. The clathrin lattice builds around the small vesicles where 
cargo is transported from the outside to the inside of the cell. These vesicles are 
called clathrin-coated vesicles (CCVs) and are formed at specialized domains of the 
plasma membrane called the clathrin-coated pits (CCPs) [273-274]. 
Based on ultrastructural and cell biology data, CCV formation occurs in five stages: 
initiation, cargo selection, coat assembly, scission, and uncoating. Several adaptors 
and accessory proteins are involved in the process. In the first stage of vesicle 
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budding, or nucleation, a clathrin-coated pit, in the form of a membrane invagination 
if formed and is triggered when the highly conserved adaptor protein 2, AP2, is 
recruited to the plasma membrane [275]. AP2 can bind to the cytoplasmic tails of 
receptors for the specific cargo being endocytosed and plasma membrane specific 
lipids such as phosphatidylinositol-4, 5-bisphosphate (PtdIns (4,5)P2) and facilitates in 
cargo selection [276, 279-280]. Nucleation promotes polymerization of clathrin into 
curved lattices which aid in the formation and constriction of the vesicle neck, 
bridging the two membranes at the neck into close apposition. The F-BAR domain of 
the FCH domain only containing proteins (FCHO) proteins, which come into play 
during nucleation, provides the membrane-bending activity that is needed to 
generate curvature at the neck for the membrane to bridge close to each other [277]. 
Cargo selection is mainly mediated by AP2 at the plasma membrane, while other 
isoforms such as AP1, AP3, and AP4 are found to aid in cargo selection at the internal 
membranes [278].  AP2 binds clathrin and most other accessory proteins and helps 
in the maturation of the forming clathrin-coated vesicle. During the assembly 
process, clathrin triskelia get recruited at the pits where AP2 concentrations are 
higher. The absence of clathrin recruitment at these sites prevents maturation of the 
coated vesicle [277]. After the mature coated vesicle has formed, Dynamin, a small 
molecule GTPase, is recruited to this site by BAR-domain-containing proteins such as 
amphiphysin, endophilin, and sorting nexin 9 (SNX9), which have SRC homology 3 
(SH3) domains that bind to the proline-rich domains of Dynamin [278-285]. Dynamin 
forms a helical polymer around the neck, constricting it. Clathrin polymerization 
facilitates a conformational change in Dynamin powered by GTP hydrolysis which 
mediates scission of the mature coated vesicle [286-289]. The clathrin-coated 
vesicles are subsequently released by proteins such as the ATPase heat shock 
cognate 70 (HSC70) and its cofactor, auxilin, that allows the uncoated vesicle to now 
travel to its targeted endosome [290-291]. Additionally, alterations in 
phosphoinositide composition of the clathrin-coated vesicles mediated by the 
phosphatase, synaptojanin, are required for the uncoating process [292]. Eventually, 
uncoating allows disassembly of the clathrin machinery and its adaptor proteins 
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from the membrane back to the cytosol for recycling in subsequent rounds of 
clathrin-dependent endocytosis.  
Clathrin-independent endocytosis 
Several endocytic pathways have now been identified that traffic cargo inside cells 
without using clathrin and these are collectively grouped under the clathrin-
independent endocytic pathways. These pathways can be further classified based on 
their use of Dynamin. Some clathrin-independent (CI) pathways use Dynamin, such 
as those involving caveolae and Rho families of GTPases, while there are others that 
use members of the CDC42 and ADP-ribosylation factor (Arf) families of small 
GTPases to mediate vesicle scission, which is central to subsequent vesicle 
internalization [293].  
Of the Dynamin-dependent CI pathways, caveolae-mediated endocytosis is the most 
studied process. It utilizes formation of caveolae at the plasma membrane, which is 
50-80nm flask-shaped membrane invaginations marked by the Caveolin family of 
proteins [294-295]. Caveolae are enriched in cholesterol, sphingolipids, signaling 
proteins and glycosyl phosphatidylinositol-anchored proteins (GPI-APs) [296, 297]. 
Cargo transported by caveolae includes lipids, proteins, and lipid-anchored proteins. 
The second type of Dynamin-independent CI pathways utilizes the GTPase, RhoA, as 
noted in internalizing transmembrane receptors such as the interleukin-2 receptor β 
chain in fibroblasts and immune cells [298]. It is thought that the actin machinery is 
recruited through the actions of RhoA, to mediate this type of endocytosis [295]. 
Dynamin-independent CI pathways use either the Rho family member CDC42 or the 
Arf family of small GTPases, chiefly Arf6. Most GPI-anchored proteins are 
transported via this process using CDC42 [299]; while Arf6 mediates endocytosis of 
class I MHC, β1 integrins, carboxypeptidase E, E-cadherins and some other GPI-
anchored proteins [300-301].  
How cargo enters cells through the different CI pathways is not clear when 
compared to clathrin-mediated processes, simply because no well-defined adaptors 
or accessory proteins have been identified yet. Ubiquitination of cargo has been 
suggested as a possible mode to tag cargo proteins for entry via this pathway, for 
example, receptor tyrosine kinases such as epidermal growth factor (EGF), by the E3 
36 
 
ubiquitin ligase c-Cbl, preferentially enters cells via the caveolae [302]. Flotilin-1 and 
-2, are integral membrane proteins that mediate endocytosis of GPI-anchored 
proteins and cholera toxin b (CtxB) in cells that lack Caveolin [303] and can form 
dynamic punctate structures that allow endocytosis at sites that are distinct from 
clathrin and Caveolin sites at the plasma membrane [304]. Despite the discovery of 
many proteins that mediate the different CI pathways, the exact mechanisms are still 
poorly understood. 
The components of the endocytic pathway 
In mammalian cells, distinct membrane-bound compartments called endosomes, 
serve as carriers of internalized cargo molecules. They shuttle cargo from the plasma 
membrane to the inside (early endosomes) or recycle internalized cargo back to the 
cell surface (recycling endosomes), or sort them to degradative compartments such 
as the late endosomes or lysosomes. 
Early endosomes: It is the starting point for cargo entry into the cell [305] 
irrespective of the endocytic route used (clathrin-dependent, -independent, caveolar, 
or Arf6-dependent pathways) [293]. They are small and have a characteristic 
tubulovesicular structure ranging up to 1µm in diameter and patrol the cell 
periphery close to the plasma membrane along microtubules [306]. The limiting 
membrane of early endosomes contains various subdomains that vary in their 
composition and function [307]. Early endosomes are identified by the presence of 
Rab5, Rab4 GTPases, with Rab5 being key in maintaining organelle identity, together 
with its effector molecule VPS34/p150, a phosphatidylinositol 3-kinase (PI3K) 
complex that generates phosphatidylinositol-3-phosphate (PtdIns3P) [307-308]. 
Rab5 oversees early endosomal maturation and eventually becomes the main 
regulator for conversion of early endosomes to late endosomes. Early endosomes 
are weakly acidic in nature (pH 6.8-5.9) [309] and contain low levels of Ca2+ within 
them [310]. The subdomains located in the tubular extensions of the early 
endosomes are the epicenters for molecular sorting and generate vesicles either 
targeted to the other cell organelles or the plasma membrane, recycling endosomes, 
late endosomes or the Trans-Golgi network (TGN) [311]. 
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Recycling endosomes: Endocytic uptake and recycling are key to ensure the plasma 
membrane composition. Cargo that is endocytosed faces one of two fates; either 
they are targeted to the lysosomes for degradation or they are recycled back to the 
cell surface [311]. Most peripheral early endosomes are capable of recycling cargo; 
however, most cells have a distinct subset of endosomes, called the recycling 
endosomes or endosomal recycling compartment (ERC), located along the 
perinuclear microtubule-organizing center (MTOC) [312]. These recycling endosomes 
have a slightly higher pH of ~6.4 [315] and are incredibly heterogeneous in 
morphology and composition due to dynamic trafficking to and fro between early 
endosomes and plasma membrane [313-314]. Rab11 is the most important GTPase 
that adorns recycling endosomes [316]. Rab11 interacts with the Ral/Exocyst 
complex (made up of RalA/B GTPases and the exocyst complex comprising of Sec5, 
Sec6, Sec8, Sec10, Sec15 and Exo70 proteins), a multi-protein complex, that is 
essential for polarized targeting of vesicles in most cells including epithelial cells 
[317-319]. Recycling back to the cell surface occurs either through the faster Rab4-
dependent short-loop (allows trafficking back to the plasma membrane) or the 
slower Rab11-dependent long loop (where cargo moves from early endosome to 
endosomal recycling compartment (ERC) and then recycles back to the plasma 
membrane) [320]. Arf6, a small GTPase belonging to the mammalian Arf family of 
proteins, has a distinctive plasma membrane and peripheral localization that plays a 
key role in endocytic recycling back to the plasma membrane [321].  
Late endosomes: Cargo that is destined to the lysosome passes through the late 
endosomes en route, arriving either from early endosomes, trans-Golgi network, or 
the phagosome. Mature late endosomes are round or oval shaped with a diameter 
of 250-1000 nm and their pH ranges from 6.0-4.9 [309]. Limiting membranes of 
these endosomes contain several lysosomal membrane glycoproteins such as LAMP-
1 and numerous acid hydrolases are present in their lumen. Late endosomes localize 
to the perinuclear region of the cell and can sometimes fuse with each other to form 
larger late endosomes or can fuse with the lysosomes or with endosomes to form 
hybrid endolysosomal organelles [322]. Rab7-positive late endosomes are derived 
from the vacuolar domains of the early endosomes and starts with the generation of 
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a Rab7 domain in a process facilitated by Rab5-GTP [323]. Post GTP hydrolysis, the 
Rab5-to-Rab7 switch occurs with the GDP-bound Rab5 dissociating with its effectors 
from this newly formed late endosome. Rab5 (early) and Rab7 (late) are the master 
regulators of the endocytic pathway and provide the most important organelle 
identity markers for their respective compartments. Rab7 and its effector molecules 
determine the functions of late endosomes and lysosomes [324].  
Lysosomes: They are the final and largest compartment, sized at 1-2 µM, of the 
endocytic pathway where cargo is degraded. Lysosomes utilize a host of acid 
hydrolases to accomplish the process of cellular waste turnover to generate new 
building blocks for the cell. Inside the lumen of the lysosomes, the pH drops to ~4.5 
[309]. Lysosomes are also important in energy metabolism, plasma membrane repair, 
cell signaling and secretion [325].  
Multivesicular bodies: An intermediate intracellular organelle that incorporates 
cargo that gets sorted for degradation and operates in the endosome-to-lysosome 
route of endocytosis. Multivesicular bodies (MVBs) arise during maturation of the 
early to late endosome process. Cargo that is destined for lysosomal degradation is 
ubiquitinated and then incorporated into the intermediate intraluminal vesicle (ILV) 
that buds from the limiting membranes of the early endosome, giving rise to the 
MVB, which can eventually fuse with or mature into lysosomes [368-369]. Cargo 
trafficking to MVBs provides a mechanism for damaged or misfolded proteins to be 
degraded, especially plasma membrane receptors (e.g., EGFR) [370] that undergo 
downregulation or clearing from the cell surface as part of their regulation. MVBs 
perform diverse functions within the cell. They are the major sorting hub for 
damaged proteins as well as serve as signaling nodes within the cell. MVBs recruit 
ubiquitinated cargos, with Ubiquitin serving as a positive sorting signal for MVB-
directed degradative pathway, using the endosomal sorting complexes required for 
transport (ESCRT) machinery made up of cytosolic protein complexes: ESCRT-0, 
ESCRT-I, ESCRT-II, and ESCRT-III, together with a host of accessory proteins including 
the AAA-ATPase vacuolar protein sorting-associated 4 (Vps4) and endosome-specific 
phosphatidylinositol-3-phosphate (PtdIns3P) [371-372]. In addition to degradation, 
MVBs also function as non-degradative storage organelles as seen when von 
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Willebrand Factor (vWF) gets packaged into the lumen of alpha granules in platelets 
[41-42] or the Weibel-Palade bodies of endothelial cells [373]. Proteins such as the 
transferrin receptor, which are recycled back to the plasma membrane post-
internalization, are incorporated into the MVBs for secretion at the cell surface [374]. 
Numerous cell types including neurons, epithelial cells, mast cells, tumor cells, 
melanocytes, platelets as well as other cell types within the hematopoietic lineage 
are known to generate extracellular vesicles called exosomes, which are derived 
from MVBs [375]. MVBs have a slightly acidic pH of 6.0-5.0 [309]. 
 
Role of endocytosis in platelets  
As mentioned earlier, platelet endocytosis has been largely studied in the context of 
granule cargo packaging and αIIbβ3-mediated uptake of fibrinogen. Uptake of small 
particles and solutes by human platelets was first reported by Zucker-Franklin in 
1981 [14] into a unique membrane structure called the open canalicular system (OCS) 
by a phagocytosis-like process. Further studies using electron microscopy and 
cytochemistry provide evidence for endocytosis of circulating proteins such as 
plasma fibrinogen [15, 16] into platelets. The integrin αIIbβ3-mediated endocytosed 
fibrinogen eventually ends up in alpha granules [340]. Platelet endocytosis is 
important for granule cargo loading (such as fibrinogen and VEGF) [9, 17] and 
contributes to thrombus formation by controlling the surface expression of several 
key proteins such as the integrins, chiefly αIIbβ3, the major platelet glycoprotein 
receptor [18]. Integrin trafficking modulates platelet spreading on endothelial 
surfaces and clot retraction [19]. Endocytosis of purinergic receptors such as P2Y1 
and P2Y12 mediates their re-sensitization and response to ADP [20]. CLEC-2 and 
Thrombopoietin receptor Mpl/TPOR endocytosis regulates their surface levels and 
downstream signaling responses [21, 22].  
Coated vesicles and membranes are central to intracellular trafficking and clathrin-
mediated endocytosis in almost all eukaryotic cells. The first report of the presence 
of such coated vesicles in platelets came from studies done on aldehyde-fixed 
human platelets back in the early 1980s. The concomitant addition of alcian blue and 
tannic acid to human platelets during glutaraldehyde fixation allowed for the 
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visualization of coated membranes within platelets [326]. These coated membranes 
were found either as coated pits or vesicles or dotted around the plasma membrane 
and the secretory granules (alpha granules and lysosomes). Further evidence using 
fluid-phase markers showed that the coated pits are lined with the plasma 
membrane and open canalicular system (OCS) where the coated vesicles either 
existed by themselves or fused with the secretory granules [327]. These studies first 
demonstrated that an active endocytosis and intracellular trafficking process occurs 
in platelets. Following that, a series of experiments done by Bainton and colleagues 
provided evidence for endocytosis of plasma proteins such as albumin, IgG and most 
importantly αIIbβ3 receptor-mediated uptake of fibrinogen into both megakaryocytes 
and platelets, thereby laying the groundwork for platelet endocytosis and its 
importance [15-17, 328-329].  In support of these studies, transmission electron 
microscopy of antibody-stained ultrathin frozen sections of platelets showed that 
plasma proteins such as fibrinogen and von Willebrand factor (vWF) are taken up 
and translocate to storage granules (alpha granules in this case) [330]. Klinger et al. 
used post-embedding immunocytochemistry on platelets using the acrylic resin, LR 
white, to first show the presence of clathrin-coated vesicles colocalizing with 
fibrinogen, vWF, fibronectin on the cytoplasmic faces of the alpha granules, open 
canalicular system and the plasma membrane [331]. Morphological studies on 
quiescent platelets using fibrinogen-stabilized colloidal gold as a receptor-mediated 
endocytosis marker and acid phosphatase as a lysosome marker demonstrated that 
both clathrin-dependent and clathrin-independent endocytic pathways occur in 
platelets [332]. While fibrinogen uses a clathrin-mediated route to enter the alpha-
granules, acid phosphatase uses a clathrin-independent degradative endo-lysosomal 
route to reach the lysosomes. This report also proposes the presence of a lysosomal 
autophagy system that is tasked with degradation in platelets and could be linked to 
platelet senescence [332]. Many platelet surface receptors such as integrin αIIbβ3, 
glycoprotein Ib are internalized and cycle back to the plasma membrane [334-338]. 
In unstimulated platelets, an internal storage pool of these receptors exists which 
can be targeted to the plasma membrane upon platelet activation, thereby 
increasing their surface expression. Stimulation by agonists such as thrombin or ADP 
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often leads to re-distribution on the plasma membrane as can be noted in the case 
of glycoprotein IV (CD36) [339]. ADP-stimulation causes an enhancement in 
fibrinogen internalization in platelets [333]. Megakaryocytes but not platelets can 
endocytose plasma-derived factor V, a member of the coagulation cascade, via a 
clathrin-dependent and most likely receptor-mediated process [342], although factor 
V is a known to platelet protein part of the alpha granule repository, where it 
colocalizes with fibrinogen [341].  
Quantitative proteomic analyses have shown platelets to carry most of the proteins 
that are part of the clathrin-mediated endocytic machinery, including all three 
isoforms of the mechanochemical small GTPase Dynamin, Dynamin1 (DNM1), 
Dynamin2 (DNM2) and Dynamin3 (DNM3) [200, 343]. Human platelets contain all 
three isoforms, DNM1, DNM2 and DNM3 while mouse platelets predominantly 
express DNM2. Dynamin plays a key role in clathrin-coated vesicle fission. 
Interestingly they have been shown to play a role in megakaryopoiesis, especially 
DNM3 [344-345]. DNM3 co-localizes to the demarcation membrane system (DMS), 
which serves as a membrane reservoir during proplatelet formation in the 
megakaryocytes [345]. In several human macrothrombocytopenia disorders, the 
nonmuscle myosin IIA (MYH9) protein important for cytoskeletal reorganization, 
appears to be mutated [346] and DNM3 has been shown to bind MYH9 [345]. In vitro 
use of pan-Dynamin inhibitor such as Dynasore in megakaryocytes impaired 
proplatelet formation [347]. In fact, GWAS studies corroborate the importance of 
DNMs in regulating platelet size and formation when a single nucleotide 
polymorphism (SNP) within the DNM3 gene promoter was detected to be associated 
with variable mean platelet volume in humans [347].  
Platelets have an abundance of DNM2 [200] and mutations in DNM2 have been 
associated with thrombocytopenia and hematopoietic diseases, most notably 
Charcot-Marie-Tooth disease [348-349]. Using platelet-specific DNM2 knockout mice, 
the role of DNM2 in thrombopoiesis was determined by Bender et al. [22]. These 
mutant mice had severe macrothrombocytopenia with giant platelets but increased 
clearance from circulation leading to low platelet counts. Bone marrow 
megakaryocytes had altered demarcation membrane system packed with 
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abnormally high numbers of clathrin-coated vesicles in addition to increased 
emperipolesis (presence of intact nucleated cells within the MK cytoplasm). 
Compared to control MKs, the clathrin-mediated endocytic pathway was also 
impaired in this DNM2-null MKs as noted by mislocalization of early endosomal 
markers such as Early Endosomal Antigen 1 (EEA1) and Adaptor protein, 
Phosphotyrosine interacting with PH domain and Leucine Zipper 1 (APPL1). 
Proplatelet formation from DNM2-null MKs was also impaired as was 
Thrombopoietin receptor (TPO/Mpl) endocytosis in DNM2 null platelets leading to 
constitutive phosphorylation of downstream Janus Kinase 2 (JAK2). Constitutive JAK2 
signaling is consistent with defective endocytosis that is seen in these platelets. 
Additionally, DNM2 null mice developed MK hyperplasia, myelofibrosis, 
extramedullary hematopoiesis and splenomegaly with a concomitant increase in 
hematopoietic stem progenitor cells [22].  
DNM1 levels are very low in platelets and it is mainly expressed in the brain where it 
functions in synaptic vesicle endocytosis [350].  
Dynamin-related protein-1 (Drp1) belongs to the Dynamin family of small GTPases 
and plays a key role in mediating fission and fusion during mitochondrial biogenesis 
[352]. Platelets contain Drp1, which gets phosphorylated upon activation [351]. Drp1 
plays a key role in fusion pore stability and granule exocytosis. Inhibition of Drp1 
affects platelet accumulation during thrombus formation in vivo. Any role of Drp1 in 
mediating endocytic events in platelets is currently unknown. 
Disabled-2 (Dab2) is a clathrin, AP-2, and cargo binding adaptor protein that is 
involved in endocytic trafficking of many cell surface receptors and modulating 
intracellular signaling [353]. Alternate splicing generates two isoforms, p82-Dab2 and 
p59-Dab2 [354]. Dab2 is present in megakaryocytes and platelets and plays a key 
role in facilitating megakaryocytic differentiation [355, 358] with p82-Dab2 mainly 
expressed in human platelets while p59-Dab2 is predominant in mouse platelets 
[356]. In human platelets, p82-Dab2 is present in the cytosol and alpha granules and 
interacts with the cytoplasmic tail of αIIbβ3, gets phosphorylated by thrombin and 
upon thrombin stimulation of platelets, gets secreted but remains tethered to the 
αIIb subunit, regulates fibrinogen binding and platelet aggregation [357]. In mouse 
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platelets, p59-Dab2 is required for platelet aggregation, fibrinogen uptake, RhoA-
ROCK activation, secretion of ADP and αIIbβ3-mediated platelet activation [356]. 
Platelet-specific Dab2-deficient mice have a bleeding diathesis and defective 
thrombus formation in vivo [356]. Dab2 is a key modulator of integrin inside-out 
signaling in platelets and plays key roles in fibrinogen uptake; however the exact 
mechanistic underpinnings of how Dab2 acts, which proteins of the clathrin-
mediated endocytic pathways it interacts within platelets, remains unknown and 
needs to be further explored. 
ADP-ribosylation factor 6, Arf6, is a small GTPase from the ARF family of proteins 
that oversee endocytic trafficking and receptor recycling and has been shown to be 
involved in several steps of trafficking such as recruitment of coat proteins, coated 
pit assembly, vesicle fission, and vesicle route [359, 366]. Our group was the first to 
show the presence of Arf6 in platelets [360]. There are six members of the Arf family, 
with Arf1, Arf3, and Arf6 being present in platelets [200, 360]. In platelets, ASAP1, a 
member of the family of ArfGTPase-activating proteins (Arf-GAPs), proteins that 
induce hydrolysis of GTP bound to Arf, was detected and shown to be recruited to 
peripheral focal adhesions via CrkL, an SH2 and SH3 adaptor protein for WASP, Syk 
and STAT5 [361, 364, 367].  Previous work by our group has shown that in resting 
platelets, Arf6 is present in the GTP-bound form, and upon platelet activation, Arf6-
GTP is quickly converted to Arf6-GDP [360]. This transition is regulated by two waves 
of platelet signaling pathways, primary signaling (e.g. PAR receptor, GPVI) and 
contact-dependent signaling (e.g. αIIbβ3 integrin) [363]. This was in corroboration to 
previous studies showing the involvement of Arf6 in regulating integrin function in 
platelets [361-362]. Blocking integrin αIIbβ3 outside-in signaling could partially 
reverse the loss of Arf6-GTP, suggesting a regulation of Arf6 by signaling downstream 
of integrin αIIbβ3. Arf6 is downstream of several key platelet kinases, like PLC, PI3K, 
PKC, and Syk, indicating its importance in platelet signaling [364]. Using an inhibitory, 
myristoylated Arf6 N-terminal peptide, loss of Arf6-GTP could be blocked in human 
platelets, probably due to the inhibition of the Arf6 GAP activity by the peptide. 
Pretreatment with this peptide inhibited platelet aggregation, adhesion and 
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spreading on the collagen-coated surface, and activation of Rho family members, 
suggesting the central role of Arf6 in platelet activation [363].  
The endocytic trafficking function of Arf6 has been widely recognized in other cells 
[366]. In platelets, Arf6 was suggested to be involved in P2Y12 receptor 
internalization required for receptor desensitization and resensitization to ADP. It 
was shown that P2Y activation by ADP could stimulate Arf6 activation, and activated 
Arf6 stimulates Nm23-H1, a nucleoside diphosphate kinase, which in turn promotes 
dynamin-dependent internalization of P2Y receptors [150]. It was also proposed that 
Arf6-GTP in resting platelets is maintained by cytohesin-2, an Arf–guanosine 
exchange factor (Arf-GEF) protein, and upon platelet activation, PKC-mediated 
phosphorylation of cytohesin-2 decreases the interaction between Arf6-GTP and 
cytohesin-2, leading to loss of Arf6-GTP and platelet secretion [365]. However, it 
should be noted that these studies used Myr-Arf6 peptide and pharmacological 
inhibitors, and the dynamics of Arf6-GTP changes were not consistent with previous 
reports. 
To better understand the role of Arf6, a platelet-specific (PF4-Cre)-Arf6 conditional 
knockout mice were generated [19]. Arf6 null platelets have defective αIIbβ3-
mediated fibrinogen uptake in vitro and in vivo. Although resting and activated levels 
of αIIbβ3 were unchanged, Arf6 null platelets demonstrated enhanced spreading on 
fibrinogen-coated surfaces and the rate of thrombin-induced clot retraction, in the 
presence of fibrinogen, was faster than controls. Arf6 null platelets had no overt 
morphological defects, no secretion defects or aggregation defects. Tail bleeding 
times were normal and no occlusion defect was noted in the FeCl3-induced carotid 
artery injury model of arterial thrombosis. Taken as a whole, the noted defects in the 
Arf6 null mice could be largely attributed to altered integrin trafficking and serves as 
a viable model to study endocytic trafficking in platelets and megakaryocytes. While 
Arf6-mediated integrin trafficking largely affects platelets’ roles in acute platelet 
functions such as clot retraction and spreading, it remains to be seen what other 
platelet functions are influenced by Arf6. 
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Role of integrin trafficking in platelets 
As mentioned previously, integrins are one of the major platelet receptors and their 
function is essential for hemostasis and thrombosis. While trafficking of integrin 
heterodimers between the plasma membrane and the intracellular endosomal 
compartments is a key aspect of regulating integrin function [376], most notably in 
the context of cell migration [382-383], how much of this process occurs in platelets, 
what are the regulators for said process and the potential biological ramifications of 
integrin trafficking in platelet function still remains to be fully explored.  
Mechanistically, integrin endocytosis occurs both in a clathrin-dependent and a 
clathrin-independent manner. α5β1 and αvβ3 integrins endocytose via both clathrin-
dependent endocytosis [377-379] and caveolin-dependent endocytosis [380] while 
αIIbβ3 mainly prefers a clathrin-dependent endocytic pathway [381]. After 
internalization, integrins are recycled back to the plasma membrane via two 
temporally and spatially distinct mechanisms, a short-loop and a long-loop recycling. 
After reaching early endosomes, integrins such as αvβ3, selected for short-loop 
recycling are sorted to particular subdomains of these endosomes and then rapidly 
returned to the plasma membrane in a Rab4-dependent manner [385]. Alternatively, 
integrins β1, αvβ3, and α6β4 may pass from EEs to the recycling endosomes, from 
where they return to the plasma membrane under control of the Rab11 GTPase, 
referred as long-loop recycling [384]. These trafficking routes are under the control 
of several regulators such as Arf6 and signaling kinases such as PKB/Akt, GSK3β as 
well as several isoforms of Protein Kinase C [384].  
Integrin trafficking plays an important role in cell adhesion and migration. As such, 
inhibition of long-loop recycling events by targeting Rab11, Arf6 etc., impairs cell 
migration and motility in a number of different cell types [386]. Selective inhibition 
of the short-loop recycling of integrin αvβ3 by using dominant-negative Rab4 leads to 
impaired spreading on vitronectin-coated matrices in an ERK1-dependent manner 
[387]. Additionally, it has been demonstrated that treating cells with primaquine 
inhibits receptor recycling and leads to accumulation of integrins within endosomes 
with the consequent detachment of cells from the substratum [385]. Integrin 
trafficking also plays a key role in tumor cell invasiveness with several reports of 
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regulators such as Arf6 and Protein Kinase D1 abounds in the invadopodia of 
aggressive tumor cells [388-389]. 
In platelets, studies regarding integrin recycling have been mainly focused on how 
αIIbβ3 is trafficked in and out of platelets. While the concept of αIIbβ3 transiting back 
and forth between the plasma membrane and intra-platelet compartments has been 
largely recognized for close to three decades, the mechanistic understanding is still 
far from complete. Fibrinogen, part of the alpha granule repository in platelets, 
enters via binding to αIIbβ3, transits through the multivesicular bodies and ends up in 
alpha granules [17, 41]. Therefore, fibrinogen content in α-granules is a good 
indicator of trafficking of integrin αIIbβ3. This has been exploited to determine the 
intricacies of the process of integrin αIIbβ3 trafficking in platelets. One of the first 
insights into this process came from the studies using the molecule c7E3 Fab 
fragment, an antagonist of integrin αIIbβ3, commercially available as abciximab [390]. 
One of the startling findings of this study was that trafficking of αIIbβ3 in platelets is 
very fast where they showed that abciximab or c7E3 Fab, could be detected within 3 
hours post-infusion into a patient. Consistently, it requires much shorter time for 
abciximab to be detected in vitro after incubation with washed platelets. Open 
canalicular systems (OCS) were stained as early as 1 min showing that indeed 
trafficking of αIIbβ3 is very fast. This is in agreement with the widely held theory in 
the platelet field that the open canalicular system, which serves as a membrane 
reservoir for platelets, is the entry site for the endocytosis of various exogenous 
substances [391]. Studies using monoclonal antibody AP6, which binds to integrin 
αIIbβ3 only when the receptor is occupied by intact fibrinogen, suggested the 
presence of a pool of ligand-bound αIIbβ3 within the α-granules [392]. Platelet 
activation by ADP or thrombin receptor activation peptide (TRAP) significantly 
increases the actin cytoskeleton-dependent internalization of αIIbβ3 [335]. Studies 
using an anti-Ligand-induced binding site (anti-LIBS) antibody, which activated αIIbβ3 
by directly binding to it, showed that enhanced integrin internalization directly 
modulates platelet aggregation [393]. Our recent studies have now added to this 
growing body of integrin trafficking and its importance in platelet function. Arf6, a 
Ras-like, small guanosine triphosphate (GTP)-binding protein called adenosine 5’-
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diphosphate ribosylation factor 6 (Arf6), which is important for intracellular 
trafficking of integrins and membrane receptors, mediates fibrinogen endocytosis 
and trafficking of αIIbβ3 in platelets [19]. Loss of Arf6 leads to defective fibrinogen 
uptake and storage which manifests in enhanced platelet spreading and clot 
retraction. This could potentially be due to faster short-loop recycling of αIIbβ3, which 
could explain why αIIbβ3-bound fibrinogen resides for less time (compared to 
wildtype) within the intra-platelet compartments that are manifested as lower 
fibrinogen content of Arf6 KO platelets. Altered dynamic routing of αIIbβ3 could lead 
to enhanced surface presence of the integrins which may allow more areas of 
contact with fibrinogen-coated matrices corresponding to enhanced spreading. This 
coupled with faster thrombin-induced clot retraction could predispose Arf6 KO mice 
to become hyper thrombotic in nature. While this hyper thrombotic phenotype 
could not be detected in standard models of arterial thrombosis due to technical 
redundancies of the assays involved, it does shed some light on the global 
importance of integrin trafficking and recycling on hemostasis and thrombosis. Arf6 
KO mice do not have a secretion defect or a bleeding phenotype, yet altered integrin 
trafficking leads to defective cargo uptake and a predisposition to hyperthombosis 
(though this remains to be confirmed yet). In summary, Arf6-mediated integrin αIIbβ3 
trafficking occurs constitutively in platelets and appears to play an important role in 
the deposition of α-granule cargo, like fibrinogen, and in the modulation of other 
integrin-mediated platelet functions, like spreading, clot retraction. In my thesis, 
Arf6 null mice are used as a model system to understand how endocytosis and 
potentially integrin trafficking influences other platelet functions e.g., mediating 
innate immune responses against pathogens.  
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Figure 2 
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Figure 2 Potential platelet endocytic routes. Cargo can enter platelets either via 
clathrin-dependent endocytosis, requiring GTP hydrolysis by Dynamin and using 
specific surface receptors (e.g., αIIbβ3-mediated fibrinogen entry) or via clathrin-
independent endocytosis that may require Dynamin (via caveolin- or RhoA-
dependent pathways) or may not (via Arf6- or Cdc42-dependent pathways). 
Internalized cargo then transits through Rab4 GTPase-positive early endosomes, 
where it can be sorted to recycling endosomes (Rab 11-positive) for a return to the 
plasma membranes or to multivesicular bodies and ultimately into α-granules for 
storage (e.g., fibrinogen, vWF, thrombospondin-1). Alternatively, cargo can move 
into late endosomes, either directly from early endosomes or through multivesicular 
bodies. Cargo from late endosomes can transit into dense granules or into lysosomes 
where it may be degraded or stored. The complexity of these pathways in platelets 
has not been studied in sufficient detail.  
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Table 1:  Endocytic and sorting machinery in platelets. 
Full name of Protein* Aliases/Identifiers Abundance (copies per human platelet)& 
Clathrin-mediated endocytosis   
Clathrin Heavy Chain 1, 2 CLTC1; CLTC2 13,600; 4,300 
Clathrin Light Chain A, B CLTA; CLTB 2,800; 2,100 
AP-2 complex (α, β, σ, μ) AP-2 ND; 7,900; ND; 4,800 
AP-3 complex AP-3 3,500 
AP-4 complex AP-4 1,400 
Dynamin 1 , 2, 3 DNM1, DNM2, DNM3 5,200; 6,100; 3,600 
Endophilin A2, B2 Endo A2; Endo B2 3,500; 2,900 
Sorting Nexins (1, 2, 3, 4, 5, 
6, 7, 8, 9, 24, 29, 30) 
SXN 1,500; 5,100; 8,500; 1,400; 1,700; 2,300; 1,400; 730; 1,900; 
1,800; 810; 1,100. 
Clathrin-independent endocytosis   
Ras-related C3 botulinum 
toxin substrate 1, 2 
Rac1; Rac2 32,900; 27,900 
Cell division control protein 
42 homolog 
Cdc42 27,900 
ADP-ribosylation Factor 1, 3, 
4, 5, 6 
Arf1, Arf3, Arf4, Arf5, 
Arf6 
49,800; 44,300; 33,300; 36,200; 6,400 
Flotillin-1, 2 FLOT-1; FLOT-2 7,500; 6,000 
Rab GTPases  
Rab 1A, 1B, 2A, 2B, 3, 4, 5, 
6A, 6B, 7, 8A, 8B, 9, 20, 21, 
30, 31, 32, 33, 35, 37, 38 
 27,700; 26,000; 11,600; 7,400; 11,200; 23,200;  7,700; 20,900; 
27,500; 18,800; 17,900; 16,100; 2,500; 1,500; 5,600; 4,700; 
2,200; 8,900; 2,000; 5,600; 9,200; 4,400 
Protein Sorting Complexes  
Vacuolar Protein Sorting-
associated protein 4A , 4B, 
11, 13A, 13B, 16, 26A, 26B, 
28, 29, 33A, 33B, 35,  
VPS 4A; VPS 4B; VPS11; 
VPS 13A, VPS 13C; VPS 
16; VPS 26A, VPS 26B; 
VPS 28; VPS 29; VPS 33A; 
VPS 33B; VPS 35; VPS 36; 
VPS 37A; VPS 37B; VPS 
41; VPS 45; VPS 52 
2,900; 4,300; 1,100; 2,000; 1,600; 1,500; 1,100; 3,100; 3,600; 
4,800; 1,700; 2,100; 4,600; 2,500; 2,900; 1,900; 810; 2,200; 
900;  
Neurobeachin-like 2 protein NBEAL2 3,000 
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Other  
Early Endosome Antigen-1 EEA-1 1,700 
Lysosomal Associated 
Membrane Protein-1, 2 
LAMP-1; LAMP-2 3,000; 2,000 
Vacuolar Protein Sorting-
associated protein 33B 
Interacting Protein  
VIPAR 1,200 
Calreticulin CALR 20,300 
Calnexin CANX 10,400  
Calmodulin CaM 15,600 
*Listed are human platelet proteins that may contribute to endocytosis and/or subsequent 
cargo-sorting events. 
&Included are copy numbers, estimated based on quantitative proteomic analyses [200] . 
ND= Not determined. 
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Subsection Three: Vesicle-associated membrane protein 3 (VAMP-3/Cellubrevin) 
VAMPs in platelets 
Platelets contain multiple isoforms of the Vesicle-associated Membrane Proteins or 
VAMPs (VAMP-2,-3,-4,-5,-7,-8), based on data gleaned from proteomic analyses and 
quantitative Western blotting [199-200]. In terms of a number of copies per platelet, 
VAMP-8 and VAMP-7 are the most abundant in human platelets while VAMP-8, 
VAMP-2, and VAMP-3 are the major ones in mouse platelets. VAMP-8 which is the 
most abundant in both mouse and human platelets is the primary v-SNARE to 
mediate secretion. Loss of VAMP-8 attenuates secretion from all three granules, 
causes defective thrombosis (thrombus growth is slower and lessened in comparison 
to WT) with no bleeding diathesis [199, 201]. Loss of VAMP-3 by itself had no defect 
in secretion and hemostasis proceeded normally as measured by tail bleeding assay 
[202]. Loss of VAMP-2 is embryonic lethal [201]. Treatment of tetanus toxin which 
specifically cleaves VAMP-2 and VAMP-3 showed that platelet secretion is 
unaffected as long as VAMP-8 and VAMP-7 are present [201]. Loss of VAMP-7 does 
not lead to a bleeding diathesis or defects in platelet accumulation at sites of injury 
in the laser injury model of arterial thrombosis, although alpha granule secretion is 
attenuated in these platelets [203]. Collectively, these data imply that there is a 
ranking amongst the isoforms in mediating secretion with some amount of 
redundancy. VAMP-8 is primary with VAMP-2 and VAMP-3 playing secondary roles. 
VAMP-7 on the other hand may be less involved in secretion but mainly play a part in 
platelet spreading due to its interactions with the actin cytoskeleton via VPS9-
domain Ankyrin-repeat containing protein (VARP) and Arp2/3 [203]. 
Immunofluorescence studies have shown VAMP-7-dotted structures to be localized 
to the platelet periphery while VAMP-8 and VAMP-3 have been shown to be more 
centrally localized within the granulomere in spread platelets [204]. The central 
localization of VAMP-3 concurs with studies done in our lab where we reported the 
intracellular punctate staining of VAMP-3 containing structures that resist being 
targeted to the plasma membrane during thrombin activation [205]. These could 
very easily be VAMP-3 positive endosomes in platelets. Additionally, VAMP-8 and 
VAMP-7 could potentially mediate differential cargo release or may be differentially 
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responsive to various kinds of agonists. However, future studies need to be done to 
parse this distinction.  
VAMP-3 and its cellular localization 
Synaptobrevins are small, highly conserved integral membrane proteins that are part 
of the Vesicle-Associated Membrane Protein (VAMP) family and are abundantly 
found in synaptic vesicles within the brain [394-395]. VAMP-3 is a type of 
synaptobrevin that is ubiquitously expressed in all cells and was thus named 
cellubrevin as the cellular homolog of synaptobrevins [396]. Like synaptobrevins, 
which are targets of clostridial neurotoxins such as tetanospasmin, a protein from 
Clostridium tetani, and botulinum toxin, from Clostridium botulinum [397-398], 
cellubrevin/VAMP-3 is also cleaved by tetanus toxin substrate [396]. Using 
immunofluorescence and subcellular fractionation techniques, VAMP-3 was shown 
to be intracellularly localized to all parts of the cell with a localized concentration in 
and around the Golgi complex. Using transferrin receptor (Tfn-R) as a marker for a 
recycling receptor, it was shown that while all transferrin-positive vesicles stained for 
VAMP-3, not every VAMP-3-positive vesicles stained for transferrin [396]. This 
suggested that VAMP-3 is a component of receptor-mediated endocytosis pathway 
and is present on coated vesicles that recycle transferrin as well as other similar 
vesicles. In Chinese hamster ovarian (CHO) cells transfected with synaptophysin, 
VAMP-3 was shown to colocalize with synaptophysin, which in turn associated with 
the transferrin receptor and is targeted to the receptor-mediated endocytic pathway 
[396, 399-400]. VAMP-3 was also shown to reside in insulin-sensitive GLUT4 glucose 
transporter vesicles in 3T3-L1 adipocytes and is a part of the insulin-regulated 
membrane trafficking pathways [401]. Furthermore, subcellular fractionation of 
pancreatic acinar cells revealed VAMP-3 to be present on the smooth microsomal 
fraction consisting of small vesicles and condensing vacuoles that originate from the 
Golgi complex, indicating a possible role in the maturation of secretory granules 
within these cells [402]. Transferrin receptor recycling has been instrumental in 
shedding light regarding the subcellular localization of VAMP-3. Following the entry 
routes of Tfn-R in CHO cells using immunofluorescence microscopy, showed that 
upon internalization, Tfn enters the early endosomes that stain positive for both 
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VAMP-3 and Rab4, which marks early endosomes. Soon after that, Tfn moves into a 
subset of pericentriolar cluster or tubules and vesicles that are now referred to as 
the recycling endosomes, which stain positive for VAMP-3 but not Rab4. These 
endosomes instead stained positive for another Rab GTPase called Rab11. These 
Rab11-VAMP-3 double positive vesicles transiently accumulate Tfn inside the cells on 
its route back to the plasma membrane [403].  
Role of VAMP-3 in receptor trafficking 
VAMP-3 has been shown to be concentrated in vesicles which recycle transferrin 
receptors but its role in membrane trafficking and fusion was demonstrated by the 
use of tetanus toxin, a metallo-endoprotease that cleaves VAMP-3 (and VAMP-2) 
which partially blocked transferrin release in CHO cells [404]. Like Tfn-R, the 
intracellular glucose transporter 4 (GLUT4)-containing vesicles dock and fuse with 
the plasma membrane to facilitate insulin-controlled glucose uptake in muscle and 
fat cells. GLUT4 colocalizes with both VAMP-3 and VAMP-2 (both synaptobrevin type 
vesicle SNAREs that are tetanus toxin-sensitive) and tetanus toxin treatment 
inhibited insulin-stimulated GLUT4 translocation to the plasma membrane [405]. 
Furthermore, overexpression of VAMP-3, but not VAMP-2, in HL-1 atrial 
cardiomyocytes, prevented lipid-induced inhibition of insulin-stimulated GLUT4 
translocation from the intracellular stores to the plasma membrane, in an in vitro 
model of cardiac insulin resistance [406].  
VAMP-3 has also been implicated in the trafficking of a host of other plasmalemma 
receptors such as translocation of Na+/K+/2Cl- co-transporter (NKCC2) to the apical 
surface of the renal cells of the thick ascending limb in kidney and is required for 
NaCl absorption and regulation of blood pressure [407]. VAMP-3 regulates recycling 
of glutamate transporters in mouse cortical astrocytes, which express VAMP-3 but 
not VAMP-2, and as a result, plays a key role in Ca2+-independent recycling of these 
receptors to the surface and glutamate uptake by astrocytes [408]. VAMP-3, in 
association with the small GTPase, Rab8, regulates recycling of T-cell receptors (TCR) 
by interacting with IFT20, a component of the intraflagellar transport (IFT) system 
that modulates ciliogenesis and immune synapse assembly in non-ciliated T cells 
[409]. In dendritic cells, cross-presentation of peptides derived from phagocytosed 
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microbes, infected cells, or tumor cells to CD8+ T cells requires the action of VAMP-
3/VAMP-8/Rab11-positive endosomal recycling compartments that carry major 
histocompatibility complex I (MHC class I) receptors to fuse with phagosomes, which 
drives Toll-Like Receptor activation in response to infection [410]. Endosomal TLRs 
such as TLR7 and TLR9 that bind viral nucleic acids traffic to distinct endomembrane 
systems, namely VAMP-3-positive and LAMP-positive endosomes, for signaling [411]. 
This bifurcation of the TLRs to separate compartments allows for cytokine and type I 
interferon gene induction. Studies in RAW264.7 cells showed the involvement of the 
phosphatidylinositol 3P 5-kinase, PIKfyve, to mediate selective trafficking of TLR9 to 
VAMP-3 positive endosomes. Blocking PIKfyve activity of disruption of VAMP-3 by 
tetanus toxin, lead to a reduction in trafficking of TLR9 and consequent reduction in 
type I interferon induction [412]. 
Role of VAMP-3 in vesicle trafficking 
As discussed earlier, VAMP-3 dots the early and recycling endosomes and is essential 
for recycling of several plasma membranes and endomembrane receptors. On the 
same vein, VAMP-3 is also crucial for targeting of vesicles to specific locations within 
the cell. Autophagosomes are specialized double-membraned organelles where 
degradation of intracellular macromolecules, RNA and protein turnover as well as 
damaged organelles takes place [413]. Cargo that is destined for the 
autophagosomes passes through the sorting hubs or the Multivesicular bodies 
(MVBs) and several reports have shown that these MVBs can fuse with 
autophagosomes to form a pre-lysosomal hybrid organelle called the amphisome 
[414]. A mature amphisome can then fuse with the lysosome to form the 
autolysosomal organelle where the actual degradation of cargo occurs. Several 
SNAREs have been implicated in mediating one or more steps of these concerted 
vesicle trafficking. Key among those is VAMP-3 that oversees fusion of the MVBs 
with the autophagosomes to generate the mature amphisome. VAMP-7, another key 
v-SNARE involved in vesicle trafficking, comes into play after amphisome formation 
step and is responsible for fusing the amphisome to the lysosome. VAMP-3, however, 
does not play any role in this step [415].  
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Role of VAMP-3 in phagocytosis 
Phagocytosis or the engulfment of pathogens is an important immune response. This 
mode of entry of cargo (pathogens) can be receptor-mediated as it is in 
macrophages and require membrane expansion at the site of phagocytosis and 
several key intracellular trafficking steps. Not only is membrane trafficking in 
macrophages required for pathogen phagocytosis but it also stimulates 
proinflammatory cytokine secretion. VAMP-3 heads a trafficking pathway that 
oversees both these actions thereby ensuring efficient immune responses in 
macrophages; this pathway follows tumor necrosis factor α (TNF-α) being trafficked 
from the Golgi complex to the VAMP-3-positive recycling endosomes. TNF-α 
containing recycling endosomes are then targeted to the plasma membrane where 
the phagocytic cup forms allowing the concomitant rapid release of TNF-α and 
expansion of the membrane to engulf the pathogen [416]. VAMP-3 has also been 
shown to play a role in phagosome maturation which causes phagosomes containing 
pathogens to fuse with the lysosomes to form the phagolysosomes, using 
Mycobacterium tuberculosis var. Bovis BCG, an organism that causes phagosomal 
maturation arrest upon entering phagosomes. This allows the bacterium to evade 
lysosomal degradation. Inhibition of VAMP-3 leads to disruption in mycobacterial 
phagosomes, overcoming this arrest and thereby causing degradation of the 
pathogen in the lysosomes and protecting against mycobacterial infection [417]. In a 
process similar to phagocytosis, bacterial invasion of cells, also involves membrane 
expansion at the host cell plasma membrane where the bacteria invade. In 
Salmonella typhimurium infections, VAMP-3 has been shown to accumulates at sites 
on the plasma membrane where the bacteria invades and this accumulation leads to 
membrane protrusions in an N-ethylmaleimide-sensitive factor (NSF)-independent 
manner [418]. Though VAMP-3 does indeed play a role in phagocytosis and recycling 
of receptors, bone-marrow derived macrophages (BMM) from VAMP-3 null mice 
showed no defects in phagocytosis of IgG-beads, complement-opsonized particles, 
or latex microspheres although zymosan internalization was found to be significantly 
slower than wild-type [419]. In fact, in primary mouse embryoblast isolated from 
VAMP-3 null mice, rates of transferrin internalization (endocytosis), transferrin 
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release (recycling) and horse-radish peroxidase (HRP) uptake (pinocytosis) were 
essentially unchanged compared to wild-type [420]. Insulin-dependent glucose 
uptake in isolated primary adipocytes as well as insulin-, hypoxia-, and exercise-
stimulated glucose uptake in isolated skeletal muscle cells from VAMP-3 null mice 
were unchanged compared to wildtype [420]. Taken as a whole, it appears that 
VAMP-3 is necessary for phagocytic uptake of pathogens as well as cargo 
(receptors/macromolecules) in some cells while in others, other VAMPs such as 
VAMP-2 can play compensatory roles to tide over any possible defects caused by loss 
of VAMP-3. 
Role of VAMP-3 in exocytosis 
VAMP-3, being a v-SNARE, partners with cognate SNAREpins such as the t-SNAREs 
(SNAP-23/SNAP-25 and syntaxins) to mediate vesicle fusion during intracellular 
trafficking events as well as during granule/vesicle exocytosis. VAMP-3 usage for the 
sake of release of granule cargo varies from cell to cell. Some cells require VAMP-3 
for exocytosis while others do not. In mast cells, VAMP-7 or VAMP-8, but not VAMP-
3 or VAMP-2, are required for high-affinity IgE receptor-mediated histamine release 
[421]. Trafficking and secretion of matrix metalloproteinases (MMPs) determine 
cellular remodeling of the extracellular matrix (ECM). Studies done in invasive human 
fibrosarcoma cell lines HT-1080 showed that inhibition of SNAP-23 and VAMP-3 by 
using dominant-negative forms of these SNAREs, RNAi treatment or Tetanus toxin-
mediated cleavage of VAMP-3 leads to a reduction in the secretion of MMP2 and 
MMP9 as well as impaired trafficking of membrane type I MMP to the cell surface 
[422]. Blocking of these SNAREs also led to less invasiveness of the HT-1080 cell lines 
on gelatin substrates in vitro.  
In endothelial cells, Weibel-Palade Bodies (WPB) are the storehouses of the 
thrombogenic glycoprotein von Willebrand Factor (vWF). At the site of damage, 
endothelial cell activation triggered by thrombin or histamine leads to Ca2+-, and 
SNARE-dependent exocytosis of WPBs to release vWF into the vessels that in turn 
leads to platelet adhesion via the GPIb-IX-V complex and thrombus formation. Both 
VAMP-3 and VAMP-8 are present on WPBs; yet only VAMP-3 is required for forming 
stable SNARE complexes with plasma membrane syntaxin 4 and SNAP-23 to drive 
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membrane fusion of WPB to release vWF. Using mutant VAMP-3 and VAMP-8 
comprising of the cytoplasmic domains of the proteins, it was noted that only VAMP-
3 but not VAMP-8 inhibits with vWF release in permeabilized endothelial cells [423]. 
Cytotoxic granules containing granzymes and perforin are important for killing viral 
infected and transformed host cells by natural killer (NK) cells. The release of 
inflammatory cytokines such as TNF-α and IFN-γ is also mediated by exocytosis of 
these cytotoxic granules through SNARE-mediated pathways. Studies in NK cells have 
shown that granules that contain perforin and granzymes are different from the 
ones that contain cytokines such as TNF-α and IFN-γ. The vesicles that contain these 
cytokines are actually recycling endosomes and release of cytokines from these is 
mediated by Rab11 and VAMP-3 [424]. Inactivation of recycling endosomes or 
mutating Rab11 or inactivating VAMP-3 by tetanus toxin treatment or mutant 
versions of VAMP-3 impaired TNF-α and IFN-γ release from NK cells. VAMP-3, 
together with SNAP-23, has also been shown to be involved in the release of IL-6 and 
TNF-α in an SNARE-dependent, IL-1β-stimulated exocytosis event from human 
synovial sarcoma cell lines SW982 [425]. 
Role of VAMP-3 in cell migration 
Cell migration is a highly-regulated pathway of cell polarization that involves both 
endocytosis and exocytosis to drive membrane protrusion at the leading edge of the 
cell, adhesion of the leading edge and de-adhesion at the cell body and rear end 
followed by cytoskeletal contractions to pull the cell and move it in the direction of 
the stimulus. As with any membrane trafficking/fusion events, SNAREs play a key 
role in mediating membrane trafficking in cell migration. Inhibiting SNARE-mediated 
membrane traffic by using a dominant-negative form of the enzyme NSF and Tetanus 
toxin-mediated cleavage of VAMP-3 leads to reduced serum-induced migration of 
CHO-K1 cells in transwell migration assays with a concomitant reduction in cell 
surface α5β1 integrins [426]. This study was closely followed by Thierry Galli’s group 
who also showed that Tetanus toxin-mediated cleavage of VAMP-3 impairs epithelial 
cell migration and β1 integrin-dependent cell adhesion [427]. Tetanus toxin cleavage 
of VAMP-3 also led to enhanced adhesion of epithelial cells (CHO cells) to collagen, 
laminin, fibronectin and E-cadherin matrices with altered spreading on collagen-
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coated surfaces due to impaired recycling of β1 integrins. siRNA-induced silencing of 
VAMP-3 in CHO cells also leads to a similar reduction in chemotactic cell migration 
without affecting cell proliferation [428] agreeing with previous reports. Recycling of 
adhesion receptors is crucial for lamellipodia formation at the leading edge of a 
migrating cell. VAMP-3 containing recycling endosomes is incorporated into the 
leading edge to bring about the expansion of the lamellipodia membrane in an 
SNARE-dependent membrane fusion event that also requires SNAP-23 and syntaxin 4. 
Inhibition of VAMP-3 by tetanus toxin showed that fusion of recycling endosomes is 
necessary for lamellipodia formation and delivery of the α5β1 integrins present on 
the recycling endosomes to the cell surface necessary for efficient cell migration 
[429]. VAMP-3 together with SNAP-23 and syntaxin 4 has also been shown to 
regulate the formation of ring-like podosome structures that accumulate in the 
leading edge of spreading cells such as macrophages migrating on fibronectin. 
Lowering VAMP-3 levels or disrupting VAMP-3 function (or SNAP-23 or syntaxin 4) 
leads to disrupted trafficking of the recycling endosomes to the plasma membrane, 
impaired polarization of these podosome structures at the leading edge and reduced 
adhesion and spreading on fibronectin [430]. Since integrins are the major adhesion 
receptors, VAMP-3 mediated trafficking of integrins plays an essential role in 
regulating cell migration and by extension proliferation and survival. Surface 
expression of integrins is controlled by SNARE-mediated endo-exocytic recycling. 
While VAMP-3, by virtue of being present on recycling endosomes, does play a key 
role in this process, what determines the specificity of regulating one integrin 
trafficking event versus another often depends on the t-SNARE partners it pairs with.  
This also determines whether a particular integrin recycles directly back to the 
plasma membrane from the recycling endosomes or traverses through the trans-
Golgi network (TGN) before it reaches its cell surface destination. For example, 
syntaxin 6, a t-SNARE located in the trans-Golgi network, pairs with VAMP-3 to 
mediate trafficking of α3β1 integrins from the recycling endosomes to the TGN 
before being recycled to the plasma membrane surface in epithelial cells [431].  
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VAMP-3 and its role in platelets 
The presence of VAMP-3 in human platelets was first reported by our group [205]. 
Termed as human Cellubrevin (Hceb) was present in detergent-solubilized platelet 
membranes and participated in α-SNAP-dependent 20S SNARE complex formation 
and ATP-dependent 20S SNARE complex disassembly thereby functioning as a v-
SNARE in human platelets. Immunofluorescence microscopy showed an intracellular 
punctate staining in human platelets, megakaryocytes and HEK-293 cells agreeing 
with previous reports of how cellubrevin/VAMP-3 is located on endosomes/vesicles 
within the cell. This was confirmed when thrombin-stimulated human platelets 
resisted targeting of these Hceb-positive punctate structures to the plasma 
membrane even though all dense core and most alpha granules had been released. 
This was the first indication showing that VAMP-3 could be present on an endosomal 
organelle that is not part of the exocytic pathway in platelets. This was further 
corroborated by immunogold labeling which showed that almost 80% of VAMP-3 in 
resting human platelets was localized to platelet granule membranes including alpha 
granules [206]. The role of VAMP-3 in mediating platelet secretion was first 
monitored by introducing anti-VAMP-3 antibody in streptolysin-O-permeabilized 
platelets which resulted in a 50% reduction of Ca2+-induced alpha granule secretion, 
an effect that could be reversed by using a VAMP-3 blocking peptide [206]. These 
studies were further expanded upon by others to demonstrate the role of VAMP-3 in 
mediating secretion in human platelets. VAMP-3 and VAMP-8 were both shown to 
coimmunoprecipitate with syntaxin 4 and SNAP-23 in human platelets using 
microcapillary reverse-phase high-performance liquid chromatography-nano-
electrospray tandem mass spectrometry [433]. Introducing soluble recombinant 
VAMP-3 into streptolysin-O-permeabilized platelets led to a dramatic reduction in P-
selectin exteriorization from alpha granules as measured by flow cytometry and C14-
serotonin from dense granules as measured by radioactivity. This led to the idea that 
VAMP-3 together with SNAP-23 and syntaxin forms fusogenic SNARE complexes that 
drive granule secretion in human platelets. 
Insulin largely recognized for its role in glucose homeostasis, acts as a vasodilator in 
the vasculature in a nitric oxide synthase (NOS)-dependent manner, in part by 
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enhancing platelet-endothelial NOS activity [434]. Insulin works by inducing ATP, 
adenosine, and serotonin release from dense granules in an NO-dependent manner, 
a response that is abolished in NOS null platelets [433]. Similarly, insulin stimulation 
of human platelets requires SNAP-23/syntaxin t-SNARE heterodimers to associate 
with VAMP-3 to form the functional SNARE complexes that drive ATP release from 
dense granules via an NO-G kinase-dependent signaling cascade that is independent 
of αIIbβ3 activation [433]. 
Surprisingly, platelets isolated from VAMP-3 null mice showed no defect in secretion 
from all three granules (dense core, alpha granules, and lysosomes) tested in 
response to thrombin and collagen in both kinetic (time-course) and dosage assays 
[202]. Additionally, loss of VAMP-3 did not cause any change in levels of other SNARE 
proteins. Agonist-induced platelet aggregation was also unchanged in the VAMP-3 
null platelets as was bleeding time measurements. Collectively, these data suggests 
that there is some level of heterogeneity in VAMP usage in mouse platelets versus 
human platelets; VAMP-3 is essential for secretion in human platelets while VAMP-3 
plays a subordinate role and is not required for platelet secretion in mice. However, 
what other roles VAMP-3 plays in mouse platelets needs further exploration. 
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Subsection Four: Role of platelets as immune cells  
Overview 
Platelets have been classically studied for their roles in hemostasis and thrombosis. 
What has become increasingly clear is that platelets are, in fact, multifunctional and 
can carry out several important physiological and pathophysiological processes e.g., 
wound healing, inflammatory and immune responses. From an evolutionary 
perspective, lower invertebrates such as birds, reptiles, amphibians, and fishes, 
which have an open vasculature, only contain a single primordial cell type called 
thrombocytes or hemocytes. Hemocytes are nucleated and perform both hemostasis 
and innate immune responses within the hemolymph [435]. Invertebrate hemocytes 
mediate immune responses by virtue of bearing Toll-like Receptors (TLRs) on their 
surfaces which allow pathogen recognition, phagocytosis, and secretion of 
antimicrobial peptides [436]. They can also mediate wound healing and induce 
hemolymph coagulation and clotting at sites of tissue damage in a process that is 
similar to how mammalian platelets form clots. It is thought that as vertebrates 
climbed higher up the evolutionary tree, their hemocytes lost the nuclei, retained 
most of their hemostatic and thrombosis functions and evolved into the modern-day 
mammalian platelets, while the immune-related functions were taken over the 
professional immune cells. As recent studies over the past decade bring to light more 
immune-related functions of platelets, it essentially solidifies this concept of 
platelets being the evolutionary link between the coagulation and immune 
responses, two key facets of the vascular system. How mammalian platelets mediate 
immune responses will be covered in the following sections. 
Platelet Toll-like Receptors (TLRs) 
Pathogen-sensing and subsequent innate immune responses are carried out by a 
specialized class of pattern-recognition receptors (PRR) that recognize molecules 
called pathogen-associated molecular patterns (PAMPs) broadly expressed by 
pathogens distinct from host molecules (see Table 1) and are expressed on immune 
cells such as dendritic cells, monocytes/macrophages, neutrophils, T and B 
lymphocytes. Toll-like receptors are type I transmembrane proteins possessing: 
leucine-rich repeat (LRR) ectodomains folded into beta sheets, enabling PAMPs 
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recognition, a transmembrane domain and a cytoplasmic Toll-Interleukin-1 receptor 
(TIR) domain that does signal transduction [437]. To date, 10 TLRs in humans and 13 
TLRs in mice have been identified that can recognize PAMPs such as lipids, 
lipoproteins, proteins or nucleic acids derived from pathogens (viruses, bacteria, 
parasites, fungi etc.) or from endogenous sources, either at the cell surface or within 
intracellular compartments (endosomes, lysosomes, and endolysosomes), triggering 
distinct downstream signaling cascades based on the PAMP recognized [438].  
Several reports have demonstrated the expression of TLR1-9 in both human and 
mouse platelets [439-442] and have shown that some of these TLRs (TLR2, TLR4, 
TLR7, and TLR9) are functional and can modulate platelet responses during infection 
and thus, will be discussed in depth.  
TLR2 
TLR2 primarily resides on the plasma membrane and can recognize bacterial 
lipopeptides, peptidoglycans, and lipoteichoic acid from Gram-positive bacteria, 
mycobacterial lipoarabinomannan, yeast zymosan, and viral hemagglutinin [437]. 
TLR2 can heterodimerize with TLR1 to form TLR2/1 complexes that bind triacylated 
lipopeptides or with TLR6 to form TLR2/6 that preferentially binds diacylated 
lipopeptides [437]. Platelet TLR2 binds to the adaptor protein MyD88 to trigger its 
downstream signaling cascades. In platelets, TLR2 engagement using triacylated 
lipopeptides such as Pam3CSK4 leads to activation of the PI3K/Akt signaling pathway 
[444-445] and platelet αIIbβ3 activation, aggregation, adhesion, membrane 
expression of P-selectin from alpha granules and platelet-neutrophil aggregates 
formation [443, 446]. These responses can be blocked by treatment with PI3K 
inhibitor, LY294002, or using anti-TLR2 antibodies or TLR2 knockout mice [447]. 
Platelet TLR2 stimulation by Pam3CSK4 also leads to increases in cytosolic Ca2+ 
concentrations, the release of ATP and TxA2 generation [443]. Platelet TLR2 has also 
been implicated in enhanced phagocytosis of periodontopathogens such as P. 
gingivalis by neutrophils with a concomitant increase in TLR2-activated platelet-
neutrophil aggregates and CD40L expression in platelets [448-449]. Platelet TLR2 has 
also been implicated in platelet-viral interactions chiefly with human 
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cytomegalovirus. Human cytomegalovirus interacts with platelets via TLR2, giving 
rise to pro-inflammatory cytokine production by platelets [450].  
A pivotal study by the Freedman group using the TLR2 ligand, Pam3CSK4, was the 
first to shed light on the concept of differential stimulation of platelets. Platelets 
have been traditionally thought to be fast responders to any kind of damage though 
thrombotic damage which leads to hemostasis has only been extensively studied. 
However, when platelets encounter immune damage such as those related to TLR 
activation, the response generated is both slower and more gradual than the rapid 
and maximal thrombotic stimulation of platelets [447]. Stimulation of platelets by 
Pam3CSK4 leads to a more gradual phosphorylation kinetics of Akt, p38, and ERK 
that are present downstream of TLR2 in platelets; compared to rapid and substantial 
phosphorylation kinetics of the same under thrombin stimulation. This differential 
stimulation of platelets that we have provisionally termed “hemostatic” versus 
“immune-activation” agrees with data generated in my thesis and supports this 
shifting view of platelets being more diverse in their response curves to various 
stimuli than the originally held idea of rapid activation and maximal release of cargo 
to all kinds of stimuli from platelets.  
TLR4 
TLR4 is the most abundant Toll-like receptor on platelets [441] and binds to 
lipopolysaccharides (LPS), a major component of the cell membrane of Gram-
negative bacteria. TLR4, in a complex with an adaptor protein MD-2, binds to LPS, in 
the presence of CD14 and LPS-binding protein (LBP) [451].  
LPS-induced thrombocytopenia and tumor necrosis factor-α (TNF-α) production in 
vivo is mediated by platelet TLR4-dependent pathways [439]. LPS induced a 60% 
reduction in platelet counts as early as 4 hr post-injection in wildtype mice compared 
to a 20% reduction in TLR4 KO mice. Drop in platelet counts is often due to the 
formation of platelet-neutrophil and platelet-monocyte aggregates that get trapped 
in the lungs and are thus removed from the circulation [475]. Another possible 
mechanism by which platelet numbers drop during inflammation is due to increased 
platelet destruction caused by phagocytosis [453]. 
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LPS-induced TLR4-dependent functions of platelets have been largely studied in the 
context of bacterial sepsis. Endotoxin-induced or bacterial-induced sepsis often leads 
to severe thrombocytopenia [476]. Platelet activation during sepsis contributes to 
disseminated intravascular coagulation (DIC) or the formation of microthrombi, 
which impedes blood flow to vital organs causing death by multiple organ failures 
[477]. Platelet activation during sepsis leads to the production of both pro- and anti-
inflammatory cytokines, which triggers immune responses in the circulation [478]. 
Increased platelet and leukocyte activation, often times correlate with severity of 
DIC-induced multiple organ failures during sepsis [479]. To further probe the role of 
platelets in endotoxin-induced sepsis, experimental thrombocytopenia was induced 
in mice by the in vivo administration of anti-glycoprotein Ibα monoclonal antibody 
[480] in LPS-induced endotoxemia and a bacterial infusion mouse sepsis model [481]. 
This caused increased plasma levels of pro-inflammatory cytokines such as TNF-α 
and IL-6, followed by widespread organ failure in the liver, lungs, and spleen and 
increased mortality, an effect that could be reversed significantly by transfusion of 
healthy platelets in these septic mice [481]. This was the first detailed and conclusive 
study that showed that platelets protect from septic shock, via a mechanism that 
involves inhibiting the macrophage-dependent inflammation via the cyclooxygenase 
1 signaling pathways. In another similar study the role of platelets and specifically 
how thrombocytopenia affects the outcomes in sepsis was determined [493]. It was 
shown that thrombocytopenia caused, led to worsened outcomes that manifested as 
increased mortality strongly correlating with increased bacterial burden [493]. 
Titrating platelet counts by in vivo GPIbα administration to mice showed the diverse 
effects caused on Klebsiella pneumoniae-induced sepsis; when platelet counts were 
reduced to 5 X 109/L in blood of mice infected with Klebsiella through the airways, 
they showed impaired survival with increased bacterial burden in lungs, blood and in 
distant organs such as liver as well as causing severe hemorrhaging at primary sites 
of infection. However, this led to increased cytokine production which exacerbated 
the pro-inflammatory sepsis caused by Klebsiella. On the other hand, when platelet 
counts were titrated to 5-13 X 109/L, hemostasis could be maintained even within 
the infected lungs. Taken together, these studies showed the threshold platelet 
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counts required to maintain hemostasis in a mouse model of Klebsiella-induced 
sepsis. 
Another possible mechanism by which platelets provide protection during severe 
sepsis is by activating the neutrophil extracellular traps (NETs) in a TLR4-dependent 
mechanism that trap bacteria in septic blood [482]. Activated neutrophils release 
granule proteins and chromatin material from their nucleus in vivo that form these 
mesh-like extracellular DNA fibers containing histones and antimicrobial proteins 
and effectors called neutrophil extracellular traps (NETs) that bind and kill Gram-
positive and Gram-negative bacteria [484]. NET formation is called NETosis. In a 
series of imaging experiments in liver sinusoids and pulmonary capillaries, platelets 
were shown to bind activated neutrophils via their TLR4 to release NETs to entrap 
the bacteria [482-483]. The complex interactions between platelets and neutrophils 
in the context of NETs were also shown to be important for thrombus formation 
[485]. NETs caused platelet activation, adhesion, and aggregation by providing a 
scaffold that triggers thrombus formation. DNase treatment which degrades the 
meshwork of DNA fibers that form the NETs or treatment with the anticoagulant 
heparin can disrupt pre-formed NETs and thus inhibit thrombus formation. 
Furthermore, markers of NETs including histones were found to be inside thrombi 
within veins that also contained red blood cells, giving rise to red thrombi. This led to 
further studies showing the importance of NETs in the propagation of deep vein 
thrombosis [486-487]. In neutrophils, peptidyl arginine deiminase 4 (PAD4) mediates 
citrullination of histones, a process that is required for chromatin decondensation 
that releases the DNA fibers and NETs formation [488]. Studies using PAD4 KO mice 
showed that only 10% of these mice formed venous thrombi 48 hr after inferior vena 
cava stenosis compared to 90% of wild-type mice that formed venous thrombi, 
suggesting that PAD4-mediated chromatin decondensation in neutrophils is 
responsible for pathological deep vein thrombosis.  
Another key NET mediator is platelet P-selectin. NET formation by neutrophils 
induced by thrombin-activated platelets can be inhibited by anti-P-selectin 
glycoprotein ligand-1 (PSGL-1) inhibitory antibody or by the use of anti-P-selectin 
aptamers. The NET formation is also abolished when platelets from P-selectin KO 
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mice are used to induce neutrophils [489]. Platelet-induced NET formation by 
neutrophils has now become an increasingly growing field of research, providing new 
insights into how NETs promotes tumor growth and contribute to cancer-associated 
thrombosis [490-491]. 
While platelet TLR4 is essential in mediating inflammatory responses by platelets in 
vivo, reports elucidating the exact mechanism of how LPS stimulates TLR4 in ex vivo 
and in-vitro assays have been confusing.  Platelets lack CD14, an essential co-
receptor that engages with LPS-bound TLR4 to initiate proper downstream signaling. 
While all other TLR4-expressing cells have both CD14 and LPS-binding protein, LBP, 
unless added otherwise in the form of free plasma or recombinant versions of CD14 
and LBP to washed platelets, platelets do not respond to LPS [492]. This has led to 
controversial reports where some suggest that LPS does not stimulate platelet 
activation when measuring P-selectin expression [441] while others have reported 
otherwise [454]. However, since platelets express MyD88, the adaptor protein that is 
required for TLR4 signaling, in amounts similar to those found in leukocytes [454], 
platelets do seem to share signaling kinases that are common to TLR4 signaling 
pathway in immune cells. These include TBK-1, IRAK-1, JNKs, MAPKs, TRAF3, TRAF6, 
IRF-3, IKK complex, NF-κB p65, Akt among others [452, 492]. LPS has also been 
shown to initiate splicing of mRNA encoding IL-1β in a TRAF6-Akt-JNK activation-
dependent manner [492].  
LPS has also been shown to increase in vivo thrombopoietin (TPO) levels by 
influencing megakaryocyte TLR4, this led to a concomitant increase in circulating 
reticulated platelets (young platelets) and enhanced platelet-neutrophil aggregates 
[494]. LPS via TLR-4 also induced bone marrows to produce more TPO leading to 
more platelet production [495-496].  
TLR7 
One of the key viral sensors as part of the host’s innate immune defenses is the 
endosomal Toll-like Receptor 7 that binds to single-stranded RNA [497]. TLR7 
stimulation by ssRNA causes a type I interferon (IFN) response. Many ssRNA viruses 
(HIV-1, VSV, and influenza viruses) bind to cell-surface receptors and gain entry into 
the cell via endocytosis. Once the viruses get trafficked to an endosome, it fuses with 
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the endosomal membrane to release its capsid, followed by endosomal acidification 
that causes degradation of the envelope via TLR7-MyD88 dependent signaling 
cascade to cause IFN production; both steps being required for effective responses 
[498-499]. TLR7, being an endosomal TLR7, has been studied in the context of self-
vs-non-self-recognition of PAMPs; with ssRNA not being a part of the host, but 
clearly abundant in pathogens such as ssRNA-containing viruses that infect hosts. 
Endosomal localization may be a strategy to prevent recognition of self-nucleic acids, 
a feature that is common to most nucleotide-sensing endosomal TLRs such as TLR8, 
TLR9 and TLR3 [499]. ssRNA engagement of TLR7 initiates MyD88-dependent 
responses that signal via an IRAK4/IRAK1-TRAF3/TRAF6 pathway that leads to 
activation of the IRF7 transcription factors that cause interferon production [500]. 
In platelets, the first report about the presence of TLR7 was shown by the Freedman 
group. TLR7, which resides in an intracellular compartment and recognizes single-
stranded RNA, was found to be present in platelets [411, 437, 472]; and is required 
for mediating platelet counts and host survival in a mouse model of 
encephalomyocarditis virus (EMCV) infection. Viruses such as EMCV, HIV-1, and 
influenza virus as well as small guanosine analogs such as Loxoribine and Imiquimod 
(R837) have been shown to activate TLR7 signaling pathways [437]. EMCV-induced or 
Loxoribine-induced TLR7 activation led to PI3K/Akt, p38-MAPK phosphorylation 
events in platelets and these effects were largely abolished in the TLR7 KO platelets.  
In this dissertation, the role of the endosomal TLR7 in platelets and how it affects 
platelets responses to ssRNA-containing viruses is further explored. 
TLR9 
Like TLR7, TLR9 is also an endosomal TLR that senses unmethylated 2’-deoxyribose 
cytidine-phosphate-guanosine (CpG) DNA motifs that are present in bacteria, viruses 
and other pathogens [501]. In platelets, TLR9 is present both intracellularly and on 
the plasma membrane [442] and increased expression of the receptor occurs upon 
CpG ODN stimulation of human platelets [502]. It was reported that in both human 
and mouse platelets, TLR9 is present in a specific platelet granule, called the T 
granule, which is different from the other kinds of granules present within platelets 
(namely dense, alpha and lysosomes) [502]. In fact, TLR9 transcripts are upregulated 
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during proplatelet formation in the megakaryocytes [503]. Within the T granules, 
TLR9 has been shown to colocalize with protein disulfide isomerase (PDI) and is 
associated with either VAMP-7 or VAMP-8. These v-SNAREs allow targeting of the T 
granules to the plasma membrane during platelet activation and is thought to put 
TLR9 on the surface. However, recent studies have shown that PDI is located in an 
ER-type compartment within platelets, present near the inner surface of the platelet 
plasma membrane, which is different from the secretory granules found in platelets 
[47]. These compartments are targeted to the plasma membrane via an actin 
polymerization process and are independent of SNARE-mediated vesicle fusion. TLR9 
resides in the endoplasmic reticulum of resting dendritic cells and macrophages [505] 
and gets trafficked in COPII coated vesicles to an endo-lysosomal organelle [504]. 
CpG DNA, on the other hand, enters the cells through the early endosomes and has 
to be trafficked to a TLR9-containing organelle, where it partners with MyD88 for 
proper signal transduction to be initiated [504]. Hence, in platelets, given that PDI is 
present in ER-like compartments and TLR9 colocalizes with PDI, these T granules 
could very easily be ER-remnants instead of being a specialized separate 
compartment as previously thought.  
In platelets, TLR9 has been shown to bind to derivatives of polyunsaturated fatty 
acid oxidation such as carboxy-alkyl-pyrroles (CAPs), generated during oxidative 
stress, and activates platelet via the PI3K-Akt pathway leading to aggregation and 
secretion [506].  
While CpG motifs bearing oligonucleotides have been used as activators of TLR9 in 
dendritic cells and macrophages, a recent study, discovered an unexpected new 
mechanism of how CpG ODNs activates platelets [507]. When oligonucleotides were 
first discovered as potent therapeutics, measures had to be taken to prevent rapid 
degradation of these short single-stranded DNA molecules from cellular and plasma 
nucleases, to ensure pharmacostability of the drugs inside the host system. One such 
way was to introduce a phosphorothioate modification where the nonbridging 
oxygen molecules are replaced by sulfur [508]. This phosphorothioate modification 
of TLR9 agonists causes GP VI-dependent activation, adhesion, and aggregation of 
platelets, a response that was unchanged in TLR9 KO platelets, suggesting that this 
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mechanism of activation of platelets proceeds in a TLR9-independent manner [507]. 
These findings stress the importance of developing novel alternative chemical 
modifications of oligonucleotides used as drugs, such that they do not have spurious 
platelet activation side-effects.  
Platelet cytokines/chemokines 
Platelets store several different kinds of cytokines and chemokines within their 
secretory granules (mostly alpha granules) such as Platelet Factor 4 (PF4), RANTES, β-
thromboglobulin, MIP-1α, TGF-β [91]. Transforming growth factor-β (TGF-β) is a 
potent immunomodulatory molecule and platelets contain large amounts of it within 
their granules [509] and have been shown to regulate blood levels of TGF-β. In 
patients with immune thrombocytopenia (ITP), levels of TFG-β were markedly 
reduced and only reached normal levels upon platelet transfusions [510-511]. The 
release of cytokines and chemokines by platelets allows them to modulate their 
microenvironments in the vasculature. Platelets are the largest source of PF4, which 
can render monocytes apoptosis-resistant and induce differentiation into 
macrophages [512]; enhance neutrophil adhesion on endothelial surfaces and 
degranulation [513] among others. Platelet-derived CXC chemokines such as β-
thromboglobulin, that is stored in platelet alpha granules and released upon 
activation, can be stimulatory or can be inhibitory as in the case of neutrophil 
function [514]. Platelets release the chemokine Macrophage Inflammatory Protein-α 
(MIP-α) upon activation which can then stimulate granulocytes such as basophils and 
mast cells to release histamines [515].  CCL5 or RANTES, the second-most abundant 
chemokine after PF4, is released from platelets upon activation and can stimulate 
proplatelet production by the megakaryocytes [516]. 
One of the most important inflammatory mediators expressed by platelets is CD40L 
or CD154 that can bind to CD40, the costimulatory protein found on antigen 
presenting cells [517]. Membrane-anchored CD40L is expressed by platelets and 
upon activation, release most of it in its soluble form, as sCD40L; which makes up for 
the majority of circulating sCD40L in the plasma [518].  
One of the key functions of platelet-derived CD40L has been in linking the innate 
immunity with adaptive immunity by enhancing CD8+ cytotoxic T cell responses in 
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response to Listeria monocytogenes infection [519] as well mediating CTL-induced 
liver damage in response to Hepatitis B infection [520]. Platelets have been shown to 
bind dendritic cells (DC) in a CD40L-dependent manner to suppress DC 
differentiation, downregulate pro-inflammatory cytokine production of TNF, IL-
12p70 while upregulating IL-10 production [521]. In addition to affecting dendritic 
cells, platelet-derived CD40L can modulate B cell differentiation and antibody class 
switching [522]. Taken together, platelet-derived cytokines, chemokines and 
immune mediators such as CD40L allow platelets to modulate the effector functions 
of other immune cells, thereby forming an important link between immune systems 
and the coagulation cascades [523].  
Platelet-bacterial interactions 
In addition to the Toll-like receptors, which are the premier innate immune 
receptors to interact with bacteria and bacterial products, platelets express a wide 
range of potential receptors such as complement receptors, FcγRII as well as the 
conventional hemostatic receptors such as αIIbβ3, GPIbα, which allow bacteria to 
directly or indirectly interact with platelets via fibrinogen, fibronectin, complement 
C1q, vWF among others [524]. Bacteria can interact with platelets in three ways: (i) 
direct binding of bacteria to platelet receptors, (ii) direct binding of bacterial 
products or toxins to platelet receptors, and (iii) indirect binding of bacteria to 
proteins that are ligands of platelet receptors. Of the hemostatic receptors that are 
known to bind bacteria either directly or indirectly by binding to their cognate 
ligands bound to bacteria, αIIbβ3 and GPIbα, are the most important. Staphylococci 
express surface proteins that can bind to fibrinogen and fibronectin, ligands for αIIbβ3 
[525-527]. Protein A from Staphylococcus aureus can bind to vWF, which in turn 
interacts with GPIb β, allowing the bacteria to adhere to platelets [528-530].  
Platelets also express members of the complement factor receptors such as gC1q-R, 
the receptor for the complement factor C1q, which allows opsonization of C1q 
complement-coated bacteria [531]. This occurs during platelet activation when there 
is an increase in C1q-R surface expression. P-selectin, which is expressed upon 
platelet activation on the surface, has been shown to bind to the complement C3b 
that can act as an opsonin for bacteria [532]. 
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Platelets also express the immune receptor, FcγRII, which recognizes the Fc domain 
of IgG and enables pathogen phagocytosis and engulfment of immune complexes 
[533]. Heparin is often administered to patients as a potent anticoagulant. However, 
this occasionally leads to thrombocytopenia, which predisposes these patients 
towards thrombosis. This is the basis of heparin-induced thrombocytopenia (HIT), a 
condition where autoantibodies are generated by the body against heparin-platelet 
factor 4 complexes. Heparin acts as a hapten and thus can be recognized by IgG 
antibodies in the bloodstream. It complexes with PF4 in circulation to form PF4-
heparin complexes that can then bind to FcγRIIA on the platelet surface, leading to 
strong platelet activation, followed by internalization of these platelet-bound 
complexes by phagocytes leading to increased clearance of activated platelets [534-
535].  
Platelets have been shown to harbor bacterial pathogens such as Staphylococcus 
aureus within their vacuole-like compartments [263] that are separate from the OCS. 
These compartments could be potential endosomes, though this has not been 
confirmed yet. Porphyromonas gingivalis has also been similarly found within 
platelet vacuoles [536]. IgG-mediated opsonized particles or bacteria can be 
internalized by human platelets via FcγRIIA, resulting in activation and degranulation 
of sCD40L and RANTES, in a process that requires actin cytoskeletal rearrangements 
[537].  
What happens to bacteria that have been internalized by platelets? While this 
remains an active area of ongoing research, some insights are available [538]. 
Bacteria such as Streptococci and Staphylococci that bind via αIIbβ3 or to GPIb via vWF, 
activate platelet aggregation, release ATP from dense granules and generate TxA2 
[539]. Streptococcus sanguinis has been shown to activate platelets via ERK and p38 
MAPK phosphorylation [540]. An interesting feature of note in the context of 
bacteria-induced platelet activation is the difference in kinetics of responses as 
compared to hemostatic responses [538]. Bacteria-induced platelet aggregation 
proceeds after a lag time, dependent on the bacterial density that lasts between 3-
20 min, as compared to thrombin or ADP-mediated hemostatic responses which 
reach maximal activation in less than 3 min. This harks back to this overarching 
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hypothesis that platelets do indeed interpret different stimuli and respond 
accordingly. Thus, there exists a differential response in reacting to “immuno 
agonists” vs “hemostatic agonists”. Data generated in this thesis further consolidates 
this idea. 
Platelet-viral interactions 
As in the case with severe bacteremia, thrombocytopenia is commonly associated 
with viral infections. Platelets get activated by viruses in the circulation, present due 
to the ongoing viremia, leading to a platelet-leukocyte aggregate formation that 
causes sequestration of platelets from the circulation, possibly by macrophages that 
contribute to lowering the platelet counts. Viruses have also been found inside 
platelets, with the first electron micrographs of platelets containing influenza virus, 
is the first evidence that platelets can indeed internalize viruses [541]. Since platelets 
can internalize FcγRIIA-bound complexes, viruses that can bind to FcγRIIA are often 
found inside platelets [535]. Platelets isolated from patients infected with viruses 
such as HIV-1 [263], influenza [469], dengue virus [471] and hepatitis C virus [470], 
have been shown to harbor viral particles. Some of these cause functional responses, 
while for others the same is yet to be discovered. 
Human Immunodeficiency Virus-1 (HIV-1) 
HIV-1 is a lentivirus containing single-stranded RNA belonging to the Retroviridae 
family. It causes HIV infection that eventually becomes Acquired Immunodeficiency 
Syndrome (AIDS) over time. AIDS is a cohort of immune dysfunction related 
conditions that happens when HIV infection has significantly impaired the immune 
system to the point where opportunistic pathogens wreak havoc in an already 
immunocompromised individual. This creates infections to become life-threatening 
as well as increased propensity for cancers to thrive. In total, death is often caused 
due to one or more complications arising from this plethora of infections in HIV+ 
individuals than due to the actual HIV infection. HIV-induced AIDS is a global killer 
with estimates of over 22 million people worldwide having been killed by this disease 
ever since its discovery in the 1980s. 
The first report of platelets and megakaryocytes internalizing HIV-1 was obtained 
from electron micrographs [542] suggesting that direct infection of these cells could 
74 
 
perhaps play a role in the disease progression of HIV-related AIDS. Youssefian et al. 
have previously shown that platelets isolated from HIV-AIDS patients with severe 
thrombocytopenia contain virions inside endocytic vesicles lying close to the plasma 
membrane [263]. This observation was further clarified using genetically modified 
non-replicative HIV and vesicular stomatitis virus (VSV), which were found to be 
present within endocytic vesicles in platelets [543]. Electron micrographs showed 
that these virus-containing vesicles colocalized with alpha granules markers and 
were trafficked to the surface-connected canalicular system (SCCS) where 
degradation of the lentiviral particles occurred when in contact with alpha granule 
proteins. In cultured megakaryocytes, lentiviral particles were also found in 
endocytic vesicles and then trafficked into acid-phosphatase-containing 
Multivesicular bodies (MVBs).  
HIV-1 entry into platelets is mediated by a host of surface receptors. While 
megakaryocytes express CD4, which is the main receptor for viral entry, 
megakaryocytes also express other co-receptors such as CXCR1, 2, 4, and CCR3 [544-
545]. HIV-1 viruses can be transferred from CXCR4+ megakaryocytes to CXCR4- cells, 
aiding in viral dissemination [546]. Platelets, on the contrary, do not express CD4 but 
only express CXCR1, 2, 4 and CCR1, 3 and 4 [546-549]. HIV-1 can also bind the 
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-
SIGN/CD209 and the C-type lectin-like receptor 2 (CLEC-2) to enter platelets [550].  
In patients with HIV-1 infection, increased plasma levels of PF4, increased platelet-
leukocyte aggregates as well as increased sCD40L levels, all suggest platelet 
activation [551]. HIV-1 trans-activator of transcription protein (Tat) directly activates 
platelets to release sCD40L in a CCR3 and β3 integrin-dependent manner [552]. 
Various soluble endothelial activation markers like sVCAM-1, sICAM-1, and von 
Willebrand Factor levels are higher in HIV-1 infected patients [544].  
Anti-retroviral therapies have been successful in lessening deaths caused due to AIDS. 
This has also led to a decreased severity in thrombocytopenia by containing the bone 
marrow damage caused by HIV-1 replication, reduction in pro-inflammatory 
cytokines and festering of opportunistic infections [553]. Highly active anti-retroviral 
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therapies (HAART) have also reduced markers of endothelial and platelet activation 
such as P-selectin and CD40L levels in HIV-infected patients [554].  
HIV-1 infects platelets and megakaryocytes. Yet how it enters and much of what it 
does upon entry remains unclear. The bigger questions remain whether infection of 
platelets is beneficial or detrimental to HIV viral dissemination. Do platelets 
encounter the virus at the early stages of infection or does it occur, when the 
infection is truly systemic and widespread in the circulation? Do platelet responses 
to the virus facilitate immune clearance by allowing detection of virus-containing 
platelets by the macrophages, monocytes, dendritic cells, T-cell populations etc.? 
Conversely, do platelet responses to the virus exacerbate the process of viral 
infection?  Further studies will help answer some of these questions.  
Hepatitis C Virus (HCV) 
Like HIV-1 infections, HCV infections also cause thrombocytopenia in addition to 
hepatic complications like liver cirrhosis [555]. Hepatitis C virus is a small enveloped 
positive-sense, single-stranded RNA virus belonging to the Flaviviridae family and is 
known to cause Hepatitis C infections as well as some liver cancers such as 
hepatocellular carcinoma, although the mechanisms are unclear. Thrombocytopenia 
in Hepatitis C patients strongly correlates with hepatic dysfunction, HCV viral load 
(HCV RNA) and severity of cirrhosis and is thought to be a consequence of bone 
marrow damage, inhibition of thrombopoietin production by the liver, coupled with 
autoimmune activation that leads to increased platelet clearance [555-556]. Platelets 
bind to HCV via their envelope-residing glycoprotein E2, in a CD81-independent 
manner [557]. The E2 glycoprotein of HCV has been known to bind CD81 to allow 
viral attachment and entry to a target cell [558]. CD81-lacking platelets still seem to 
bind HCV, although the mechanisms of viral attachment and entry remain unclear. 
The presence of HCV-bound platelets isolated from HCV patients indicates that there 
are other potential receptors that could perhaps mediate HCV binding; what those 
may remain to be seen. Liver sequestration of HCV-bound platelets has been thought 
to be a way by which HCV evades the immune system, facilitating viral dissemination 
and persistence in the body [557]. Further studies are required to fully understand 
how HCV binds platelets and modulates platelet functions in causing 
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thrombocytopenia, in an effort to develop antiviral strategies to combat this 
infection.  
Dengue Virus 
Another member of the positive-sense, single-stranded RNA virus of the Flaviviridae 
family, is Dengue virus, which causes dengue hemorrhagic fever. Thrombocytopenia 
and platelet dysfunction go hand-in-hand with dengue viral infection and are related 
to the clinical outcomes of this disease [559, 563]. Platelets isolated from dengue 
hemorrhagic fever (DHF) have increased levels of P-selectin expression, lysosomal 
CD63 expression, and αIIbβ3 activation compared to healthy control platelets [561]. In 
dengue patient platelets, the intrinsic pathway of apoptosis is activated with 
concomitant elevation in phosphatidylserine exposure, mitochondrial depolarization, 
and activation of caspase-3 and caspase-9. This phenotype is strongly correlated with 
increased platelet activation. Studies have further shown that increased platelet 
activation during DHF leads to increased production of pro-inflammatory cytokines 
as well as increased vascular permeability [560]. In vitro exposure to dengue virus 
caused increased expression of the pro-inflammatory cytokine, IL-1β, in platelets, a 
phenotype mimicking in vivo analyses of platelets and platelet-like microparticles 
isolated from DHF patients that showed elevated levels of IL-1β synthesis. The 
nucleotide-binding domain leucine-rich repeat containing protein (NLRP3) 
inflammasomes, which are present in platelets, are turned on by dengue virus 
infection. NLRP3 activation leads to caspase-1 activation that mediates secretion of 
IL-1β from platelets [560]. Dengue virus infects human dendritic cells via DC-SIGN 
(CD209) receptor [562]; dengue virus also uses DC-SIGN to infect platelets [561]. 
Dengue virus has been shown to replicate inside the platelet cytosol producing 
infectious viral particles, upon DC-SIGN and heparan sulfate proteoglycan-mediated 
viral binding and entry [565]. qRT-PCR and ELISA assays confirmed the presence of 
newly synthesized ssRNA as well as presence of the highly antigenic viral NS1 protein, 
with copies of about 800 viruses bound per platelet, when platelets were incubated 
with dengue virus in vitro at 37°C. This was the first report to describe an active 
process of viral replication inside platelets. This replicative ability becomes a serious 
issue while storing platelet transfusion units, which might be already unknowingly 
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(due to lack of testing) infected with the dengue virus.  Dengue virus can persist and 
replicate, albeit at a much lower level in these storage units. Upon entering a new 
host, during platelet transfusion, dengue virus can then infect the host and 
disseminate in circulation to cause dengue fever [566].  
Dengue hemorrhagic fever is commonly associated with elevated plasma levels of 
pro-inflammatory cytokines such as MIP-1β, RANTES, IL-7, IL-12, IL-5, and PDGF, 
caused due to increased platelet activation [564]. Clearly, DHF caused by dengue 
virus leads to a complex disease etiology, that oversees a dynamic interplay between 
dengue virus, platelets and other participating immune cells and future studies will 
aim to better understand how to ameliorate some of the platelet-related 
dysfunctions prevalent in dengue viral infections.  
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Thesis overview 
Ever since their discovery, platelets have almost exclusively been studied in 
the context of hemostasis and thrombosis. Recent research over this past decade 
has challenged this canonical view of platelets and has provided insights into how 
platelet functions extend beyond hemostasis and thrombosis. Platelets have been 
shown to be important for immune and inflammatory responses, wound healing, 
angiogenesis, tumor progression and cancer metastasis among others. Platelet 
activation and exocytosis remain the cornerstone for mediating platelets’ functions 
in hemostasis and thrombosis. Endocytosis, on the other hand, has been shown to 
be involved in granule cargo loading (e.g., fibrinogen and VEGF), receptor trafficking 
of integrins (αIIbβ3, αvβ3) and purinergic receptors (P2Y1, P2Y12), and thereby for 
normal platelet function. However, platelet endocytosis could potentially be critical 
for actively sensing changes in vascular microenvironments and responding 
accordingly to vascular damage and exogenous substances that are being taken up 
by platelets (i.e. pathogens, PAMPS and DAMPS). We posit that endocytosis confers 
platelets with the ability to become vascular sentries providing active and dynamic 
“immune surveillance” against circulating pathogens and “hemostatic surveillance” 
against prothrombotic vascular damage. The mechanistic underpinnings of 
endocytosis, its importance in platelets, and the molecular machinery required and 
possible trafficking routes are however understudied, in part due to a lack of 
experimental tools. The work presented here puts forth new players that regulate 
endocytosis and mediate cargo loading and hemostasis as well as provides a novel 
mechanistic understanding of how endocytosis allows platelets to act as immune 
cells and become the first responders to pathogens in the vasculature. 
Work presented in the first part of the thesis identifies a v-SNARE protein called 
Cellubrevin/VAMP-3 as a key mediator of endocytosis in modulating platelet 
functions. Together with another previously identified endocytic regulator, Arf6, a 
small GTPase that mediates cargo uptake and integrin trafficking in platelets, we 
probe the varied roles of endocytosis in mediating the innate immune responses of 
platelets to circulating pathogens in the bloodstream, in the second part of the thesis. 
Taken together, we uncover novel mechanistic understandings of how endocytosis is 
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important for platelet functions, shedding light on some of the critical regulators of 
the process, in general, and how it allows platelets to act as effector immune cells.  
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Chapter Two: Reagents and methods 
Reagents and antibodies 
Rabbit anti-cellubrevin/VAMP-3 antibody (Ab) was obtained from Novus Biologicals 
(Littleton, CO). FITC-anti-CD41/61, PE-anti-Jon/A, FITC-P-selectin, PE-LAMP1 Abs 
were from Emfret Analytics (Eibelstadt, Germany). Rabbit anti-Integrin β3, anti-β-
actin Ab, rabbit anti-Akt, rabbit anti-phospho-Akt (Ser32), rabbit anti-TLR7, rabbit 
anti-TLR9, mouse anti-IRAK4 were from Cell Signaling (Danvers, MA).  Rabbit anti-
fibrinogen Ab was from Dako (Glostrup, Denmark). Rabbit anti-vitronectin Ab was 
from Molecular Innovation (Novi, MI); mouse anti-fibronectin and rabbit anti-TPOR 
Abs were from Abcam (Cambridge, MA). Anti-rab4, anti-rab11, anti-dynamin 2, and 
anti-clathrin heavy chain Abs were from BD Transduction Laboratories (San Jose, CA). 
Anti-JAK2 and anti-phospho (Tyr 1007/1008) JAK2 Abs were from EMD Millipore 
(Darmstadt, Germany). Rabbit anti-murine PF4 Ab, ELISA kit for mouse PF4 detection 
and thrombopoietin were from R&D Systems (Minneapolis, MN). Rabbit anti-
RabGDI-Ab was generated by our laboratory using recombinant RabGDIα as antigen 
and described in [202]. The anti-SNAP-23 antibody was used as described in [202]. 
Anti-SNAP-23-pSer95 antibody that specifically recognizes phosphorylation at the 
Ser95 site in mouse SNAP-23 was previously characterized [457] and was generously 
gifted to us by Dr. Paul Roche (NCI). Rabbit Anti-Arf6 serum was homemade as 
described before [360]. FITC-Fibrinogen, Dextran (10,000 MW) Oregon Green 488, 
Alexa 647-Fibrinogen were obtained from Molecular Probes, Invitrogen (Carlsbad, 
CA). Prolong Diamond Antifade Reagent was from Invitrogen (Carlsbad, CA). Human 
fibrinogen, fibronectin, poly-D-lysine, hirudin, ammonium chloride and apyrase were 
all from Sigma (St. Louis, MO). Thrombin, collagen, and ADP were from Chrono-log 
(Havertown, PA). Prostacyclin (PGI2) was from Cayman Chemicals (Ann Arbor, MI). 
Trypan Blue was from Thermo Scientific (Waltham, MA). [3H]-tryptamine was from 
Perkin Elmer (Waltham, MA).  RGDS peptide was from Anaspec (San Jose, CA). 
Apyrase, human fibrinogen, poly-D-lysine, hirudin, paraformaldehyde, and 
proteinase K were from Sigma (St. Louis, MO). Thrombin, Collagen, ADP, and 
CHRONO-LUME reagent were from Chrono-log (Havertown, PA). U46619 and 
prostaglandin I2 (PGI2) was from Cayman (Ann Arbor, MI). A23187 was from 
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Calbiochem (San Diego, CA). Convulxin was from Centerchem (Norwalk, CT). 
PAR1/PAR4-peptide was from Bachem (Bubendorf, Switzerland). Fibronectin-free 
fibrinogen was from Enzyme Research Laboratory (South Bend, IN). DNA ligation Kit 
was from Enzymax (Lexington, KY). Fura-2/acetoxymethyl ester (AM) was from 
Molecular Probes (Eugene, OR). Calcein-AM was from BD Biosciences (San Jose, CA). 
Complete, EDTA-free protease inhibitor cocktail was from Roche (Indianapolis, IL). 
Acid citrate dextrose (ACD) blood collection tubes were from BD Diagnostics (Sparks, 
MD). All other reagents used were of analytical grade. 
Mice  
The following mice were used for the experiments enlisted in this thesis.  All work 
with animals was under the supervision of the University of Kentucky Institutional 
Animal Care and Use Committee (IACUC) as described in the approved protocol 
884M2005. 
WT mice (C57BL/6 background), initially purchased from Jackson Laboratory and 
bred in our animal vivarium. 
IKKβfl/fl/PF4-Cre+ and IKKβfl/fl generated by Dr. Zubair Karim in our lab [242]. 
Polymerase Chain Reaction (PCR)-based genotyping was performed using genomic 
DNA isolated from tail tip of an individual mouse. For IKKβ gene, the PCR analysis 
was carried out using following primer set:  
Forward primer, (MB1F) 5’-ATGTCTTGTGCCCTCTGGAAAGA-3’, 
Reverse primer, (IKK49 antisense) 5’- TCCTCTCCTCGTCATCCTTCG-3’. 
The PCR yields a 436 bp DNA product for WT allele and a 533 bp one for floxed allele.  
The PCR conditions for IKKβ reactions were: 94°C for 7 min for 1 cycle, followed by 
40 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 1 min, and lastly 72°C for 10 
min for 1 cycle. 
Global VAMP-3 KO mice were bred and genotyped as described [202]. 
Forward primer, (3F) 5’-CACAGGCACTCTGTTGCATT-3’, 
Reverse primer, (6R) 5’-CCACACAGGCTCCTGATCTT-3’, 
Neo primer, (mutant allele) 5’-GAGCAGCCGATTGTCTGTTG-3’. 
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The PCR reactions were run for WT (with 3F WT and 6R reverse) and for KO (with 
Neo and 6R reverse). The PCR yields a 500 bp DNA product for WT allele and a 750 
bp one for the mutant allele. 
 The PCR conditions for VAMP-3 reactions were: 94°C for 7 min for 1 cycle, followed 
by 30 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 90 sec, and lastly 72°C for 
10 min for 1 cycle. 
Arf6fl/fl/PF4-Cre+ and Arf6fl/fl was generated in our lab by Dr. Yunjie Huang [19].   For 
Arf6 gene, the PCR analysis was carried out using following primer set:  
Forward primer, 5’-GACCCCATGAGTGTTGTCAC-3’, 
Reverse primer, 5’-GGGATACATAGAGAAACCTTGTCTCAGG-3’. 
The PCR yields a 240 bp DNA product for WT allele and a 270 bp one for floxed allele. 
The PCR analysis for the Cre transgene was carried out using the following primer set:  
For the wild-type allele,  
Forward primer 5’-CCCATACAGCACACCTTTTG-3’, 
Reverse primer 5’-GAAACAACAGGCCCAGAAGC-3’;  
For the Cre allele,  
Forward primer 5’-CCCATACAGCACACCTTTTG-3’, 
Reverse primer 5’-TGCACAGTCAGCAGGTT-3’.  
PCR yielding a 450 bp DNA product indicates the presence of PF4-Cre gene.  
PCR conditions for both Arf6 gene and PF4-Cre gene are 94°C for 10 min for 1 cycle, 
followed by 30 cycles of 94°C for 1 min, 54°C for 45 sec and 68°C for 30 sec, and 
lastly 68°C for 7 min for 1 cycle. 
Global TLR23479-KO mice were a generous gift from Dr. Jayakrishna Ambati, 
University of Virginia, VA. 
 
Genomic DNA isolation from mouse tail tip  
Mouse tail tips (3-5 mm) were digested overnight (O/N) at 55°C in 400 µl tail lysis 
buffer (50 µM Tris/HCl, pH 7.5, 100 µM EDTA, 100 µM NaCl, and 1% SDS after 
autoclave) containing 20 µl 10 mg/ml proteinase K., Protein/peptide was 
precipitated by mixing with 200 µl saturated 6 M NaCl and centrifuged at 13,000 x g 
for 30 min at room temperature (RT). The supernatant containing DNA was 
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harvested and mixed with equal volume of 100% ethanol. After incubation for 10 
min at RT, DNA was pellet down by centrifuge at 13,000 x g for 10 min. DNA pellets 
were washed once with 1 ml 70% ethanol and then dried in a vacuum centrifuge for 
around 20 min. Genomic DNA was finally dissolved in 100 µl autoclaved ddH2O.  
Whole blood count 
Blood was drawn via cardiac puncture from VAMP-3 KO and control WT littermates 
and whole blood counts were performed using a Hemavet (Drew Scientific, Dallas, 
TX). Mean Platelet Volume (MPV) measurements were taken using the Z2 Coulter 
Counter (Beckman Coulter, Inc., Miami, FL). Statistical analyses were done using the 
statistical software program in SigmaPlot (v13.0).  
Preparation of mouse platelets 
Mouse blood was harvested via cardiac puncture into 0.38% sodium citrate (final) 
and diluted (1:1 v/v) in PBS, incubated with 0.2 U/mL apyrase and 10 ng/mL 
prostacyclin (PGI2) and centrifuged at 237 x g at room temperature (RT). Platelet-rich 
plasma (PRP) was recovered and platelets were pelleted at 657 x g. The pelleted 
platelets were resuspended in HEPES Tyrode buffer (pH 6.5, 20 mM HEPES/KOH, 128 
mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 5 mM D-glucose, 12 mM NaHCO3, and 0.4 mM 
NaH2PO4), supplemented with apyrase, PGI2, and 1 mM EGTA, and recovered by 
centrifugation at 657 x g. Pelleted platelets were finally resuspended in HEPES 
Tyrode buffer (pH 7.4) and concentrations were measured using Z2 Counter 
(Beckman Coulter, Inc., Miami, FL). 
Preparation of fresh human platelets 
Fresh whole blood was drawn from an informed healthy donor using acid citrate 
dextrose (ACD) collection tubes (BD Biosciences). Whole blood was diluted in HEPES 
Tyrode buffer (pH 6.5) with 1:1 ratio in the presence of 0.2 U/ml apyrase and 10 
ng/ml PGI2. After centrifugation at 215 x g for 20 min at RT, the supernatant (PRP) 
was harvested. To remove residual red blood cells and white blood cells, PRP was 
subjected to centrifugation at 155 x g for 10 min at RT. Platelets were recovered 
from the resulting PRP by centrifugation at 750 x g for 13 min at RT and then 
resuspended in HEPES Tyrode buffer (pH 6.5) in the presence of 0.2 U/ml apyrase, 10 
ng/ml PGI2 and 1 mM EGTA. Platelets suspensions were subjected to centrifugation 
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again at 750 x g for 13 min at RT and the resulting pellet was resuspended in HEPES 
Tyrode Buffer (pH 7.4) supplemented with 1 mM CaCl2. Platelet concentrations were 
determined by using Z2 Counter (Beckman Coulter, Inc., Miami, FL) and adjusted to 4 
X 108/ml with HEPES Tyrode buffer (pH 7.4) unless otherwise indicated. Platelets 
were incubated at RT for 30 min before use. 
Platelet aggregometry and ATP release from dense granules 
Washed platelets were freshly prepared and adjusted to the desired concentration 
with HEPES Tyrode buffer (pH 7.4) containing 1 mM CaCl2. Platelets suspensions (250 
or 500 µl) in a siliconized glass cuvette (Chrono-log, Havertown, PA) was warmed to 
37°C under stirring conditions (1200 rpm) for 2-3 min in a Model 460Vs Lumi-dual 
aggregometer (Chrono-log). After pretreatment with the indicated reagents, 
platelets were stimulated with the indicated agonists to initiate platelet aggregation. 
A model 810 Aggro/Link computer interface and Aggro/Link software (Chrono-log) 
were used to monitoring platelet aggregation traces. Buffer alone had been used to 
set baselines. 
ATP release from platelets dense-core granules was monitored using Chrono-Lume 
reagents (Chrono-log) while measuring platelet aggregation. Chrono-Lume reagents 
containing luciferin and luciferase enzyme were pre-incubated with platelet 
suspension (1:20 ratio) for 1 min prior to addition of agonists. Luminescence traces 
were recorded using the same interface and software as platelet aggregation. 
Graphs of platelet aggregation and ATP release was processed and assembled into 
figures using Adobe Photoshop CS5 (Adobe Inc. San Jose, CA). 
Platelet lysate preparation and western blotting 
Platelet lysates were prepared in SDS-PAGE sample buffer supplemented with 2 mM 
Na3VO4, 2 mM PMSF, protease inhibitor cocktail, and phosphatase inhibitor cocktail 
(PhosStop, Roche). Platelet proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P PVDF 
membranes (Millipore Corp., Bedford, MA). Transferred proteins were probed with 
suitable primary Abs and visualized using appropriate alkaline phosphatase-
conjugated secondary Abs and AmershamTM enhanced chemifluorescence (ECF) 
substrate (GE Healthcare Life Sciences, Piscataway, NJ). Images were recovered with 
85 
 
a Typhoon 9500 Variable Mode Imager and quantified using ImageQuantTL software 
(GE Healthcare Life Sciences, Piscataway, NJ). 
Flow cytometry analysis  
To measure the surface levels of total and activated GPIIb/IIIa, washed platelets (5 x 
107/mL) were either kept resting or stimulated with 0. 1 U/mL thrombin for 1 min. 
The reactions were stopped with hirudin (2-fold excess) and incubated with FITC-
anti-CD41/61 antibody and PE-Jon/A antibody. The mixture was analyzed by flow 
cytometry and geometric mean fluorescence intensity (GMFI) was measured. 
Washed platelets from WT and KO mice were freshly prepared and adjusted to 5 X 
107/ml in HEPES Tyrode buffer (pH 7.4) in the presence of 1 mM CaCl2. Platelets (20 
µl) were either kept resting or stimulated with 0.1 U/ml thrombin for 1 min or with 
any of the TLR agonists (Loxoribine, CpG ODN2395, LPS, Pam3CSK4 or HIV-1 
pseudovirions (HIVpp)). The reactions were stopped by adding a 2-fold excess of 
hirudin or HT pH 6.5 wash buffer in the case of TLR and HIVpp agonists. Samples 
were then incubated with fluorophore-conjugated antibodies (2.5 µl each) for 15 
min at RT. FITC-anti-CD62 antibody and PE-anti-LAMP1 antibody were used to 
measure P-selectin and LAMP1. The mixture was transferred to polystyrene FalconTM 
tubes (BD Biosciences, San Jose, CA) containing 200 µl HEPES Tyrode buffer (pH 6.5). 
Unlabeled platelets were used as background controls. Samples were analyzed at the 
flow cytometry facility at the University of Kentucky. Flow cytometry analysis was 
performed using FACScanTM flow cytometer (BD Biosciences). Platelet populations 
were determined by a combination of forward light scattering (FSC) and side light 
scattering (SSC). CellQuestTM (BD Biosciences) was used to monitor platelet 
fluorescent intensities. A total of 10,000-20,000 platelet events were analyzed and 
the geometric mean of the fluorescent intensity was determined and analyzed using 
the SigmaPlot (v13.0) statistical software.  
To measure steady-state FITC-fibrinogen binding, platelets (1.0 x 109/mL) were 
incubated on ice for 20 min, and then with 0.06 or 0.12 mg/mL FITC-fibrinogen for an 
additional 20 min. Platelets were fixed with 2% paraformaldehyde (PFA) and 
analyzed by flow cytometry. The difference of geometric mean fluorescence 
intensity (GMFI) before and after 0.04% Trypan Blue addition was used to assess 
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surface fibrinogen binding (0.04% Trypan Blue quenched >95% of free FITC-
fibrinogen [19]). 
To study activated state FITC-fibrinogen endocytosis, washed platelets (1.0 x 109/mL) 
were incubated with or without ADP (10 µM) in the presence of 0.12 mg/mL FITC-
fibrinogen at 37°C for 30 min. The platelets were then put on ice for 20 min, fixed 
with 2% PFA (final conc.), and GMFI measurements were taken by flow cytometry 
before and after addition of 0.04% Trypan Blue. 
Whole blood platelet-leukocyte aggregation assay 
Whole blood (in ACD) was pre-treated for 10 min with an anti-mouse CD16/CD32 
antibody (Biolegend, San Diego, CA) to block the FcγRIII/II receptors on immune cells 
to prevent antibody-antigen immune complexes. This antibody was a generous gift 
from Dr. Ahmad Al-Attar, University of Kentucky. After pretreatment with the 
indicated reagents, platelets were kept quiescent or stimulated with the indicated 
agonists (Loxoribine, CpG ODN2395, LPS, Pam3CSK4, HIV-1 pseudovirions or 
thrombin) to initiate platelet-leukocyte aggregation. To 50 µL of whole blood in a 
polystyrene FalconTM tubes (BD Biosciences, San Jose, CA), add 5 µL each of anti-
platelet CD41-FITC conjugated antibody, anti-neutrophil Ly6G-APC/PE-conjugated 
antibody or anti-monocyte CD14-PE conjugated antibody and vortex gently while 
incubating for 15-30 min in the dark at RT. Add 500-1000 µL of 1X BD FACS/Lyse 
Solution (BD Biosciences Cat No. 349202) and vortex gently while incubating for 10 
min in the dark at RT. Centrifuge the tube contents at 500 x g for 7 min to remove 
the supernatant. This removes all the lysed red blood cells. Finally, samples were 
resuspended in 500 µL of 1X PBS pH 7.4 and take the tubes for FACS analysis. 
Samples were run on the BD LSRII machine and 500,000 events were captured per 
sample with gating around 50,000 granulocytes. Data was then analyzed using the 
FlowJo software (v7.6.5) and plotted and analyzed using the SigmaPlot (v13.0) 
statistical software.  
Static platelet adhesion 
Washed platelets (4 x 108/mL), labeled with 10 μM calcein AM (BD Bioscience) and 
0.2% of Pluronic F-127 (Invitrogen), were seeded onto 96-well opaque plates, pre-
coated with either 50 μg/mL human fibrinogen or 5% bovine serum albumin (BSA) in 
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buffer (25 mM Tris, 137 mM NaCl, pH 7.4). After incubation for 1 hr at 37°C, the 
wells were washed thrice with HEPES Tyrode Buffer (pH 7.4) and adherent platelets 
were measured by fluorescence using a SpectraMax plate reader 
(excitation/emission/cutoff: 485/538/515 nm). Standard curves were generated 
using labeled WT and KO platelets. 
Platelet spreading 
Fibrinogen-coated slides were prepared by incubating human fibrinogen (50 µg/ml in 
PBS) in the wells of a Nunc Lab-Tek II chamber slide (Thermo Scientific) overnight at 
4°C. WT and KO platelets (2 X 107/mL) were suspended in HEPES Tyrode buffer (pH 
7.4) containing 1 mM CaCl2, seeded into the fibrinogen-coated wells, and incubated 
at 37°C for the indicated times. Unbound platelets were removed by washing and 
the adherent platelets were fixed with 2% PFA overnight at 4°C. Images of spread 
platelets were taken using DIC microscopy and quantified with ImageJ software 
(v1.48, NIH). 
Clot retraction 
Acrylamide pads (polymerized 10% solution) were added to siliconized cuvettes and 
washed thrice with HEPES Tyrode buffer pH 7.4. Thrombin (0.05 U/mL) was used to 
stimulate clot formation and retraction in washed WT and KO platelets (500 µL; 3 x 
108/mL) supplemented with 1 mM CaCl2 in the presence of human fibrinogen (0.5 
mg/mL; Sigma). Images were taken at increasing times and clot sizes were measured 
using ImageJ software (v1.48, NIH). The percent of clot sizes relative to initial 
suspension volumes were determined and analyzed using SigmaPlot (v13.0). 
Plate assay to measure endocytosis 
Opaque/black 96 well polystyrene plates (Corning, USA) were coated with 5% bovine 
serum albumin (BSA) in Phosphate Buffered Saline (PBS) overnight at RT. Wild-type 
(WT) and knockout (KO) washed platelets (100 µL; 5 X 107/mL), pre-incubated with 1 
mM CaCl2 for 5 min, were added to each well and either incubated with varying 
concentrations of FITC-Fg or low molecular weight (10 kDa) Oregon Green 488-
dextran for increasing times at 37°C. Fluorescence intensities were measured using a 
SpectraMax plate reader (Molecular Devices; excitation/emission: 495/520 nm) 
before and after addition of 0.04% Trypan Blue (0.04% Trypan Blue quenched >95% 
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of Oregon green 488-dextran, data not shown) to stop reactions at various time 
points. Standard curves were generated using serial dilutions of FITC-Fg or Oregon 
Green 488-dextran.  
Cargo uptake ex vivo 
Washed platelets (1 X 109/mL) from WT and KO mice were incubated with FITC-Fg 
and Oregon Green 488-dextran (1 µM each) at 37°C for increasing times up to 30 min. 
Platelets were fixed with 2% PFA and mixed with 0.1% Trypan Blue prior to imaging. 
Platelets were visualized using epifluorescence and Differential Interference Contrast 
(DIC) microscopy on a Nikon Eclipse E600 microscope (Nikon, Melville, NY) fitted 
with an AxioCam MR camera (Zeiss, Germany) and processed using the Zen 2011 
Digital Imaging software (blue edition, Zeiss). The number of FITC-positive or Oregon 
Green 488-positive puncta per platelet in both WT and KO samples were counted 
and plotted using SigmaPlot software (v13.0).  
Cargo uptake in vivo 
WT and KO mice (n= 3, each) were injected with Alexa 647-Fg and Oregon Green 
488-dextran (2 µM each) through the retro-orbital sinus and, 24 hr post-injection, 
mice were euthanized and blood was drawn directly into fixative (0.38% sodium 
citrate containing 2% PFA and 0.05% glutaraldehyde). Platelets were harvested, 
refixed with 2% PFA, and prepared for imaging. 
3D-SIM super-resolution microscopy (3D-SIM) 
Washed WT and KO platelets (1.0 x 109/mL) were incubated ex vivo with Alexa 647-
Fg and Oregon Green 488-dextran (1 µM each) at 37°C, then fixed with PFA. 
Centrifugation (700 x g for 5 min) was used to remove fixative and platelet pellets 
were re-suspended in PBS. The platelets were fixed a second time and then allowed 
to settle onto poly-D-lysine (0.1mg/mL) coated coverslips for >90 min at RT in a 
humid chamber. To quench fixative, coverslips were incubated cell-side down in 50 
mM NH4Cl in PBS for 30 min at RT. Coverslips were washed and mounted in Prolong 
Diamond Antifade Mounting medium and cured for 2 days at RT in the dark. 
For in vivo experiments, 24 hr post-injection of Alexa 647-Fg and Oregon Green 488-
dextran, mice were euthanized and platelets were directly fixed during the blood 
draw. Platelets were then isolated and allowed to settle onto poly-D-lysine coated 
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coverslips. Imaging was done using the Nikon Ti-E N-STORM/N-SIM super-resolution 
microscope at the University of Kentucky Imaging Core. Images were processed using 
NIS-Elements v3.2 N-SIM/STORM software.  
TPO-induced JAK2 signaling 
Washed WT and KO platelets (4 X 108/mL) were pre-incubated with 1 mM CaCl2 and 
then with 50 ng/mL of thrombopoietin (TPO; R&D Systems) for 0 to 30 min at 37°C. 
Platelet extracts were prepared in SDS-PAGE sample buffer (supplemented with 
protease inhibitors) and analyzed by western blotting using anti-JAK2 and anti-
phospho JAK2 (Tyr 1007/1008) and anti-TPOR antibodies.  
Measurement of platelet granule cargo release (secretion assays) 
Platelet-rich plasma (PRP) from WT and KO mice were prepared and labelled with 0.4 
µCi/mL [3H]5-HT (serotonin, Perkin Elmer, Waltham, MA) for 30 min at 37°C. After 
washing, platelets were resuspended in HT buffer pH 7.4 fortified with 0.7mM CaCl2 
for 5 min prior to stimulation with thrombin or TLR agonists (LPS, Pam3CSK4, 
Loxoribine, CpG ODN) for indicated times or doses. 2X Hirudin was added to stop the 
reaction for thrombin-treated samples while centrifugation at 13, 800 x g for 2 min 
was done to stop the TLR agonist reactions. For each time point or dose reaction, 
samples were prepared in triplicates. The supernatant and pellet was separated 
post-centrifugation, kept on ice and the pellets were lysed with 1% Triton X-100 
solution in 1X PBS on ice for about 45 min. The supernatant and pellet samples were 
vortexed and centrifuged one final time (13, 800 x g for 1 min) before doing the 
individual granule assays. 
For dense granule assay, 25 µL of supernatant or pellet is added to 3 mL of 
scintillation cocktail (Econo-safeTM, Research Products International Corp, Mt. 
Prospect, IL) and the radioactivity is read as counts per minute using a Tri-Carb 
2100TR liquid scintillation analyzer (Beckman, Fullerton, CA). For alpha granule assay, 
sandwich enzyme-linked immunosorbent assay (ELISA) is used to detect the release 
of platelet-specific alpha granule cargo, Platelet Factor 4, PF4, a chemokine, in the 
supernatant and pellet fractions of resting and activated platelets. The assay is 
performed according to the manufacturer’s instructions (R&D Systems, Minneapolis, 
MN). For lysosomal secretion, a colorimetric assay to measure the release of β-
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hexosaminidase in the pellet and supernatant fractions is measured by analyzing its 
enzymatic activity on its substrate p-nitrophenyl-N-acetyl-β-D-glucosaminide (Sigma). 
Optical density from each sample (pellet and supernatant) is measured at 405 nm 
using a Biotek Elx808 plate reader and data is collected using the Softmax Pro 6 
software (Molecular Devices, Sunnyvale, CA). The percent release for each marker at 
each data point was calculated by using the supernatant fraction measurements 
divided by the total measurements (supernatant + pellet values) multiplied by 100. 
TLR activation of platelets 
Washed WT and KO platelets or freshly isolated human platelets (4 X 108/mL) were 
pre-incubated with 1 mM CaCl2 and then with increasing times or increasing 
concentrations of various TLR compounds such as TLR2 agonist (Pam3CSK4), or TLR4 
agonist (LPS O111:B4), or TLR7 agonist (Loxoribine) or TLR9 agonist (CpG ODN2395 
Class C) at 37°C. In some instances, platelets were either pre-treated with 
ammonium chloride or Dynasore (to inhibit endocytosis) prior to TLR stimulation. 
Platelet extracts were prepared in SDS-PAGE sample buffer (supplemented with 
protease inhibitors) and analyzed by western blotting using anti-Akt, anti-phospho-
Akt (Ser473), anti-SNAP-23, anti-phospho-SNAP-23 (Ser95), anti-IRAK4, anti-
phospho-IRAK4 (Thr345) (Abbomax), anti-IκBα and anti-phospho-IκBα (Ser32/36) 
antibodies (in the case of human platelets).  
Preparation of HIV-1 pseudovirions 
Plasmids 
Viral vectors to make the HIV-1 pseudovirions were a generous gift from Dr. Gregory 
Melikyan, Emory University. These were: (i) A chimeric Ecph-TM expressing vector 
containing the ecliptic pHluorin, derived from the original ecliptic pHluorin construct 
[455] and transmembrane (TM) domain of ICAM-1 (intercellular adhesion molecule 
1). The pCDM8 ICAM-1 vector (Addgene) was used as the template for the TM 
domain of ICAM-1 while the MLV (murine leukemia virus) Gag-EcpH-expression 
vector was used as a template for the EcpH [456]. (ii) The HIV-1 Gag-mCherry 
expression vector was constructed by cloning the Gag fragment of the 
p96ZM651gag-opt vector [National Institutes of Health ARRRP (AIDS Research and 
Reference Reagent Program)] into pcDNA3.1zeo (+) plasmid (Invitrogen) together 
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with the mCherry fragment, which was obtained from pRSET-BmCherry (from Dr. R. 
Tsein, University of California, San Diego). The other two vectors were (iii) HIV pR8 
delta Env and (iv) pCAGGS.HXB2 Env.  
Pseudovirion Preps 
The vectors were first amplified in E. coli expression systems by Midi-Prep. Viral 
preps were made by Dr. Gabriel J. Popa and Dr. Michael D. Mendenhall at the 
University of Kentucky Genetic Core. Pseudovirions were then prepared by 
transfecting 293-LTV cell lines with all four viral vectors in the following proportions 
[HIV pR8 delta Env (30%), HIV-Gag-mCherry (12.5%), 3x FLAG-EcpH-ICAM (12.5%) 
and pCAGGS.HXB2 Env (45%)] using polyethyleneimine (PEI). Cells were transfected 
and after 5-6 hrs, the transfection medium was withdrawn and fresh medium 
(DMEM+ fortified with 10% FBS) was added. Cells were grown for 48-72 hrs 
depending on GFP and mCherry expression. Viruses were then harvested and 
concentrated by centrifugation at 4°C over a 20% sucrose cushion. Viral titers in the 
concentrates were quantified by measuring amount of p24 using the ZeptoMetrix 
HIV-1 p24 antigen ELISA kit (Cat No. 0801111) (ZeptoMetrix, Franklin, MA).  
Ex vivo uptake of HIV-1 pseudovirions 
Washed WT and KO platelets were resuspended at concentrations of 1 X 109/ml in 
supernatants from the 293-LTV cells (containing the HIV-1 pseudovirions) or in 
HPEPS Tyrode Buffer containing 1% BSA and 1 mM CaCl2 that was supplemented 
with 100X concentrated pseudovirions. Platelets (100 µl) were incubated for varying 
times at 37°C in the CO2 incubator. Aliquots were drawn at different intervals and 
fixed with 2% paraformaldehyde at 4°C overnight. Platelets were recovered by mild 
centrifugation and resuspended in 15 µl HEPES Tyrode buffer. Microscopic slides 
with 5 µl platelets mixed with 1 µl Trypan Blue (stock 4%) were prepared and 
visualized using Nikon Eclipse E600 microscope (Nikon, Melville, NY) with a 
100X/1.40 numeric aperture DIC H oil objective lens (Nikon). Images were taken 
using Zeiss camera (AxioCam MR, Germany). Images were processed using Zen 2011 
(blue edition, Zeiss). As a metric of viral uptake, the number of GFP-mCherry double-
positive puncta per platelet was counted. To eliminate non-specific fluorescence 
signal from the EcpH-TM-labelled particles that are probably membrane vesicles 
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lacking the Gag-mCherry, only the double-positive virions were counted. The 
presence of double-positive pseudovirions within the platelets should thus reflect 
virus internalization. 
In vivo uptake of HIV-1 pseudovirions 
Mice from WT and KO groups (age-matched and sex-matched) were anesthetized 
under isoflurane inhalation and HIV-1 pseudovirions were injected using a 27G 
needle (BD Biosciences) through the retro-orbital sinus. 24-hr post-injection, mice 
were euthanized, blood was drawn directly into fixative and platelets isolated as 
previously described. Microscopic slides with 5 µl platelets mixed with 1 µl Trypan 
Blue (stock 4%) were prepared and visualized using Nikon Eclipse E600 microscope 
(Nikon, Melville, NY) with a 100X/1.40 numeric aperture DIC H oil objective lens 
(Nikon). Images were taken using Zeiss camera (AxioCam MR, Germany). Images 
were processed using Zen 2011 (blue edition, Zeiss). As a metric of viral uptake, the 
number of GFP-mCherry double-positive puncta per platelet was counted. 
HIV-1 pseudovirion activation of human and mouse platelets 
Washed WT and KO platelets or freshly isolated human platelets (4 X 108/mL) were 
pre-incubated with 1 mM CaCl2 and then with increasing times or increasing 
concentrations of HIV-1 pseudovirions at 37°C. In some instances, platelets were 
either pre-treated with ammonium chloride or Dynasore (to inhibit endocytosis) 
prior to HIV-1 pseudovirion stimulation. Platelet extracts were prepared in SDS-PAGE 
sample buffer (supplemented with protease inhibitors) and analyzed by western 
blotting using anti-Akt, anti-phospho-Akt (Ser473), anti-SNAP-23, anti-phospho-
SNAP-23 (Ser95), anti-IRAK4, anti-phospho-IRAK4  (Thr345) (Abbomax), anti-IκBα and 
anti-phospho-IκBα (Ser32/36) antibodies (in the case of human platelets).  
Study approval 
All animal procedures were done under an approved protocol (884M2005) from the 
University of Kentucky Institutional Animal Care and Use Committee (IACUC). Human 
blood drawn from healthy donors was obtained at the Kentucky Clinic Lab by a 
phlebotomist. 
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Statistics 
Where appropriate, Student’s t-test or Mann-Whitney U test (from the SigmaPlot 
statistical software) were used to determine statistical significance. The data from 
secretion assays and FACS-based experiments were analyzed by two-way ANOVA. A 
one-tailed Student’s t-test was used to analyze the properties of platelets from KO 
mice. In all cases, the p values are indicated. 
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Chapter Three: VAMP-3-mediated endocytosis and trafficking regulate platelet 
functions  
Introduction 
Blood platelets respond to repair vascular damage via activation and subsequent 
granule exocytosis [458]. Platelet endocytosis is essential for cargo packaging (e.g., 
fibrinogen (Fg)) [14, 9, 340]. However, platelet endocytosis could be critical for 
actively sensing changes in vascular microenvironments and responding accordingly 
to what is being taken up. This is a more dynamic view of platelets as active 
surveyors of the vasculature; extending the importance of platelet endocytosis 
beyond granule biogenesis and perhaps even hemostasis. The mechanistic 
underpinnings of endocytosis and its importance in platelets are however 
understudied, in part due to a lack of experimental tools.  
Endocytosis refers to cargo uptake and receptor trafficking to and from the plasma 
membrane through distinct membrane-bound compartments. Seminal studies, from 
the 1980s, provided the first glimpses into the presence of an active endomembrane 
system in platelets. Platelets have clathrin-coated vesicles [326, 331]; can 
endocytose several plasma proteins (e.g., albumin, IgG, Fg, von Willebrand Factor 
(vWF), fibronectin) and translocate them to α-granules [340, 15-17, 328-330]. Both 
clathrin-mediated and clathrin-independent endocytosis has been reported in 
platelets [327]. Additionally, several platelet surface receptors such as integrin αIIbβ3 
and glycoprotein Ib are internalized and then recycled back to the plasma membrane 
[334, 336-337]. Platelet CLEC-2 is internalized in a Syk-independent manner whereas 
Arrestin and Arf6 have been shown to be crucial to endocytic trafficking of the P2Y12 
receptors [21, 459]. ADP and thrombin stimulation leads to translocation of internal 
pools of receptors and surface re-distribution [333, 335-336, 338-339]. Consistent 
with these reports of platelet endocytosis, platelets do contain key endocytic 
proteins and regulators including the vesicle scission-inducing large GTPase, 
Dynamin, Dynamin-related protein 1 (Drp1), and adaptor proteins such as Disabled-2 
(Dab-2) [22, 344, 347, 351, 356-357]. Recently, we highlighted the role of ADP-
ribosylation factor 6 (Arf6), a small GTP-binding protein, that specifically regulates 
αIIbβ3-mediated Fg uptake/storage and hence modulates acute platelet functions 
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such as clot retraction and spreading [19]. These studies are supported by “omics” 
analyses [200, 343] that highlight the burgeoning importance and complexity of 
endocytosis in platelets. 
Here we describe a role for Cellubrevin/Vesicle-Associated Membrane Protein-3 
(VAMP-3) in mediating endocytosis and trafficking in platelets. This v-SNARE has 
been reported to be localized to intracellular punctate structures within platelets 
[30]. Using a knockout (KO) mouse, with normal hemostasis and whose platelets had 
no aggregation or secretion defects [202], we determined that VAMP-3 plays a role 
in Fg uptake and governs platelet endocytosis. VAMP-3 deletion caused defective 
αIIbβ3-mediated Fg uptake and accumulation while fluid phase pinocytosis, as 
monitored by dextran uptake, was marginally affected, both in vivo and ex vivo. 
Platelet spreading on Fg and thrombin-stimulated clot retraction was faster in the 
VAMP-3 KO platelets. Additionally, we demonstrate that platelets sort endocytosed 
cargo into discrete compartments in vivo and ex vivo. Taken together, our work 
presents VAMP-3 as a regulator of platelet endocytosis and this knockout mouse 
adds to the repertoire of tools for studying endocytic trafficking in platelets while 
maintaining normal exocytosis and hemostasis. 
VAMP-3 KO platelets were fibrinogen-deficient 
Given past reports of fibrinogen (Fg) endocytosis by platelets [340, 329] and the 
intracellular localization of VAMP-3 [205], we asked if VAMP-3 played a role in Fg 
uptake and/or accumulation. In Figure 1A-B, VAMP-3 KO platelets, isolated from 3 
individual mice, had less associated Fg (~40% less, p≤ 0.001) than their 
corresponding WT littermate controls, indicating a defect in uptake and/or 
accumulation of Fg. Plasma Fg levels were unchanged suggesting that loss of VAMP-3 
did not affect Fg production (Figure 7). The major platelet integrin that binds Fg 
[337], αIIbβ3, was also unaffected by loss of VAMP-3 as evidenced by the unchanged 
levels of β3 in the KO platelets (Figure 3C). Ligands for other platelet integrins, e.g., 
fibronectin (binding to α5β1 and αvβ3) and vitronectin (binding to αvβ3), were either 
unchanged or slightly elevated in KO platelets (Figure 3D). Of note, vitronectin levels 
were also slightly increased in the Arf6 KO platelets as compared to WT [19]. Since 
VAMP-3 is thought to localize on both early and recycling endosomes [403, 458], 
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Rab4 (early) and Rab11 (recycling) levels were measured and found to be unchanged 
in KO platelets (Figure 3C-D). Other platelet endocytic markers e.g., Dynamin-2, 
Clathrin Heavy Chain and Disabled-2 (Dab2) were also unchanged (Figure 3C-D). 
Levels of de novo synthesized cargo such as platelet factor 4 (PF4) and other platelet 
SNARE proteins were unaltered in the VAMP-3 KO platelets, consistent with normal 
granule secretion [202]. Defective Fg endocytosis did not alter the gross morphology 
of VAMP-3 KO platelets. Moreover, the KO mice had normal platelet, RBC and WBC 
counts (See Table 2), although their platelet size was ~5% smaller than age-matched 
WT littermate controls. Thus the reduced intra-platelet Fg observed in KO platelets 
was not due to alterations in any endocytic proteins and regulators or due to 
decreased levels of β3 integrins and circulating plasma Fg, suggesting that VAMP-3 is 
essential for uptake and/or accumulation of Fg in platelets. 
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Figure 3 VAMP-3 KO platelets had lower fibrinogen levels. (A) Fg levels in washed 
platelet extracts from 3 WT and KO mice were measured by western blotting. β-actin 
was used as loading control. (B) Quantification of Fg levels in (A) was done using 
ImageQuantTL and plotted with SigmaPLot (v 13.0). (C) Comparison of protein levels 
by Western blotting between WT and KO platelets. Washed platelet extracts (5 X 
107platelets/lane) were loaded, and the indicated proteins were probed by western 
blotting. (D) Quantification of protein levels was done using ImageQuantTL and data 
was plotted as the ratio of KO over WT. The dashed line represents the ratio 1 of 
KO/WT protein levels. Statistical analysis was done using Student’s t-test where *** 
represents p-value of ≤0.001. Data for (C) and (D) is representative of platelets 
pooled from 2-3 mice in at least 2 independent experiments. 
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Surface αIIbβ3 levels and Fg-binding was unchanged on the VAMP-3 KO platelets  
Reduced levels of internalized Fg could be due to decreased surface and/or activated 
αIIbβ3. By flow cytometric analysis, levels of surface αIIbβ3, under resting conditions, 
were unchanged in the KO platelets (Figure 4A i-iii). As expected [19], thrombin-
induced activation mobilized an internal pool of αIIbβ3 integrins. We observed a ~25% 
increase in the total surface αIIbβ3 levels upon stimulation. While this ~25% increase 
was noted in both WT and KO platelets, there was no significant difference between 
the two. Similarly, in Figure 4B (i-iii), levels of activated αIIbβ3, as measured by JonA 
binding, were unchanged in VAMP-3 KO platelets, consistent with normal 
aggregation [202]. Defective Fg uptake, despite normal levels of αIIbβ3, could be 
attributed to defective surface-binding of Fg to αIIbβ3. Under steady-state conditions, 
FITC-Fg binding at two different concentrations (0.06 and 0.12 mg/mL) was 
unaffected in the VAMP-3 KO platelets (Figure 4C). Taken together, these results 
indicated that the lower Fg levels in KO platelets were not due to defective binding 
or reduced surface levels of αIIbβ3. 
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Figure 4. Total surface and activated αIIbβ3 and fibrinogen-binding were unchanged 
in VAMP-3 KO platelets. (A) Using FITC-anti-CD41/61 antibody, surface levels of total 
αIIbβ3 between WT (dark gray, solid lines) and KO platelets (light gray, dotted lines) (5 
X 107 platelets/mL) and (B) Using PE-Jon/A antibody, activated αIIbβ3, in resting state 
(i) or thrombin-stimulated (ii) were compared using flow cytometry. Unlabeled 
platelets (black, solid lines) were used as background controls. (iii) Quantification of 
data shown in Ai or Bi and Aii or Bii expressed as geometric mean fluorescence 
intensity (GMFI) was plotted. WT is depicted in black while KO is depicted in gray. (C) 
Fg-binding to αIIbβ3 between WT (black) and KO (gray) platelets was compared. 
Washed platelets (1 X 109 platelets/mL) were held on ice for 20 min, and then 
incubated with FITC-Fg (0.06 mg/mL and 0.12 mg/mL) for a further 20 min on ice. 
Platelets were fixed with 2% PFA and analyzed using flow cytometry. Data expressed 
as GMFI was quantified as shown. Data shown here is representative of at least 3 
independent experiments (mean ± SEM) for (A), (B) and (C). 
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VAMP-3 KO platelets had defective Fg uptake  
ADP-stimulation enhances internalization of Fg-bound αIIbβ3 into platelets [333, 335]. 
We verified this observation using flow cytometric analysis to measure FITC-Fg 
uptake in resting and ADP-stimulated WT and VAMP-3 KO platelets. Similar to Huang 
et al. 2016 [19], we used 0.04% Trypan Blue (TB) to quench external FITC 
fluorescence (including the fluorescence that is trapped within the open canalicular 
system) and measured TB-resistant fluorescence of internalized cargo as a metric of 
endocytosis. Platelets were incubated with FITC-Fg, either in the presence or 
absence of ADP, at 37°C, and then chilled on ice to arrest further endocytosis, fixed 
with 2% PFA, analyzed using flow cytometry prior to (darker bars) and after (lighter 
bars) addition of TB. In the absence of TB, geometric mean fluorescence intensity 
(GMFI) measurements represent the total fluorescence intensity of FITC-Fg present 
both inside the platelet and on the surface. In Figure 5A, under resting conditions, 
the total fluorescence intensity prior to the addition of TB was equivalent between 
WT and KO platelets, confirming equal amounts of FITC-Fg bound in each sample. 
Post-TB quenching, KO platelets had ~50% less FITC-Fg signal (p≤ 0.03 at 0.06 mg/mL 
and p≤ 0.006 at 0.12 mg/mL) indicating that under steady-state conditions, VAMP-3 
loss affected platelet internal accumulation of Fg. In Figure 5B, activation by ADP (10 
µM) stimulation increased overall net fluorescence for both WT and VAMP-3 KO 
platelets by ~30 fold, indicative of αIIbβ3 activation caused by ADP receptor signaling 
[333, 335]. Although VAMP-3 KO platelets had enhanced Fg association comparable 
to WT, less FITC-Fg was resistant to TB addition, consistent with a ~50% deficit in 
internalized FITC-Fg (p≤ 0.039 at 0.06 mg/mL and p≤ 0.023 at 0.12 mg/mL). 
Collectively, these data suggest that VAMP-3 deletion leads to impaired endocytic 
uptake and/or accumulation of Fg into platelets in both resting and activated states. 
Endocytosis defects in VAMP-3 KO platelets: receptor-mediated vs. fluid-phase 
endocytosis 
Platelets can endocytose diverse cargo e.g., VEGF [459], bacteria, and viruses [[263] 
and Banerjee, et al. (in preparation)] etc., thus we asked whether loss of VAMP-3 
affected other cargo. Uptake of fluorescently tagged, receptor-mediated cargo (Fg) 
and fluid-phase pinocytosis cargo (low mol. wt. dextran) was tracked in a plate-based 
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assay using TB as a quencher of external fluorescence. In Figure 5C and 5E, WT 
platelets internalized FITC-Fg in a time-dependent manner (up to 60 min) and dose-
dependent manner (up to 5 μM) respectively while VAMP-3 KO platelets showed a 
robust defect in both time- and dose-dependent Fg uptake. Arf6 KO platelets were 
also defective in FITC-Fg uptake (Figure 10A, C) confirming our earlier studies [19]. 
Based on these data, Fg internalization within platelets exhibited time- and dose-
dependence that appears to saturate. This was indicative of a receptor-mediated 
endocytosis process. 
Unsurprisingly, fluid phase endocytosis/pinocytosis occurs constitutively in WT 
platelets and showed a linear increase in dextran uptake with time (Figure 5D) and 
concentration (Figure 5F). Loss of either VAMP-3 or Arf6 renders platelets nominally 
defective in dextran uptake, but there was still a time- and dose-dependence similar 
to WT. Our data agrees with reports of normal pinocytosis of small molecules such as 
horseradish peroxidase in VAMP-3 KO mouse embryonic fibroblasts (MEFs) when 
compared to wildtype MEFs [419-420]. Interestingly, from a quantitative perspective, 
more of the fluid phase marker (dextran) was endocytosed than Fg (1018 vs. 1015 
molecules/platelet over 60 min). These data were consistent with fluid phase 
pinocytosis having a higher overall capacity than receptor-mediated uptake. Arf6 KO 
platelets had only a modest decrease in dextran uptake as compared to WT (Figure 
10B, D). Collectively, our data suggests that both VAMP-3 and Arf6 are more 
important for receptor-mediated uptake of Fg in platelets than for fluid-phase 
pinocytosis.  
We used fluorescence microscopy to further confirm these results. WT and VAMP-3 
KO platelets were incubated with 1 µM of FITC-Fg for 30 min, fixed, treated with 0.04% 
TB to quench external fluorescence, and imaged by epifluorescence. WT platelets 
had more FITC-Fg+ puncta than VAMP-3 KO platelets after 30 min (Figure 5G). 
Quantification of total fluorescent puncta present per platelet showed that over 80% 
of VAMP-3 KO platelets (vs ~30% in WT) had no puncta consistent with defective Fg 
uptake (Figure 5H; overall p≤ 0.01). Only WT platelets had ≥ 3 puncta compared to 2 
or less in KO platelets. Consistent with our ex vivo plate-based assay, quantification 
104 
 
of dextran+ fluorescent puncta (indicative of dextran uptake) in WT and VAMP-3 KO 
platelets showed no significant differences (Figure 11A-B). 
Collectively, these data show that Fg uptake and/or accumulation is dramatically 
reduced in the VAMP-3 KO platelets and comparatively more affected than dextran 
uptake and/or accumulation. Since αIIbβ3 activation and Fg-binding to αIIbβ3 remained 
unaffected in the VAMP-3 KO platelets, it appears that VAMP-3 could be mediating 
membrane trafficking step(s) that are downstream of Fg binding and internalization 
but required for accumulation of Fg inside platelets. 
Platelets sorted different classes of endocytic cargo 
In VAMP-3 and Arf6 KO mice, Fg uptake and/or accumulation was more affected 
than dextran uptake. This suggested that VAMP-3 and Arf6 are more important for 
receptor-mediated uptake of Fg than for fluid-phase pinocytosis of dextran. Could 
the two different cargos be endocytosed differently and access different 
compartments upon internalization? We used 3D-Structured Illumination 
Microscopy (3D-SIM) to address this question. Ex vivo platelets were co-incubated 
with equimolar concentrations of Alexa 647-Fg and Oregon Green 488-dextran and 
imaged over time. In Figure 6A, at 1 min, Fg (depicted in magenta) was found on the 
platelet plasma membrane (possibly via binding to αIIbβ3), while dextran (depicted in 
green) already appeared to be internalized within punctate structures inside the 
platelet. Surface staining for dextran was minimal; most likely because no specific 
dextran receptor is present on platelets. At 5 min, while surface staining was still 
visible, Fg+ puncta started to appear, with a concomitant increase in dextran+ puncta. 
By 30 min, more Fg-positive puncta appeared, and the surface localization was 
minimal. Strikingly, Fg and dextran puncta did overlap but in a very limited way, 
suggesting that the two cargo might be in distinct compartments. This implies that 
platelets can distinguish and perhaps sort their internalized cargo. Consistently, 
VAMP-3 KO platelets have fewer Fg puncta compared to WT while dextran uptake 
was less affected. Loss of VAMP-3, however, did not completely compromise cargo 
sorting as discrete punctate localization of Fg and dextran was still seen in the KO 
platelets, similar to WT.  
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To further confirm the defects in the accumulation of Fg and dextran in the VAMP-3 
KO platelets in vivo, equimolar amounts of Alexa 647-Fg and Oregon Green 488-
dextran were injected via the retro-orbital sinus of WT and VAMP-3 KO mice. 
Platelets were harvested 24 hr post-injection and imaged by 3D-SIM. In both WT and 
VAMP-3 KO platelets, Fg and dextran were localized to distinct compartments 
(Figure 6B). VAMP-3 KO platelets had a robust defect in Fg accumulation with very 
few fluorescent puncta visible. Surprisingly, dextran+ puncta were also diminished in 
KO platelets, suggesting that loss of VAMP-3 may have a greater effect on 
accumulation over longer incubation times (24 hr; i.e., when in circulation), than 
during acute uptake at shorter times (up to 60 min). This would argue that VAMP-3 is 
essential for both acute uptake and long-term accumulation/storage of receptor-
mediated cargo (Fg) whereas it preferentially affects accumulation/storage over 
acute uptake of fluid-phase pinocytic cargo. The integrity of the fluorescently-tagged 
dextran was not evaluated so its degradation could also explain our findings. 
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Figure 5 VAMP-3 KO platelets had defective fibrinogen uptake. WT and KO platelets 
(1.0 x 109/mL) were either kept resting (A) or stimulated with ADP (10 µM) (B), then 
incubated with FITC-Fg (0.06 mg/mL or 0.12 mg/mL) at 37°C for 30 min. The platelets 
were then put on ice for 20 min, fixed with 2% PFA and GMFI measurements were 
taken by flow cytometry before and after addition of 0.04% Trypan Blue (TB). 
Quantification of data shows both GMFI measurements before addition of TB 
(WT/KO –TB) which gives the total fluorescence and after addition of TB (WT/KO + 
TB) which gives the measure of internal fluorescence. As explained in “Methods” 
under plate assay to measure endocytosis, WT and KO platelets were added to each 
well and either incubated with FITC-Fg (0.1-5 µM) (E) or low mol. wt. (10 kDa) 
dextran-Oregon green 488 (1-100 µM) (F) or for times 0 to 60 min (C-D) at 37°C. 
Reactions were stopped at given time points and fluorescence was measured before 
and after addition of 0.04% TB. Data were plotted using SigmaPlot (v13.0) and 
graphed as number of molecules of Fg or dextran endocytosed per platelet. (G) 
Washed WT and KO platelets (1 X 109/mL) were incubated with FITC-Fg at final 
concentrations of 1 µM at 37°C for increasing times up to 30 min. Platelets were 
fixed with 2% PFA (final conc.) and mixed with 0.1 % TB prior to imaging. Platelets 
were visualized as in the Methods section. Exposure times for DIC were 100 msec 
while for FITC laser were 500 msec. Scale bars are 5 µM. (H) Quantification of the 
number of FITC+ puncta/platelet in both WT and KO samples and plotted using Sigma 
Plot software (v13.0). Statistical significance (**) denoted by p-value ≤0.01. Data is 
representative of 3 independent experiments (mean ± SEM) for all.  
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Figure 6 Platelets sorted endocytosed cargo. (A) Washed WT and KO platelets (1.0 x 
109/mL) were incubated ex vivo with Alexa 647-Fg and Oregon green 488-dextran at 
final concentrations of 1 µM each and incubated at 37°C for 1 min to 30 min and 
prepared for 3D-SIM imaging as described in ”Methods”. (B) WT and KO mice were 
injected with Alexa 647-Fg and Oregon Green 488-dextran, at a concentration of 2 
µM each, through the retro-orbital sinus. 24 hours post-injection, platelets were 
harvested and prepared for 3D-SIM analysis. Slides from (A) and (B) were then 
imaged using the Nikon Ti-E N-STORM/N-SIM super-resolution microscope and 
images were processed using the NIS-Elements v3.2 N-SIM/STORM suite software. 
Scale bars are 5 µm. Data is representative of at least 2 independent experiments. 
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 WT (n= 10) KO (n=10) P value 
WBC (K/µL) 9.79 ± 1.9 9.54 ± 1.59 0.57 
RBC (M/µL) 7.68 ± 1.72 7.57 ± 1.59 0.695 
Platelets (K/µL) 878.62 ± 
520.7 
945.8 ± 496.1 0.74 
Mean Platelet 
Volume (fL) 
4.36 ± 0.32 4.18 ± 0.19 0.014 
 
  
Table 2 Characteristics of blood Cells from WT and KO mice 
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Loss of VAMP-3 caused faster platelet spreading on Fg and enhanced clot 
retraction  
VAMP-3 has been shown to modulate β1 integrin-dependent cell adhesion and 
migration in epithelial cell lines [426-427]. We asked whether VAMP-3 plays a similar 
role in αIIbβ3-mediated platelet spreading. Consistent with our data in Figure 4C 
where there was no change in Fg-binding to αIIbβ3 in the VAMP-3 KO platelets, there 
was no statistically significant difference in static adhesion to Fg between WT and KO 
platelets (Figure 7C). To determine whether VAMP-3 loss affected platelet spreading, 
we monitored WT and KO platelet spreading on Fg-coated surfaces from 0 to 120 
min at 37°C. VAMP-3 deletion caused faster spreading on Fg-coated surfaces with 
significantly larger platelet surface areas covered in as early as 30 min (p≤ 0.05), and 
continuing to later time points [45 min (p≤ 0.001), 60 min (p≤ 0.001) and 90 min (p≤ 
0.01)] (Figure 7A-B). The rate of spreading was 82% faster in the KO platelets (rate of 
0.80 µm2/min for KO vs 0.44 µm2/min for WT; assuming spreading is a linear function 
over time). Consistent with increased spreading, clot retraction was also faster in KO 
platelets compared to WT (Figure 7D-E). Unlike spreading, which is a linear function, 
clot retraction proceeded exponentially over time, with the decay constant for WT 
being 0.011 % of initial clot size/min and that for KO is 0.015 % of initial clot size/min. 
This led to a 36% enhancement in the rate of clot retraction in the KO platelets as 
early as 30 min (p≤ 0.05) and continued at 60 min (p≤ 0.05) and 120 min (p≤ 0.05). 
Note that exogenous Fg was added in excess and was not limiting in these assays. 
Thus, loss of VAMP-3 led to enhanced platelet spreading and clot retraction. These 
alterations, however, do not affect platelet aggregation and hemostasis on a global 
scale, as both were normal in the VAMP-3 null mice which also have no bleeding 
diathesis [202]. 
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Figure 7 VAMP-3 KO platelets spread faster on Fg and had enhanced clot retraction. 
(A) Representative images of WT and KO platelets allowed to spread for 60 min are 
shown. Images of spread platelets were taken using DIC Microscopy as described in 
“Methods”. Exposure times for DIC images were 100 msec. (B) Quantification of 
platelet surface area from WT and KO Fg-spread platelets for indicated times. Data is 
representative of 2 independent experiments (mean ± SEM). (C) Quantification of 
static adhesion on 50 μg/mL human Fg and 5% BSA-coated surfaces for WT and KO 
calcein-labeled platelets harvested from 3 different KO and WT mice. Adherent 
platelets were measured by fluorescence using a SpectraMax plate reader. Data was 
plotted using SigmaPlot (v13.0). (D) Representative images of thrombin-stimulated 
(0.05U/mL; denoted by +) clot retraction in WT and KO platelets at increasing times. 
(E) Clot sizes were measured and the percent of clot size relative to initial suspension 
volume (measured at time 0 and set as 100%) were determined and plotted. Three 
different KO and corresponding WT littermate controls were used in this experiment. 
Statistical significance (*) denoted by p-value ≤0.05, (**) denoted by p-value ≤0.01, 
(***) denoted by p-value ≤0.001, and n.s stands for not significant.  
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Loss of VAMP-3 led to increased JAK2 phosphorylation downstream of TPOR/Mpl 
receptor 
Since VAMP-3 mediates trafficking of several transmembrane receptors such as the 
Transferrin receptor in other cell types [404], we asked what other platelet receptors 
could rely on VAMP-3-dependent trafficking step(s). Thrombopoietin (TPO) binding 
to its receptor Thrombopoietin Receptor (TPOR/Mpl) induces internalization of the 
receptor in a Dynamin-2 and clathrin-mediated process that initiates signaling via 
Janus Kinase 2 (JAK2) phosphorylation [22, 460]. We asked whether VAMP-3 
contributes to this process. In contrast to Dynamin-2 KO platelets, VAMP-3 KO 
platelets did not exhibit constitutive JAK2 phosphorylation. Instead, they showed a 
time-dependent increase in phospho-JAK2 levels similar to WT. However, at each 
time point, phospho-JAK2 levels were markedly elevated in VAMP-3 KO vs. in WT 
platelets (Figure 8A-B) with statistically significant differences at 15 min (p≤ 0.05) 
and at 30 min (p≤ 0.05). The levels of total JAK2 appeared to be lower in the VAMP-3 
KO platelets compared to WT and the levels of total TPOR were unchanged (Figure 
8A). Our data suggests that while TPOR levels may be unaffected, there exists a 
VAMP-3-mediated membrane trafficking step(s) that occurs upon TPO-bound TPOR 
internalization, which affects JAK2 phosphorylation. Given that Arf6 is important for 
integrin trafficking, we asked whether it could play a role in signaling through the 
TPOR-JAK2 axis. Arf6 KO platelets demonstrated normal JAK2 phosphorylation upon 
TPO induction similar to WT platelets, with no change in TPOR levels (Figure 12A-B). 
Arf6, thus, may be less important than VAMP-3 or Dynamin-2 in regulating 
TPOR/Mpl-JAK2 signaling.  
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Figure 8 Loss of VAMP-3 led to increased JAK2 phosphorylation downstream of 
TPOR/Mpl receptor. (A) Platelet extracts were prepared from washed WT and KO 
platelets (4 X 108/mL) were incubated with 50 ng/mL of thrombopoietin (TPO) for 0 
to 30 min at 37°C. Western blotting was performed using anti-JAK2 and anti-phospho 
JAK2 (Tyr 1007/1008) and anti-TPOR antibodies. Images were taken on a Typhoon 
9500 Variable Mode Imager and quantified using the ImageQuantTL software. (B) 
Volumetric quantification of phospho-JAK2 levels over total JAK2 levels was plotted 
as a ratio of pJAK2/JAK2 (arbitrary units) over time of TPO incubation. Statistical 
significance (*) denoted by p-value ≤0.05 and is representative of at least 3 
independent experiments (mean ± SEM). 
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Figure 9 Plasma Fg levels were unaffected in VAMP-3 KO mice. 
Western Blotting showing levels of plasma Fg from 2 different VAMP-3 KO and 
corresponding WT littermate controls. Equal amounts of protein 30 µg/lane, 
quantified by protein BCA assay, were loaded. 
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Figure 10 
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Figure 10 Arf6 KO platelets had a greater negative defect in Fg uptake than in 
dextran uptake. 
100 µL of WT and Arf6 KO washed platelets (5 X 107/mL), pre-incubated with 1 mM 
CaCl2 for 5 min, were added to each well in a 96-well black opaque plate and either 
incubated for increasing times (0-60 min) (A-B) or with varying concentrations of 
FITC-Fg (0.1-5 µM) (C) or low mol. wt. (10,000 MW) dextran-Oregon green 488 (1-
100 µM) (D) at 37°C. Reactions were stopped at given time points and fluorescence 
intensity was measured using a SpectraMax plate reader (Molecular Devices; 
excitation/emission at 495/520 nm) before and after addition of 0.04% Trypan Blue. 
Data were plotted using SigmaPlot (v13.0) and plotted as number of molecules of Fg 
or dextran endocytosed per platelet. Data are representative of at least 2 
independent experiments. 
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Figure 11 
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Figure 11 VAMP-3 deletion did not affect dextran uptake. Washed platelets (1 X 
109/mL) from WT and KO mice were incubated with Dextran-Oregon Green 488 at 
final concentrations of 1 µM each at 37°C for increasing times up to 30 min. (A) 
Representative images at 30 min are shown here. Platelets were fixed with 2% PFA 
(final conc.) and mixed with 0.1 % Trypan Blue prior to imaging. Platelets were 
visualized using the using Differential Interference Contrast Microscopy on a Nikon 
Eclipse E600 microscope (Nikon, Melville, NY) fitted with an AxioCam MR camera 
(Zeiss, Germany) and processed using the Zen 2011 Digital Imaging software (blue 
edition, Zeiss). Exposure times for DIC was 100 ms while for FITC laser was 500 ms. 
Scale bars are at 5 µM. (B) Quantification of the number of Oregon Green 488-
positive puncta per platelet in both WT and KO samples that were counted and 
quantified using Sigma Plot software (v13.0). Data are representative of 2 
independent experiments.  
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Figure 12 Arf6 KO platelets had normal TPO-induced JAK2 phosphorylation. (A) 
Washed WT and KO platelets (4 X 108/mL) were pre-incubated with 1 mM CaCl2 for 5 
min and incubated with 50 ng/mL of Thrombopoietin (TPO; R&D Systems) for 0 to 30 
min at 37°C. Platelet extracts were prepared in SDS-PAGE sample buffer 
(supplemented with protease and phosphatase inhibitor cocktail mix). Western 
blotting was performed using anti-JAK2 and anti-phospho JAK2 (Tyr 1007/1008) and 
anti-TPOR antibodies. Images were taken on a Typhoon 9500 Variable Mode Imager 
and quantified using ImageQuantTL software (GE Healthcare Life Sciences, 
Piscataway, NJ). (B) Volumetric quantification of phospho-JAK2 levels over total JAK2 
levels was plotted as a ratio of pJAK2/JAK2 (arbitrary units) over time of TPO 
incubation. Data shown here are representative of 2 independent experiments 
(mean ± SEM). 
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Conclusions 
Endocytosis is key to fibrinogen (Fg) uptake, receptor trafficking of integrins (αIIbβ3, 
αvβ3) and purinergic receptors (P2Y1, P2Y12), and thereby for normal platelet function. 
However, the molecular machinery required and possible trafficking routes are still 
ill-defined. Using VAMP-3 KO mice, that are otherwise unaffected in their activation, 
aggregation and secretion responses, we examined the role of a vesicle-residing 
Soluble N-ethylmaleimide Factor Attachment Protein Receptor (v-SNARE) called 
Cellubrevin/Vesicle-Associated Membrane Protein-3 (VAMP-3) in platelet function. 
In this chapter, we explored the role of VAMP-3 in mediating endocytosis in platelets. 
Platelets from VAMP-3 KO mice had less platelet-associated Fg, indicating a defect in 
Fg uptake/storage. This defect was not attributed to any alterations of endocytic 
machinery components, surface expression levels of αIIbβ3, or reduced plasma Fg 
levels. Loss of VAMP-3 led to a defective uptake of fluorescently-tagged Fg and low 
molecular dextran in platelets though it had a greater negative effect on receptor-
mediated Fg uptake than on the fluid-phase marker uptake. Additionally, we 
followed the time-dependent trafficking of Fg and dextran into platelets using 3D-
Structured Illumination Microscopy. Wild-type platelets endocytosed both cargoes 
but quickly sorted them into distinct compartments with partial overlap occurring 
only at early time points. This is the first demonstration of platelets being able to 
sort cargo upon endocytosis. Sorting was unaffected in VAMP-3 KO platelets. The 
VAMP-3 loss did affect some acute platelet functions leading to enhanced spreading 
on Fg and faster clot retraction compared to wild-type, suggesting that VAMP-3 is 
involved in endocytic trafficking of integrin αIIbβ3. Additionally, the rate of JAK2 
phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl) 
activation, was affected in VAMP-3 KO platelets. Collectively, our studies show that 
platelets are capable of a range of endocytosis steps with VAMP-3 being pivotal in 
these processes. This is the first report of v-SNARE being involved in endocytic 
trafficking in platelets. How VAMP-3-mediated endocytosis affects other platelet 
functions will be explored in the next chapter. 
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Chapter Four: Endocytosis mediates innate immune responses by platelets in the 
vasculature 
Introduction 
How multifunctional platelets can act as immune cells, bridging the gap between 
coagulation cascades and immune systems in the vasculature, has in recent years 
become an active field of research [464]. Being the most abundant “responsive” cell 
type in circulation, it is hardly surprising when studies showed that platelets are, 
indeed, the first responders to trap bacteria and present them to leukocytes, even 
before the professional immune cells encounter the pathogen [463]. In fact, studies 
within activated high endothelial venules (HEVs) showed that neutrophils hone in on 
inflammatory damage by actively seeking P-selectin-bearing activated platelets to 
mediate responses [611]. 
Systemic viral and bacterial infections have long been associated with severe 
thrombocytopenia especially in the cases of sepsis [465], viral hemorrhagic fevers 
[466], hepatitis C virus infections [467], and human immunodeficiency virus-1 
infections [468] among others. The severity of thrombocytopenia often predicts the 
clinical outcomes of viremia and bacteremia. Platelets isolated from patients 
infected with viruses such as HIV-1 [263], influenza [469], dengue virus [471] and 
hepatitis C virus [470], have been shown to harbor viral particles, yet the molecular 
machinery that is required for viral entry is unclear.  
Platelets express several Toll-like Receptors (TLRs) that are pattern-recognition 
receptors that can recognize viral and bacterial pathogen-associated molecular 
patterns (PAMPS) or damage-associated molecular patterns (DAMPS) [437, 439-442]. 
Of the ones that are present in platelets, the plasma membrane-residing TLR2 and 
TLR4 and the intracellular-residing TLR7 and TLR9 have been found to be functionally 
relevant [411].  Recently, TLR7, which resides in an intracellular compartment and 
recognizes single-stranded RNA, was found to be present in platelets [411, 437, 472]; 
and is required for mediating platelet counts and host survival in a mouse model of 
encephalomyocarditis virus (EMCV) infection. Viruses such as EMCV, HIV-1, and 
influenza virus as well as small guanosine analogs such as Loxoribine have been 
shown to activate TLR7 signaling pathways [437]. In plasmacytoid dendritic cells, 
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responses to HIV-1 are mediated by virus phagocytosis/endocytosis, degradation to 
release Toll-like Receptor ligands, and subsequent receptor activation [473]. 
Whether all or some of this process is recapitulated in platelets is unknown.  
Towards this direction, we queried the molecular machinery that is required for HIV-
1 entry into platelets and how does viral endocytosis affect platelets in determining 
the clinical outcomes in these HIV-1+ patients. We first examined platelets’ 
responses to two specific nucleotide-based, TLR agonists, loxoribine (TLR7) and 
unmethylated CpG oligonucleotides (TLR9). Using secretion assays to measure 
release from all three classes of granules (alpha, dense and lysosomes), we found 
that both TLR agonists elicited a small (compared to hemostatic agonists, i.e., 
thrombin) secretory response that was sufficient to form platelet-leukocyte 
aggregates as measured by FACS. Additionally, both activated IKK and PI3K-Akt 
pathways as measured by immunoblotting. Inhibitor studies (using known inhibitors 
of endocytic trafficking such as Dynasore, ammonium chloride) and analysis of 
platelets from two different endocytosis mutants (VAMP-3 KO and Arf6 KO) 
demonstrated the importance of platelet endocytic trafficking in regulating 
responses to these intracellular TLRs. To further understand this process, we used 
HIV-1 pseudovirions that contain ssRNA which can be recognized by the endosomal 
TLR7, showing that platelets did endocytose and degrade retroviral particles to 
release TLR agonists, which initiate platelet activation and secretion. Fluorescence 
micrographs showed uptake of HIV-1 pseudovirions in both in-vitro and in vivo 
analyses of wild-type platelets. Consistently, HIV-1 uptake and subsequent activation 
were abolished in endocytosis-deficient VAMP3 KO or Arf6 KO platelets. 
Taken together, our data supports that platelets can act as early damage responders 
by recognizing pathogenic viruses and mount an appropriate immune response to 
them. 
Platelets responded differentially to different stimuli: “immuno-activation” versus 
“hemostatic activation” 
Given that platelets express TLR7 (binds to ssRNA) and TLR9 (binds to DNA, 
unmethylated CpG motifs) [472, 442], we asked how these TLRs activates platelets. 
Using bioactive, pathogen-mimetics such as Loxoribine a guanosine analog that 
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specifically activates TLR7 and CpG oligonucleotides Class C (CpG ODN2395) that 
specifically turns on TLR9; we measured platelet secretion as an indicator of 
activation. Wildtype platelets when stimulated with thrombin (0.05 U/mL), which is 
the most potent activator of platelets, showed rapid and robust secretion that 
reached maximum saturation levels within 3 min of stimulation, from all three types 
of granules (Figure 13A i, ii, iii). When platelets were stimulated with TLR7 agonist 
Loxoribine (1 mM) and TLR9 agonist CpG ODN2395 (5 µM), the kinetics of release 
were much slower and lower in terms of percent secretion. Thrombin stimulation of 
platelets causes 80-90% secretion of [3H]-serotonin from dense granules, 50-60% 
secretion of platelet factor 4 (PF4) and 20-30% secretion of β-hexosaminidase from 
lysosomes. Compared to that, both Loxoribine and CpG ODN2395 stimulated roughly 
30-40% release of [3H]-serotonin from dense granules, 15-20% secretion of platelet 
factor 4 (PF4) and hardly any secretion of β-hexosaminidase from lysosomes. It is to 
be noted here that lysosome secretion is usually the weakest of the three granules. 
This lower extent of release held true even for longer times of incubation with the 
respective agonists. Thrombin reaches its maximum saturation within 3-5 mins while 
it takes much longer for the TLR agonists to reach even half of thrombin’s maximum 
release percentages.  
P-selectin (CD62P), which is exteriorized by platelets upon exocytosis of alpha 
granules during activation, functions as a cell adhesion molecule by binding to the 
leukocyte receptor, P-selectin glycoprotein ligand-1 (PSGL-1) that are essential for 
forming the platelet-leukocyte aggregates and serve as markers for thrombo-
inflammation in the circulation [474]. We measured whether these TLR agonists 
could stimulate P-selectin exteriorization from platelet alpha-granules. In Figure 13B, 
Loxoribine at two different concentrations (0.1 mM and 1mM) and CpG-ODN (at 2.5 
µM and 5 µM) stimulated platelets, when incubated for 30 min at 37°C, to exocytose 
P-selectin, that was higher than resting levels (p values ≤ 0.05) but was markedly 
lower than the P-selectin levels expressed by platelets upon thrombin stimulation 
(0.1 U/mL for 3 min). TLR-stimulated P-selectin levels (at least in the case of 
Loxoribine) were even lower than those exteriorized by sub-optimal doses of 
thrombin (25 mU/mL for 3 min). Consequently, we measured platelet-neutrophil 
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aggregates in whole blood using anti-CD42b antibodies (platelets) and anti-CD11b 
antibodies (neutrophils and monocytes), in response to Loxoribine (1 mM) and CpG 
ODN (5 µM) stimulated for 30 min and compared that with thrombin (0.1 U/mL) 
stimulation for 3 min. As expected, TLR agonists stimulate low levels of CD11b-
CD42b aggregates compared to thrombin stimulation (Figure 13C). Taken together, 
we show using three different assays, that platelets respond differently (slower and 
lower levels of activation) to “immune agonists” than they do to “hemostatic 
agonists” such as thrombin, where responses are extensive and robust. 
Responses to endosomal TLRs required Dynamin-mediated endocytosis and acidic 
compartments 
TLRs 3, 7, 8, and 9 are present in intracellular compartments. Response to these 
endosomal TLRs requires Dynamin-dependent endocytosis of their specific ligands, 
followed by trafficking to an acidic endosomal compartment, where receptor binding 
and signaling occurs [411]. We asked whether the response to these endosomal TLRs 
also proceeds via similar endocytic trafficking routes in platelets. Washed platelets 
were pre-incubated for 30 min, at 37°C, with either Dynasore (80 µM), a small 
molecule Dynamin inhibitor [577], at concentrations that do not inhibit ATP 
secretion from platelets [351] or with ammonium chloride (20 mM), which 
neutralizes the pH of acidic compartments to determine whether activation-induced 
signaling downstream of TLR7 and TLR9 was affected.  Loxoribine stimulation 
activates PI3K-Akt pathways in platelets [472], while TLR9 stimulation also activates 
PI3K and MAPK pathways in platelets [506]. IKK-β-mediated SNAP-23 
phosphorylation drives SNARE complex formation and granule secretion [242]. We 
have a phospho-peptide specific antibody that detects SNAP-23 phosphorylation, at 
Ser95, that allows us to measure SNAP-23 phosphorylation as a metric of secretion. 
This antibody only works in mouse platelets [242].  In Figure 14A, Akt and SNAP-23 
phosphorylation was measured in platelets in response to Loxoribine (1 mM) (TLR7), 
CpG ODN2395 (5 µM) (TLR9) and HIV-1 pseudovirions (100x) (TLR7) stimulation, 
incubated for 30 min, either in the presence or absence of NH4Cl (20 mM).  In Figure 
14B, Akt phosphorylation was reduced in the presence of NH4Cl, in response to 
Loxoribine, CpG ODN and HIV-1 pseudovirions (HIVpp), suggesting the need for 
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trafficking into acidic compartments for efficient TLR-induced signaling.  In Figure 
14C, SNAP-23 phosphorylation was affected in CpG ODN and HIVpp stimulated 
platelets, while NH4Cl-mediated inhibition of Loxoribine-stimulated SNAP-23 
phosphorylation appeared to be much weaker than the others.  In a similar vein, we 
monitored signaling responses to these TLR ligands in response to Dynasore-
mediated Dynamin inhibition. In Figure 15A, Akt and SNAP-23 phosphorylation was 
measured in platelets in response to Loxoribine (1 mM) (TLR7), CpG ODN2395 (5 µM) 
(TLR9) and HIV-1 pseudovirions (100x) (TLR7) stimulation, incubated for 30 min, 
either in the presence or absence of Dynasore (80 µM).  In Figure 15B, Akt 
phosphorylation was reduced in the presence of Dynasore, in response to Loxoribine, 
CpG ODN and HIV-1 pseudovirions (HIVpp), suggesting the need for Dynamin-
dependent endocytosis for efficient trafficking to TLR-containing compartments to 
initiate TLR-induced signaling.  In Figure 13C, SNAP-23 phosphorylation was also 
affected in Loxoribine-, CpG ODN- and HIV-1pp-stimulated platelets. Collectively, our 
data suggests that responses to endosomal TLRs proceed via Dynamin-mediated 
pathways, followed by trafficking into acidic compartments, where engagement of 
the TLR ligand with its receptor initiates downstream signaling responses. To 
determine whether platelet activation by these TLR ligands indeed occurs through 
the actions of TLRs, we probed platelet activation by measuring Akt and SNAP-23 
phosphorylation in response to LPS (TLR4), Pam3CSK4 (TLR2), Loxoribine (TLR7) and 
CpG ODN (TLR9) in TLR23479 mutants. In Figure 21, we see the loss of signaling (both 
Akt and SNAP-23 phosphorylation) in response to each of these agonists in the 
quintuple mutants, indicating that signaling through these ligands indeed proceeds 
via their cognate TLR receptors. Of note, thrombin-induced responses are unchanged 
in these mutants suggesting that defective Akt and SNAP-23 phosphorylation is due 
to inability to induce signaling upon ligand binding and not due to any other 
hemostatic or platelet activation defects.  
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Figure 13 Platelets responded differently to “hemostatic activation” vs “immuno-
activation”. (A) Washed platelets (2.5 X 108 platelets/mL) were stimulated with 
Loxoribine (1 mM), CpG ODN2395 (5 µM) and Thrombin (0.05 U/mL) for the 
indicated times and percent secretion (i) [3H]-Serotonin from dense core granules, (ii) 
PF4 from alpha granules and (iii) β-hexosaminidase from lysosomes was measured. 
(B) anti-FITC-P-selectin antibody was added to platelets (5 X 107/mL) stimulated with 
Loxoribine (0.1 mM and 1 mM), CpG ODN2395 (2.5 µM and 5 µM) for 30 min and 
thrombin (0.025 U/mL and 0.1 U/mL) for 3 min and geo mean fluorescence intensity 
was plotted for each condition. (C) Anti-APC-CD11b and anti-FITC-CD42b antibodies 
were added to 50 µL of wildtype whole blood, stimulated with Loxoribine (1 mM), 
CpG ODN2395 (5 µM) stimulated for 30 min and Thrombin (0.1 U/mL) for 3 min or 
buffer control (for unstimulated) and samples with analyzed for double-positive 
CD42b-CD11b stained conjugates using BD LSRII Flow Cytometer. Data was then 
analyzed using FlowJo (v5.6.7 software) and plotted as percent of aggregate 
formation. Data is representative of at least three independent experiments with 
statistical significance represented by p≤0.05 (*). 
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Figure 14 Responses to endosomal TLR7, TLR9, and HIV-1 pseudovirions required 
endosomal maturation. (A) Washed platelets (4 × 108 platelets/mL) were pre-
incubated with or without NH4Cl (20 mM) for 30 min and then stimulated with 
Loxoribine (1 mM), CpG ODN2395 (5µM), HIV-1 pseudovirions (HIV-1pp) for 30 min 
at 37°C.  Western blotting was performed using anti-phospho-Akt (Ser473), anti-Akt, 
and anti-phospho-SNAP-23 (Ser95) and anti-SNAP-23 antibodies. Images were taken 
on a Typhoon 9500 Variable Mode Imager and quantified using the ImageQuantTL 
software. (B) Volumetric quantification of the percent of phospho-Akt relative to 
total Akt and (C) of phospho-SNAP-23 over total SNAP-23. Statistical significance (*) 
denoted by p-value ≤0.05, (**) denoted by p-value ≤0.01 and is representative of at 
least 3 independent experiments (mean ± SEM). 
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Responses to endosomal TLRs required VAMP-3 and Arf6-mediated endocytosis 
Our data suggests that platelets utilize endocytosis to mediate responses to 
endosomal TLR ligands. Using fibrinogen uptake as a metric for endocytosis, we have 
identified two key endocytic regulators in platelets. Both Arf6 and VAMP-3 loss 
causes a robust defect in fibrinogen uptake. Arf6, the Ras-like small GTPase, that is 
involved in integrin trafficking and Fg uptake in platelets has also been shown to be 
involved in the pathogenic invasion of various cell types [587-590]. Inhibition of Arf6 
in RAW264.7 macrophages by siRNA knockdown or dominant-negative mutants, 
show impaired uptake of CpG oligonucleotides, reduced PI3K/Akt signaling and 
impaired TLR9-dependent immune responses [612]. On the other hand, data 
presented in this thesis demonstrates VAMP-3 is critical for receptor-mediated 
uptake of fibrinogen. VAMP-3/Cellubrevin has also been shown to be critical for 
phagocytosis of pathogens and various particles [416-417]. However, the importance 
of both Arf6 and VAMP-3 in mediating uptake of endosomal TLR ligands in platelets 
remains to be determined. We queried whether platelets utilize a common 
endocytic machinery to internalize granule cargo and pathogens or “immunogenic 
cargo”.   
Towards this direction, we incubated washed WT and VAMP-3 KO platelets with 
either TLR7-Loxoribine (1 mM) or TLR9-CpG ODN2395 (5 µM) for 0 to 60 min at 37°C 
and platelet lysates were prepared and probed for Akt and SNAP-23 phosphorylation 
as metrics of activation. As shown in Figure 16, in WT platelets, both Loxoribine and 
CpG ODN induced Akt and SNAP-23 phosphorylation in a time-dependent manner, 
with the VAMP-3 KO platelets showing robust attenuation in Akt and SNAP-23 
phosphorylation at each time point measured. There appears to be a lag in 
generating appreciable phosphorylation (usually about 15 min) in platelets treated 
with Loxoribine and CpG oligonucleotides, possibly due to the time taken by 
respective ligands to internalize and traffic to the right compartment that has the 
endosomal TLRs. Similarly, as shown in Figure 17, time-dependent Loxoribine and 
CpG ODN stimulation were also affected in the Arf6 KO platelets. It would appear 
that while both TLR7-Loxoribine and TLR9-CpG ODN signaling responses are 
significantly affected in VAMP-3 KO platelets while as expected, TLR9-CpG ODN 
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stimulation induced Akt and SNAP-23 phosphorylation is more affected in the Arf6 
KO platelets than the TLR7-Loxoribine induced responses. This would suggest that 
there exists some heterogeneity in endocytic regulator usage by these TLR ligands to 
target them to their respective TLR-bearing endosomal compartment. VAMP-3 may 
be more central in coordinating trafficking to both TLR7+ and TLR9+ endosomes, 
while Arf6 may be preferred for trafficking cargo into TLR9+ endosomes and to a 
lesser extent to TLR7+ endosomes. While this diversity in trafficking routes and 
regulator usage is indeed interesting in platelets, at this point it is unclear whether 
platelets have discrete TLR7+ and TLR9+ endosomes or whether both TLRs co-exist in 
the same endosome. Immunofluorescence studies will shed more light on this 
complex trafficking system. What other potential endocytic proteins and regulators 
are involved in this process in platelets remains to be seen. 
The observed reduction in Akt and SNAP-23 phosphorylation in response to TLR7 and 
TLR9 stimulation in the Arf6 or VAMP-3 mutants could be due to loss of any or both 
of the TLR, unstable receptors (prone to degradation) or some aberrant dysfunction 
that could potentially explain the impaired signaling responses. To exclude this 
possibility, we probed for both TLR7 and TLR9 in platelet extracts from the mutants 
and compared them to littermate-matched controls. In nucleated cells, processing of 
the endosomal TLRs (7, 9, etc.) occurs in the endoplasmic reticulum, where the full-
length receptor gets cleaved to generate the functional component of the TLR (that 
which initiates ligand-binding and downstream activation) that gets trafficked into 
the appropriate endosome [411]. Platelets, much like the nucleated cells, have both 
the full-length and the cleaved ligand-binding functional form and western blotting 
showed that the levels of both forms appear to be unchanged in the VAMP-3 and 
Arf6 mutants (Figure 20A-B). This holds true for both TLR7 and TLR9. This argues that 
the impairment of signaling in these mutants is possibly due to defective endocytosis 
of ligands and not due to altered levels of the TLRs. However, the possibility of the 
presence of both full-length and cleaved, but functionally inactive, forms of the TLR7 
and TLR9 receptor in the VAMP-3 and Arf6 mutants, that could arguably give similar 
defects in signaling responses, cannot be excluded at present. Further experiments 
will need to confirm this possibility. 
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Figure 15 Responses to endosomal TLR7, TLR9, and HIV-1 pseudovirions required 
Dynamin. (A) Washed platelets (4 × 108 platelets/mL) were pre-incubated with or 
without Dynasore (80 µM) for 30 min and then stimulated with Loxoribine (1 mM), 
CpG ODN2395 (5µM), HIV-1 pseudovirions (HIV-1pp) for 30 min at 37°C.  Western 
blotting was performed using anti-phospho-Akt (Ser473), anti-Akt, and anti-phospho-
SNAP-23 (Ser95) and anti-SNAP-23 antibodies. Images were taken on a Typhoon 
9500 Variable Mode Imager and quantified using the ImageQuantTL software. (B) 
Volumetric quantification of % of phospho-Akt levels over total Akt levels and (C) of 
phospho-SNAP-23 levels over total SNAP-23 levels. Statistical significance (*) 
denoted by p-value ≤0.05, (**) denoted by p-value ≤0.01 and is representative of at 
least 3 independent experiments (mean ± SEM). 
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Endocytosis of HIV-1 pseudovirions required VAMP-3 and Arf6 
Like the small bioactive TLR ligands, the more physiologically relevant agonist, HIV-1 
pseudovirions also require endosomal uptake and processing to generate TLR ligands. 
In plasmacytoid dendritic cells, Dynamin-dependent endocytosis internalizes HIV-1 
virions upon CD4-mediated entry; virus gets trafficked through endosomal 
compartments and eventually reaches the late endosomes and lysosomes, where it 
gets degraded. We asked how much of this process is recapitulated in platelets. 
Figure 14 and 15, indicates that response to HIV-1 pseudovirions requires dynamin-
mediated uptake and trafficking to acidic compartments, where the viral particles 
get degraded to release TLR ligands that might then activate Akt and SNAP-23 
phosphorylation. Additionally, Arf6 is also required for HIV-1 endocytosis in T-cells 
[586]. Use of siRNA against Arf6, or inhibiting Arf6 function by using GDP-bound or 
GTP-bound inactive mutants, led to a decrease in HIV-1 viral membrane fusion, entry 
and infection of T lymphocytes. Furthermore, Arf6 inhibition impaired cell-to-cell 
transmission of HIV-1 viral particles in CD4+-T lymphocytes. On the other hand, 
VAMP-3/Cellubrevin has been critical for phagocytosis of pathogens and various 
particles [416-417]. However, the importance of VAMP-3 in mediating HIV-1 
endocytosis is unclear. We sought to determine, whether VAMP-3 and Arf6 play a 
role in mediating viral uptake. 
Using our plate assay to measure endocytosis as described in Methods, we 
incubated WT, VAMP-3 KO and Arf6 KO platelets with two different concentrations 
of FITC-conjugated CpG ODN2395 (5 µM and 10 µM) at 37°C for 30 min. Reactions 
were stopped by addition of 0.04% Trypan Blue. Similar to Huang et al. 2016 [19], we 
used 0.04% Trypan Blue (TB) to quench external FITC fluorescence (including the 
fluorescence that is trapped within the open canalicular system) and measured TB-
resistant fluorescence of internalized cargo as a metric of endocytosis. In Figure 18A, 
WT platelets internalized more CpG ODN in a dose-dependent manner, while VAMP-
3 KO and Arf6 KO platelets had robust defects in uptake. This argues that the 
signaling that we measure in terms of Akt and SNAP-23 phosphorylation is caused 
due to endocytosis of CpG ODN molecules and this response is significantly affected 
in the endocytosis mutants. To determine whether the same holds true for the HIV-1 
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pseudovirions, we tested viral endocytosis in our plate assay. Figure 18B shows a 
schematic of the HIV-1 pseudovirion construct that was obtained from Dr. Gregory 
Melikyan’s lab [613]. These genetically modified non-infectious HIV-1 viral particles, 
provisionally called “pseudovirions” retain most of the actual HIV-1 viral backbone, 
with modifications introduced in the form of double fluorescent tags such that the 
green fluorescent protein is fused to the plasma membrane-residing intercellular 
adhesion molecule-1 (ICAM-1) and the viral core has an mCherry fluorescent tag 
encoded with the viral Gag protein. Viral expression in 293-LTV (lentiviral derived) 
cell lines generated red-green double-tagged pseudovirions that were produced by 
the Genetics Core Facility, here at the UK. Pseudovirions obtained were incubated 
with WT, VAMP-3 KO and Arf6 KO platelets at increasing concentrations (1x and 2x) 
at 37°C for 30 min and Trypan Blue-resistant fluorescence intensities were measured. 
In Figure 18C, WT platelets internalized more HIV-1pp in a dose-dependent manner, 
while VAMP-3 KO and Arf6 KO platelets had robust defects in uptake. These data 
provide the first indication that VAMP-3 and Arf6 may be involved in viral uptake. 
We used fluorescence microscopy to further confirm these results. WT, VAMP-3 KO, 
and Arf6 KO platelets were incubated with HIV- pseudovirions (100x concentrated) 
at 37°C, for 0 to 6 hr, fixed with PFA, treated with 0.04% trypan blue to quench 
external fluorescence, and imaged by epifluorescence. WT platelets had more GFP-
mCherry double positive puncta than either of the endocytosis mutants (Figure 16D). 
Based on Miyauchi et al 2011 [613], the GFP-ICAM-1 molecule often gets 
incorporated into the membrane to form membrane vesicles; these are not virions 
and hence were excluded from measurements. Only double-positive red-green 
viruses were considered whole virions and were counted to denote viral uptake 
inside platelets. Quantification of total fluorescent puncta present per platelet 
showed that over time, WT platelets accumulated more HIV-1 pseudovirions and the 
number of red-green double-positive puncta increased, while the VAMP-3 KO and 
Arf6 KO platelets failed to do to any great extent, even up to 6 hr of incubation with 
HIV-1pp (Figure 18E), consistent with our ex vivo plate-based assay. 
To further confirm the ex vivo defects in the endocytosis of HIV-1pp, age-matched 
WT and VAMP-3 KO mice were intravenously injected with the pseudovirions (100X) 
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via the retro-orbital sinus of the mice. Platelets were harvested 24 hr post-injection 
and imaged by fluorescence microscopy. As shown in Figure 18F-G, quantification by 
counting the number of double-positive viral particles in WT and VAMP-3 KO 
platelets showed viral particles were present in WT platelets, even 24 hr post-
injection while there were hardly any detectable viral particles within VAMP-3 KO 
platelets. Our data indicates that VAMP-3 and Arf6 are not only involved in the acute 
uptake of HIV-1pp (over shorter times) but also on chronic accumulation (24 hr; i.e., 
when in circulation) of the viral particles. In an essence, uptake of HIV-1pp in WT 
platelets and its lack thereof in the endocytosis mutants mirrors that of Fg uptake in 
both acute and chronic phases of endocytosis. Given that HIV-1pp requires a surface 
receptor (CLEC-2, DC-SIGN or any other potential receptor) to internalize, it is hardly 
surprising that its endocytosis proceeds in a similar fashion to αIIbβ3-mediated Fg 
binding and uptake. Further experiments are in the works to clarify this theory. 
Given that CLEC-2 and DC-SIGN are the potential HIV-1-binding receptors on 
platelets (which lack CD4), defective endocytosis of the pseudovirions in the VAMP-3 
and Arf6 mutants could be due to decreased levels of one or more of the receptors. 
We, thus, probed for DC-SIGN levels in the VAMP-3 KO and Arf6 KO platelets. Only 
15% of platelets express DC-SIGN [543] which explains the low levels of detection of 
the protein by western blotting. However, the levels of DC-SIGN appear to be 
unaltered in the mutants (Figure 18E). The other receptor, CLEC-2, remains unaltered 
in the Arf6 KO platelets (Figure 18D). Surprisingly, VAMP-3 KO platelets showed 
lower levels of CLEC-2 than WT platelets (Figure 18C). While this could partly explain, 
why VAMP-3 platelets have such a severe phenotype in their ability to internalize the 
virions; the fact that Arf6 KO platelets are still defective in viral uptake despite 
expressing normal levels of CLEC-2, suggest that viral uptake by platelets may have 
multiple components with viral-binding by CLEC-2 being one aspect of it. Low levels 
of CLEC-2 on VAMP-3 KO platelets portend towards a biogenesis defect at the 
megakaryocyte level. What this entails will require further experiments at probing 
the role of VAMP-3 in platelet formation, cargo biogenesis and/or packaging in the 
megakaryocytes. 
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Collectively, these data show that HIV-1pp uptake and/or accumulation is 
dramatically reduced in the VAMP-3 KO and Arf6 KO platelets suggesting the need 
for endocytosis to internalize the virus. Our data provides the first mechanistic 
understanding as to the molecular machinery required for HIV-1 endocytosis in 
platelets. 
Endocytosis of HIV-1 pseudovirions triggered platelet activation 
What happens to the viral particles once it gets endocytosed within platelets? In 
Figure 19A-B, washed WT, VAMP-3 KO, and Arf6 KO platelets were incubated with 
HIV-1pp (100X) for 30 min at 37°C and probed for activation markers. HIV-1pp 
stimulated Akt and SNAP-23 phosphorylation in the WT platelets but had a 
significant loss of activation in the endocytosis mutants. This indicates that 
endocytosis of the HIV-1 pseudovirions, mediated by VAMP-3 and Arf6, leads to 
platelet activation.  
Activation-induced signaling through PI3K/Akt pathway and IKKβ-mediated SNAP-23 
phosphorylation converges to drive platelet granule secretion. We measured HIV-
1pp-induced platelet secretion by probing for P-selectin exteriorization by flow 
cytometry, as a metric of alpha granule secretion. In Figure 19C, HIV-1pp caused P-
selectin exteriorization from WT platelets. Loss of either VAMP-3 or Arf6 significantly 
inhibited P-selectin exteriorization from platelets (p≤ 0.01). Similarly, Loxoribine (1 
mM) and CpG ODN (5 µM) stimulated P-selectin from platelet alpha-granules and 
this response was also impaired in the mutants. Consistent with the activation-
induced Akt and SNAP-23 phosphorylation, defects in endocytosis leads to severe of 
HIV-1pp-induced immune responses in platelets. 
P-selectin exteriorization by activated platelets acts as a “beacon of damage” for 
patrolling leukocytes, alerting them to existing inflammatory or immune-induced 
damage in the circulation. As a result, these platelet-leukocyte aggregates serve as 
“units of inflammation” and initiates host immune responses [611]. Patients with 
active HIV-1 infection often have increased levels of platelet-leukocyte aggregates, 
which strongly correlated with platelet activation [614]. Based on these reports, we 
sought to determine whether endocytosis of HIV-1 pseudovirions triggers platelet-
leukocyte aggregate formation. In Figure 19D, while compared to unstimulated 
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controls, thrombin-induced robust platelet(CD41/61)-neutrophil(Ly6G) aggregates, 
as measured by flow cytometry, in whole blood and was unaffected in the VAMP-3 
and Arf6 mutants (these mutants are not secretion-deficient to hemostatic agonists). 
Loxoribine, CpG ODN and HIV-1pp all induced aggregate formation in WT, but 
showed significant reductions in the mutants. Of note, the level of platelet-
neutrophil aggregate formation in response to thrombin (hemostatic activation) is 
almost two-fold higher than all the other TLR ligands, including HIV-1pp activation 
(immuno-activation). This harkens back to our initial findings that platelets do 
interpret and respond differentially to “immune agonists” than they do to stronger 
and more potent “hemostatic agonists”. While agonist potency drives rates and 
extents of secretion [91], platelets appear to interpret between different classes of 
agonists and respond accordingly. How this mechanism will warrant future studies to 
parse the distinguishing signaling aspects that lead to variable activation patterns 
observed in platelets. Conceivably, these platelet-neutrophil aggregates generated 
by HIV-1pp, get recognized by professional phagocytes and are cleared from the 
circulation, dropping platelet counts, which may, in part, explain the severe 
thrombocytopenia observed in HIV-1+ patients.  
Our studies provide a novel mechanistic understanding of how viral particles enter 
platelets and why platelets from HIV-1+ patients with chronic HIV-1 infection show 
signs of platelet activation. 
To determine whether platelet activation by HIV-1 pseudovirions occurred through 
the actions of TLR7, which is the physiological sensor for viral ssRNA, we probed 
platelet activation by measuring Akt and SNAP-23 phosphorylation in response to 
HIV-1pp in TLR23479 mutants. Unlike Loxoribine, which binds to TLR7 and shows loss 
of signaling in the mutant platelets, HIV-1pp induced activation only shows a partial 
loss of Akt and SNAP-23 phosphorylation, suggesting that there may be a TLR-
independent component (in addition to a TLR-dependent component) of HIV-1pp-
induced platelet activation (Figure 21). Other potential TLR ligands that may be 
generated by viral degradation inside platelet endosomes, or activation by surface 
binding to any surface TLR, such as TLR2, 4, 3 or 9 has been already excluded in these 
mutants. As a result, we posit that viral activation may be through some other 
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platelet receptor that leads to signaling responses. Once such receptor that binds to 
HIV-1pp and can induce signaling downstream in platelets is the hem(ITAM)-receptor, 
CLEC-2, that leads to activation of Syk and SFK, PLCγ and activates Akt and eventually 
causes platelet secretion. Use of specific inhibitors such as PP2 (which inhibits Src-
family kinases (SFK)) or Dasatinib, another Src family tyrosine kinase inhibitor, or use 
of CLEC-2 null platelets, may be useful in determining whether this partial loss of 
signaling is indeed due to CLEC-2 activation or not.  
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Figure 16 VAMP-3 was required for signaling through TLR7 and TLR9 in platelets. (A) 
Washed platelets (4 × 108 platelets/mL) from WT and VAMP-3 KO mice were 
incubated with TLR7-Loxoribine (1 mM) or TLR9-CpG ODN2395 (5 µM) for the 
indicated time points at 37°C. Western blotting was performed using anti-phospho-
Akt (Ser473), anti-Akt, and anti-phospho-SNAP-23 (Ser95) and anti-SNAP-23 
antibodies. Images were taken on a Typhoon 9500 Variable Mode Imager and 
quantified using the ImageQuantTL software. (Bi-ii) Volumetric quantification of % of 
phospho-Akt levels over total Akt levels and of phospho-SNAP-23 levels over total 
SNAP-23 levels in response to Loxoribine. (Ci-ii) Volumetric quantification of % of 
phospho-Akt levels over total Akt levels and of phospho-SNAP-23 levels over total 
SNAP-23 levels in response to CpG ODN2395. Statistical significance (*) denoted by 
p-value ≤0.05, (**) denoted by p-value ≤0.01 and is representative of at least 3 
independent experiments (mean ± SEM). 
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Figure 17 Arf6 was required for signaling through TLR7 and TLR9 in platelets. (A) 
Washed platelets (4 × 108 platelets/mL) from WT and Arf6 KO mice were incubated 
with TLR7-Loxoribine (1 mM) or TLR9-CpG ODN2395 (5 µM) for the indicated time 
points at 37°C. Western blotting was performed using anti-phospho-Akt (Ser473), 
anti-Akt, and anti-phospho-SNAP-23 (Ser95) and anti-SNAP-23 antibodies. Images 
were taken on a Typhoon 9500 Variable Mode Imager and quantified using the 
ImageQuantTL software. (Bi-ii) Volumetric quantification of % of phospho-Akt levels 
over total Akt levels and of phospho-SNAP-23 levels over total SNAP-23 levels in 
response to Loxoribine. (Ci-ii)  Volumetric quantification of % of phospho-Akt levels 
over total Akt levels and of phospho-SNAP-23 levels over total SNAP-23 levels in 
response to CpG ODN2395. Statistical significance (*) denoted by p-value ≤0.05, (**) 
denoted by p-value ≤0.01 and is representative of at least 3 independent 
experiments (mean ± SEM). 
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Endocytosis of HIV-1 pseudovirions in human platelets required Dynamin-
mediated internalization and trafficking to acidic compartments 
Given that endocytosis of HIV-1pp causes platelet activation, we asked whether this 
process occurs in human platelets. Freshly isolated human platelets, from healthy 
donors, were prepared and stimulated with HIV-1pp, in the presence of Dynasore or 
NH4Cl, to inhibit either Dynamin-mediated endocytosis or neutralize endosomal 
maturation process required for normal processing and signaling. In Figure 22A, 
human platelets endocytose viral particles, much in the same way as mouse platelets 
do. Human platelets lack CD4; hence probable viral binding occurs through CLEC-2 or 
DC-SIGN. In Figure 22B, use of Dynasore (80 µM) inhibits phosphorylation of IκBα, 
that is used as a surrogate metric for IKK-β-mediated SNAP-23 phosphorylation and 
hence platelet activation. NH4Cl (20 mM), also inhibited phosphorylation of IκBα. In 
Figure 22C, formation of platelet (CD41/61)-neutrophil (Ly6G) aggregates in 
response to HIV-1pp was also significantly inhibited in the presence of Dynasore and 
NH4Cl. Taken together, our data suggests that Dynamin-dependent endocytosis, 
targeting to acidic compartments and activation of signaling cascades, in response to 
the HIV-1 pseudovirions, can be recapitulated in human platelets, indicating that 
human platelets probably utilize similar VAMP-3 and Arf6-dependent pathways for 
viral endocytosis and response. 
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Figure 18 Endocytosis of HIV-1 pseudovirions required VAMP-3 and Arf6. (A, C) 
Washed WT, VAMP-3 KO and Arf6 KO platelets (5 x 107/mL) were incubated with 
FITC-CpG ODN (5 µM or 10 µM) or with GFP-HIV-1pp (1X and 2 X concentrations) at 
37°C for 30 min as described in the Methods section, under endocytosis plate-based 
assay. (B) Schematic of the HIV-1pp viral constructs showing the GFP-fused ICAM-1 
on the surface and mCherry-fused gag protein inside the viral core. (D) 
Representative micrographs from washed WT, VAMP-3 KO, and Arf6 KO platelets (1 
X 109/mL) that were incubated with red-green HIV-1pp (100X) for indicated time 
points at 37°C. Platelets were fixed with 2% PFA (final conc.) and mixed with 0.1 % 
Trypan Blue prior to imaging. Platelets were visualized as described in the Methods 
section. Exposure times for DIC were 100 msec, for FITC laser were 1000 msec and 
for the mCherry was 500msec. Scale bars are 5 µM. (E) Quantification of the number 
of GFP+-mCherry+ puncta/platelet in WT, VAMP-3 KO, and Arf6 KO samples and were 
plotted using Sigma Plot software (v13.0). Data is representative of 2 independent 
experiments. (F) Age-matched WT and VAMP-3 KO mice were injected with HIV-1pp 
(100X) through the retro-orbital sinus and platelets were harvested 24 hr post-
injection, fixed and mixed with 0.1 % Trypan Blue prior to imaging. Platelets were 
imaged using the Nikon E600 Eclipse fitted with a Zeiss Axiocam MR camera and 
visualized under 100X oil-immersion lens. Representative micrographs show 
endocytosed viral particles within platelets. (G) Quantification of the number of 
GFP+-mCherry+ puncta/platelet in WT and VAMP-3 KO samples and were plotted 
using Sigma Plot software (v13.0). 394 platelets (for WT) and 323 platelets (for 
VAMP-3 KO) over 6 different fields were counted.  
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Figure 19 Endocytosis of HIV-1 pseudovirions triggered platelet activation. (A) 
Washed platelets from WT, VAMP-3 KO, and Arf6 KO mice were either kept resting 
or stimulated with HIV-1pp (100X) for 30 min at 37°C and lysates were prepared for 
western blotting using anti-phospho-Akt (Ser473), anti-Akt, and anti-phospho-SNAP-
23 (Ser95) and anti-SNAP-23 antibodies. Images were taken on a Typhoon 9500 
Variable Mode Imager and quantified using the ImageQuantTL software. (B) 
Volumetric quantification of % of (i) phospho-Akt levels over total Akt levels and (ii) 
of phospho-SNAP-23 levels over total SNAP-23 levels. (C)  Anti-FITC-P-selectin 
antibody was added to WT, VAMP-3 KO and Arf6 KO platelets (5 X 107/mL) 
stimulated with Loxoribine (1 mM), CpG ODN2395 (5 µM) or HIV-1pp (100X) for 30 
min at 37°C and geo mean fluorescence intensity was plotted for each condition.  (D) 
Whole mouse blood from WT, VAMP-3 KO, and Arf6 KO mice was either kept 
unstimulated or stimulated with thrombin (0.1 U/mL) for 3 min, Loxoribine (1 mM), 
CpG ODN (5 µM), or HIV-1pp (100X) for 30 min. Using BD LSRII, platelet (FITC-
CD41/61)- neutrophil (PE-Ly6G) aggregates were acquired by gating around 50, 000 
granulocytes and percentage of double-positive events were plotted over total 
granulocytes. Data was analyzed using FlowJo (v.5.6.7). Statistical significance is 
denoted by (*) p≤0.05, (**) p≤ 0.01. Data is representative of at least three 
independent experiments. 
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Endocytosis of Eco-HIV required Dynamin-mediated internalization, trafficking to 
acidic compartments and proteolytic degradation  
Our overarching hypothesis is to determine how platelet endocytosis contributes to 
viral dissemination and disease etiology in HIV-1 infections. Towards this goal, we 
have acquired viral constructs that produce Eco-HIV virions from Dr. David Volsky at 
Mt. Sinai Icahn School of Medicine. These chimeric viruses have the gp120 of HIV-1 
replaced by the gp80 of the murine leukemia virus to render it infectious to rodents 
only. The virus behaves similar to its human counterpart, infects mouse T cells, 
generating viral infection with the production of pro-inflammatory cytokines [602]. 
The Eco-HIV virus is neuroinvasive and causes blood-brain barrier (BBB) disruption. 
We have Preliminary studies performed with the virus was to determine, whether it 
behaves like the pseudovirions and does viral endocytosis of Eco-HIV lead to platelet 
activation. 
In Figure 23A, Eco-HIV (100X) induced platelet activation by phosphorylating Akt and 
SNAP-23, in a time-dependent manner. Dynasore treatment-, NH4Cl treatment- and 
protease inhibitor cocktail treatment of mouse platelets, incubated with Eco-HIV 
virions, showed robust inhibition. In Figure 23B-C, quantification of Akt and SNAP-23 
phosphorylation shows that protease inhibition caused the most dramatic inhibition, 
possibly due to the prohibition of degradative processing of the virus that is essential 
for signaling. Dynasore and NH4Cl inhibition follow the pattern observed in mouse 
platelets (and human platelets) in response to HIV-1pp. Taken together, our data 
suggests that Eco-HIV virions get internalized by platelets using Dynamin, get 
trafficked into acidic compartments where proteolytic processing of the virus leads 
to activation-induced signaling in platelets. 
In a future series of experiments, we will determine whether VAMP-3 and Arf6-
mediated endocytosis affect infection and neuroinvasiveness in mice infected with 
Eco-HIV viruses. 
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 Figure 20 Receptor levels of TLRs in VAMP-3 and Arf6 mutant platelets. Lysates 
were prepared from platelets (4 x 108/mL) isolated from WT and VAMP-3 KO and 
Arf6 KO mice and western blotted for the indicated protein using specific antibodies 
(A) TLR7 levels in WT, VAMP-3 KO, and Arf6 KO platelets. β-actin was used as a 
loading control. (B) TLR9 levels in WT, VAMP-3 KO, and Arf6 KO platelets. β-actin was 
used as a loading control. (C) CLEC-2 levels WT and VAMP-3 KO platelets. RabGDI 
was used as a loading control. (D) CLEC-2 levels WT and Arf6 KO platelets. RabGDI 
was used as a loading control. (E) DC-SIGN (CD209) levels in WT, VAMP-3 KO and 
Arf6 KO platelets with RabGDI as a loading control. Data is representative of at least 
two independent experiments. 
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Figure 21 Response to Loxoribine, CpG ODN required TLR signaling. Washed 
platelets (4 × 108 platelets/mL) were from WT and TLR23479 KO platelets were 
either kept resting or stimulated with thrombin (0.1 U/mL), LPS (100 ng/mL), 
Pam3CSk4 (10 µg/mL), Loxoribine (1 mM), CpG ODN2395 (5 µM), HIV-1pp (100X) for 
30 min at 37°C. Lysates were prepared and western blotting was performed using 
anti-phospho-Akt (Ser473), anti-Akt, and anti-phospho-SNAP-23 (Ser95) and anti-
SNAP-23 antibodies. Images were taken on a Typhoon 9500 Variable Mode Imager 
and images were processed using the ImageQuantTL software.  
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Figure 22 Endocytosis of HIV-1 pseudovirions in human platelets required 
Dynamin-mediated internalization and trafficking to acidic compartments. (A) 
Representative fluorescent micrographs of washed human platelets containing red-
green HIV-1pp showing platelets with endocytosed pseudovirions (denoted by 
arrows). (B) Human platelets were incubated with HIV-1pp for 30 min either in the 
presence or absence of Dynasore (80 µM) or NH4Cl (20 mM) and lysates were 
prepared for western blotting with anti-phospho-IκBα and anti-IκBα antibodies. (C) 
Whole human blood was pre-incubated with either Dynasore (80 µM) or NH4Cl (20 
mM) and stimulated with HIV-1pp for 30 min. Using BD LSRII, platelet (FITC-
CD41/61)- neutrophil (PE-Ly6G) aggregates were acquired by gating around 50, 000 
granulocytes and percentage of double-positive events were plotted over total 
granulocytes. Data was analyzed using FlowJo (v. 5.6.7). Statistical significance is 
denoted by (*) p≤0.05, (**) p≤ 0.01. Data is representative of at least three 
independent experiments. 
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Figure 23 Eco-HIV-stimulation of platelets required Dynamin-mediated 
internalization, trafficking to acidic compartments and proteolytic degradation. (A) 
Washed platelets (4 × 108 platelets/mL) were stimulated with Eco-HIV (100x) for the 
indicated time points at 37°C or pre-incubated with Dynasore (80 µM), or NH4Cl (20 
mM) or protease inhibitor cocktail mixture (PIC) (100X) for 30 min and then 
stimulated with Eco-HIV (100X) for 30 min at 37°C.  Western blotting was performed 
using anti-phospho-Akt (Ser473), anti-Akt, and anti-phospho-SNAP-23 (Ser95) and 
anti-SNAP-23 antibodies. Images were taken on a Typhoon 9500 Variable Mode 
Imager and quantified using the ImageQuantTL software. (B) Volumetric 
quantification of % of phospho-Akt levels over total Akt levels and (C) of phospho-
SNAP-23 levels over total SNAP-23 levels. Data is representative of one experiment. 
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Conclusions  
It is becomingly increasingly clear that platelets bridge coagulation cascades with 
inflammation. Platelets respond to changes in the vasculature and modulate their 
response accordingly. Platelets also interact with pathogenic bacteria and viruses to 
mediate immune responses against them. Infection-related platelet activation can be 
strongly correlated with thrombocytopenia that leads to further cardiovascular 
complications that can prove to be detrimental to prognosis and cure. Chronic viral 
infections, e.g., HIV-1, severely increase the risk of acute myocardial infarction (MI), 
possibly via some level of platelet activation, contributing to increased thrombotic 
potential. Platelets do endocytose viruses and bacteria, but the molecular machinery 
is ill-defined. In nucleated cells, responses to HIV-1 are mediated by virus 
phagocytosis/endocytosis, degradation to release Toll-like Receptor ligands, and 
subsequent receptor activation. Is this process recapitulated in platelets? Here we 
show that platelets indeed use VAMP-3 and Arf6-dependent pathways to 
endocytose HIV-1 virions, degrade retroviral particles to release TLR ligands, which 
initiate platelet activation and secretion. HIV-1 uptake and subsequent activation are 
abolished in VAMP-3 and Arf6 KO mice.  
Collectively, our studies shed light on how platelets act at the early stage of 
pathogen recognition and are able to process them to initiate an immune response. 
Our overarching hypothesis is to determine how platelet endocytosis contributes to 
viral dissemination and disease etiology in HIV-1 infections. Future experiments 
planned with the Eco-HIV viruses in a mouse model of HIV infection using our 
endocytosis mutants will go a long way in elucidating the relevance of platelet 
endocytosis in mediating disease outcomes. 
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Figure 24 
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Figure 24 Model diagram showing the role of Dynamin-, VAMP-3- and Arf6-
mediated endocytosis of HIV-1 pseudovirions and TLR ligands in platelet activation. 
Platelets can internalize bacterial and viral ligands via Dynamin-, VAMP-3- and Arf6-
dependent endocytosis. Viruses such as HIV-1 or TLR ligands such as unmethylated 
CpG oligonucleotides, Loxoribine etc. can then be trafficked to an endosomal 
compartment bearing their respective Toll-like receptors. Viruses require acidic 
compartments to allow degradation of the viral capsid, releasing ssRNA or TLR 
ligands, which can then bind to TLR7 and initiate a response. Receptor-ligand 
interactions lead to the recruitment of the adaptor protein MyD88, which then 
triggers downstream signaling through TRAF6, TAK1, and IRAK-1 activation, 
phosphorylating IRAK-4. Concomitant PI3K activation also leads to Akt activation, 
driving IKK activation. IKK then activates SNAP-23, which drives SNARE complex 
formation and ultimately granule secretion. TLR and HIV-1 pseudovirion activation of 
platelets leads to P-selectin exteriorization from alpha granules, which can then form 
platelet-leukocyte aggregates with PSGL-1-bearing leukocytes in the circulation.  
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Chapter Five: Endocytosis in platelet function: roles in hemostasis and innate 
immunity 
Through the work presented in this thesis, we have taken several key steps in 
understanding how endocytosis modulates platelet functions in the context of 
hemostasis and innate immunity. We have identified VAMP-3 to be a critical 
regulator of fibrinogen (Fg) uptake in platelets. Loss of VAMP-3 causes defective 
fibrinogen uptake, which manifests itself as dysfunctional integrin trafficking of αIIbβ3 
that translates into increased platelet spreading and clot retraction. However, these 
defects do not cause obvious alterations in thrombus formation or hemostasis. 
Additionally, using 3D super-resolution microscopy, we present the first report of 
differential sorting of receptor-mediated endocytic (fibrinogen) and fluid-phase 
pinocytic (low mol. wt. dextran) cargos in platelets.  Future research will determine 
the intricacies of the different routes and endosomal compartments utilized by the 
two kinds of cargos in platelets. How platelets respond to pathogenic viruses and 
bacteria that determine the disease outcomes in viremia and bacteremia is still 
unclear. Using both Arf6 KO and VAMP-3 KO mutants as tools to probe the 
importance of endocytosis in platelets, we posited that platelet endocytosis could 
potentially be critical for actively sensing pathogenic damage in the vascular 
microenvironments and allowing platelets to act as immune cells. Using non-
replicative, genetically modified HIV-1 pseudovirions, we show that platelets 
endocytose HIV-1 via VAMP-3 and Arf6-mediated endocytic pathways, degrade viral 
particles, causing platelet activation, as measured by PI3K/Akt and IKKβ-mediated 
SNAP-23 phosphorylation that drives secretion of P-selectin from alpha granules to 
form platelet-neutrophil aggregates. HIV-1 uptake and subsequent activation are 
abolished in VAMP-3 and Arf6 KO mice. This mechanism of viral endocytosis and 
subsequent activation also occurs in human platelets and may, in part, explain some 
of the platelet-associated phenotypes seen in HIV-1-infected individuals.   
VAMP-3 is required for accumulation of fibrinogen in platelets 
Fibrinogen, made by hepatocytes and not megakaryocytes [461], is an alpha-granule 
cargo because it is taken up via a αIIbβ3-mediated process. VAMP-3 deletion results in 
defective intra-platelet Fibrinogen accumulation (Figures 3A-B, 5). Data presented in 
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this thesis is the first report of this v-SNARE protein being involved in internal 
membrane trafficking steps in platelets. These trafficking steps are needed for αIIbβ3-
mediated Fg uptake, endocytic trafficking of cargo, platelet spreading, clot retraction, 
and proper regulation of JAK2 phosphorylation downstream of TPOR. Global loss of 
VAMP-3 did not affect the gross hematological profile of the mutant mice, with 
whole blood counts unaltered in the KO (Table 2). Electron micrographs depicted 
normal platelet ultrastructure in the VAMP-3 KO platelets [202]. Western blotting 
analysis showed that loss of VAMP-3 did not cause overt defects in levels of other 
endocytic cargo, endosomal markers, or proteins involved in endocytosis (Figure 3C-
D). Levels of total surface and activated αIIbβ3 were unaltered in resting and 
thrombin-stimulated platelets (Figure 4A-B) as was the steady-state binding of Fg 
(Figure 4C). ADP-stimulated WT platelets showed enhanced Fg-binding and increased 
uptake of Fg; however, ADP-stimulation of VAMP-3 KO platelets was unable to 
override the defect in Fg internalization (Figure 5A-B). In sum, the loss of VAMP-3 
had no gross effects on many aspects of platelet function, yet it affected Fg 
accumulation. Of note, the ~40% deficit in Fg seen in platelets from KO mice was not 
sufficient to affect hemostasis [202]. 
Using TB as a quencher of external fluorescence of FITC/Alexa 488, we could monitor 
cargo uptake by platelets. Our plate-based endocytosis assay allows more flexibility 
for testing a variety of conditions and more sensitivity than flow cytometry-based 
assays. Using this assay, we showed that Fg internalization reached saturation in WT 
platelets and demonstrated classical receptor-ligand saturation kinetics over the 
range of concentrations tested (Figure 5C, E). Conversely, uptake of small molecules 
usually occurs via fluid-phase pinocytosis and is generally a non-specific process. In 
platelets, dextran uptake appeared to occur constitutively and rapidly. In as early as 
1 min, dextran uptake was detected and it linearly increased over time and dose 
(Figure 5D, F). In platelets, dextran uptake had at least a 1,000-fold higher capacity 
(as measured by total molecules internalized) than Fg uptake. This argues that fluid-
phase pinocytosis is more efficient in platelets, but further studies with other cargo 
are needed to strengthen that conclusion. Fluorescence micrographs depicting 
endocytosed FITC-Fg showed that VAMP-3 KO platelets indeed had a robust defect in 
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Fg uptake/accumulation. The number of fluorescent puncta was significantly lower in 
the KO platelets (Figure 5G-H). Dextran uptake, alternatively, did not show any 
robust differences between WT and VAMP-3 KO platelets, both in the plate-based 
endocytosis assay (Figure 5D, F) and in the fluorescence images (Figure 11). This 
argues that, in platelets, VAMP-3 is important for an endocytic trafficking step(s) that 
is part of the path taken by Fg bound to αIIbβ3; more so than cargo internalized by 
constitutive pinocytosis. However, whether VAMP-3 is involved in mediating uptake 
of cargo via other types of platelet endocytosis processes remains to be determined.  
Platelets can sort different kinds of endocytic cargo 
Can platelets decipher and sort endocytosed cargo or is it passively internalized via a 
common endocytic route? Using 3D-SIM microscopy, we demonstrated that platelets 
actively sort endocytosed cargo, exhibiting a more complex endocytic system than 
previously imagined. Fg binds to surface αIIbβ3, at initial time points and then 
proceeds to accumulate inside platelets as discrete puncta within 30 min. At this 
time, surface binding was less apparent (Figure 6A). Fg is thought to enter platelets, 
transit through two classes of multi-vesicular bodies, and end up in α-granules [41]. 
Platelets contain roughly 50-80 α-granules [34-35], yet we did not see equivalent 
numbers of Fg puncta at 30 min or even after the overnight incubation in vivo (Figure 
6B). The global distribution of Fg into α-granules, seen in recent immuno-electron 
microscopy studies, would seem at odds with our data [55]. While unclear at present, 
our observations could mean that only specific α-granules are readily loaded with 
endocytosed cargo during circulation and that most cargo loading occurs at the 
megakaryocyte stage. Our previous studies are not totally consistent with that 
scenario since we failed to observe FITC-Fg in bone marrow megakaryocytes, 24 hr 
post injection [19]. Alternatively, our data could imply the Fg loading into all α-
granules requires more time, perhaps the lifetime of a platelet. It is equally possible 
that larger amounts of FITC-Fg are needed to fully label all the granules. In contrast, 
dextran uptake occurred very quickly and platelets accumulate more dextran+ 
puncta than Fg+ puncta over time (Figure 6A-B). Both cargoes showed partial overlap 
at early time points but mostly existed as discrete puncta. VAMP-3 deletion did not 
compromise the platelets’ ability to sort cargo but did affect their ability to 
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accumulate it. Surprisingly, when dextran was injected for an overnight period, less 
dextran accumulated in the VAMP-3 KO platelets (Figure 6B) compared to WT. This 
was in contrast to Figure 6A, where no clear defect in dextran uptake was seen in the 
VAMP-3 KO platelets up to 30 min of incubation and in the plate-based endocytosis 
assay (Figure 5D). This could indicate that loss of VAMP-3 causes a defect in chronic 
accumulation of cargo, irrespective of the initial endocytic pathway employed. 
Potential role of VAMP-3 in integrin αIIbβ3 endocytic trafficking in platelets 
Our previous studies of Arf6 KO platelets suggested that Fg uptake and integrin 
recycling are important for some acute platelet functions e.g., clot retraction and 
spreading [19]. VAMP-3 KO platelets had a similar phenotype. VAMP-3 is important 
for epithelial cell migration, particularly mediating trafficking at the lamellipodia and 
it also localizes to focal adhesions [426-427]. Tetanus toxin-mediated cleavage of 
VAMP-3 reduced epithelial cell migration but enhanced adhesion to collagen, 
laminin, and fibronectin; perhaps due to impaired recycling of β1 integrins [427]. In 
Figure 7A-B, the rate of platelet spreading on immobilized Fg was faster in VAMP-3 
KO than in WT platelets. This, together with the Arf6 KO phenotype, reinforces the 
notion that altered αIIbβ3 trafficking affects platelet spreading. Unlike epithelial cells 
where migration is directional, platelet spreading on coated surfaces is not vectorial 
but seems to occur in all directions. In our assays, loss of VAMP-3 enhanced platelet 
spreading. If VAMP-3 controls spatially-specific membrane fusion steps that facilitate 
vectorial platelet spreading in a thrombus, its loss could make random, 
multidirectional fusion more efficient leading to enhanced spreading in all directions 
on a coated surface. Alternatively, loss of VAMP-7, a key v-SNARE in platelets, leads 
to granule exocytosis defects and reduced spreading [203]. VAMP-3 KO platelets had 
no defect in exocytosis; however, its deletion causes a modest secretion rate 
enhancement [202]. Given that VAMP-7-mediated exocytosis is important for 
spreading, enhanced secretion could enhance spreading. Loss of VAMP-3, which 
could be acting as an inhibitory SNARE (i-SNARE) and competing with VAMP-7 [462], 
could increase the efficacy of exocytic SNARE complex formation (containing VAMP-
7, or -8, Syntaxin-8 or -11, and SNAP-23) and thus increase the fusion needed for 
spreading. These two potential mechanistic explanations for our phenotypes are 
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difficult to distinguish; but, comparing platelets from VAMP-3 and VAMP-7 KO mice 
will be invaluable in understanding how membrane trafficking affects platelet 
spreading. The enhanced spreading and clot retraction phenotype is subtle and 
might be expected to predispose these mice towards a more pro-thrombotic 
phenotype. However, that was not detected in the tail-bleeding or FeCl3-injury [[19] 
and Joshi, et al. in preparation] models that we have tested nor was an effect seen 
with the VAMP-7 KO mice [203]. More refined assays will be needed to parse the 
biological ramifications of these observations. Additionally, Fg deficiency causes 
bleeding diathesis in both mouse and humans [607-608]. Both VAMP-3 and Arf6 KO 
mice have about 50% defect in Fg levels, yet have normal hemostasis with no 
bleeding defects. Thus it is not clear whether platelet-derived Fg is functionally 
important for physiological processes or not; and if it's, how much Fg do platelets 
contribute to form the fibrinous thrombus at the site of injury. 
 “Immuno” versus “hemostatic” stimulation of platelets: differential kinetics and 
extent of responses 
How platelets respond to “immune agonists” such as those tested in this thesis as 
well as in previously published reports, have challenged the canonical view of 
platelets being “all-or-none” type responders to vascular damage. Platelets need to 
be able to respond to hemostatic damage rapidly in order to contain blood loss. This 
is usually achieved via rapid degranulation of the already docked dense core 
granules, which secrete ADP and ATP that allow paracrine activation of additional 
platelet to form the platelet plug. The dense core granules are the first to secrete 
their granular contents [91]. Agonist potency determines the extent and rate of 
cargo release, stronger agonists such as thrombin and collagen prompted rapid 
release that was extensive and maximal compared to weaker agonists such as PAR4-
peptide that elicited a lower degree of release. Agonist-induced secretion was 
random and heterogeneous in nature bearing no thematic pattern in the distribution 
of cargo within the releasates [91]. However, reports explaining the differential 
release of proangiogenic and antiangiogenic factors in response to specific agonists 
suggest that the observed platelet release heterogeneity could be a function of 
partial platelet activation [567-569]. Platelet stimulation by the “immune agonists” 
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such as the Toll-like receptor ligands and HIV-1 pseudovirions, are markedly slower 
in their kinetics and have a less extensive release, irrespective of the dose of agonist 
or time of stimulation, a phenomenon that could be attributed to partial platelet 
activation. Our findings are corroborated by previous reports showing differential 
activation of signaling pathways, differences in alpha granule release, and unique 
protein-protein interactions when platelets were stimulated with thrombin versus 
when they were stimulated with Pam3CSK4, a TLR2-specific agonist [447]. 
Additionally, bacteria-induced platelet aggregation proceeds after a lag time, 
dependent on the bacterial density that lasts between 3-20 min, as compared to 
thrombin or ADP-mediated hemostatic responses which reach maximal activation in 
less than 3 min [538]. Taken together, these data suggest that platelets can interpret 
between various kinds of activating stimuli and respond accordingly. While we have 
not yet tested the platelet “secretome” in response to TLR/HIV-1 agonists using 
antibody arrays similar to the ones used in [91], it could be possible that response to 
“immuno-agonists” elicits differential releasates compared to hemostatic agonist-
stimulated releasates. While hemostatic-stimulation gives rise to factors and 
mediators that allow containment of vascular damage by sealing the breached 
endothelial vessel walls, thereby initiating a cascade of responses that lead to 
hemostasis and thrombus formation; immune-stimulation may elicit platelets to 
release immunomodulators that either allow platelets to directly annul the 
pathogenic threat (ways how these works have been explained in the introduction 
under platelet-bacterial/viral interactions) or alert the surveilling professional 
immune cells to eliminate the infectious damage. A low-grade of activation may be 
sufficient to generate an “immunomodulatory phenotype” for platelets, while at the 
same time preserving its inherent hemostatic activities. This feature harkens back to 
the evolutionary nature of platelets, having been descended from the primordial 
hemocytes that were capable of hemostasis, coagulation and immune functions 
[435]. How this differential response works, in terms of what signaling pathways it 
activates, potential differences in calcium transients (which effectively determine 
agonist potency in mediating aggregation and eventual thrombus formation [570]) 
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etc, are some of the potential future questions that will help uncover the basis of this 
differential response. 
Differential usage of the SNARE-machinery may provide useful insights into 
differential responses of the platelet release reaction to “immune” versus 
“hemostatic” stimuli. Major SNAREs that are essential for release from all three 
classes of granules are VAMP-8 [201], SNAP-23 [39, 198, 210-212] and syntaxin 11 
[209]. Loss of VAMP-3 does not affect platelet secretion [202] while the loss of 
VAMP-7 preferentially affects alpha granule release [203]. Loss of VAMP-8 has less 
effect on dense core granule but profoundly affects alpha granule and lysosomal 
secretion [201]. Loss of syntaxin 11 affects serotonin release from dense granules 
and PF4 release from alpha granules more than it affects β-hexosaminidase release 
from lysosomes [209]. Loss of SNARE regulator, Munc18b, has a similar phenotype to 
syntaxin 11 [216]. These differences in affecting release reactions from the three 
granules suggest heterogeneity between fusogenic SNARE complexes. While other 
SNAREs can participate in forming fusogenic SNARE complexes, the efficacy of 
secretion is maximal when VAMP-8/SNAP-23/syntaxin 11 complexes are formed. Can 
platelets utilize different SNARE complexes to mediate differential secretion in 
response to different secretagogues (“immune” versus “hemostatic”)? Future 
investigations will be required to answer this question in greater details.  
Platelets endocytose HIV-1 using Dynamin, VAMP-3, and Arf6-mediated pathways 
Platelets and megakaryocytes have been shown to endocytose HIV-1 viruses [542, 
263] into an endosomal-like vacuole, thought to be part of the OCS in platelets [263]. 
Megakaryocytes utilize CD4 to bind to HIV-1 [547] whereas platelets, which lack CD4, 
utilize CLEC-2 and DC-SIGN to bind the virus [550]. However, the molecular 
machinery required to mediate viral endocytosis is unknown in platelets. Data 
presented in this thesis provides the first report on the elements of the platelet 
endocytic machinery that mediate HIV-1 uptake in platelets. Our studies show that 
Dynamin, VAMP-3, and Arf6 are at least some of the proteins that mediate viral 
endocytosis.  
Enveloped viruses, such as HIV-1, require endocytosis for entry into cells. Surface 
viral glycoproteins such as Env (gp120), interact with CD4 and coreceptors such as 
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CCR5 or CXCR4 to allow initial binding [571]. Except for CD4, platelets express 
members of the CXCR family including CXCR4 [549]. Following binding, it is thought 
that HIV viruses fuse with endosomes and macropinosomes [572-573]. Clathrin-
mediated endocytosis is thought to play a role in viral uptake as inhibition of this 
route of endocytosis reduces the efficacy of viral fusion and infection in HeLa-
derived cells [574]. Use of dynasore, the small molecule inhibitor that blocks 
Dynamin activity [577], inhibits HIV-1 uptake, fusion, and infection in TZM-bl cells 
[575]. Using similar conditions as in Miyauchi et al. 2009 [613], we treated mouse 
platelets with Dynasore (80 µM) to determine the effects on HIV-1 mediated platelet 
activation. It is to be noted here, Dynasore concentrations were selected so as to not 
affect platelet granule secretion [351 and data not shown]. Dynasore treatment 
inhibited HIV-1 pseudovirion-mediated activation of platelets, leading to a reduction 
in levels of phospho-Akt and phospho-SNAP-23. This result indicates that, like 
monocytes and T-cells, HIV-1 requires Dynamin-mediated activity to enter platelets, 
possibly via clathrin-mediated endocytosis. Dynamin2 has been specifically shown to 
be required for the enhancement of HIV-1 infection by directly interacting with HIV-1 
virulence factor Nef [585].  Inhibition of Dynamin2 activity, using either dominant-
negative DNM2 or siRNA against DNM2, inhibited Nef-mediated HIV-1 infectivity of 
293T cells. Incidentally, Dynamin2 is rather abundant in mouse platelets and also 
present in human platelets [343], hence it could very easily play a role in HIV-1 
endocytosis in platelets and possibly contribute to subsequent activation.  
Plasmacytoid dendritic cells utilize a similar Dynamin-dependent endocytosis to 
uptake HIV-1 virions and upon CD4-mediated entry; virus gets trafficked through 
endosomal compartments that stained positive for EEA1, Rab5, Rab7, Rab9 and 
LAMP-1 [576]. A study in plasmacytoid dendritic cells shows time-dependent 
trafficking of the virions starting from the early endosomes (EEA1-positive and Rab5-
positive compartments) to late endosomes (Rab7-positive and Rab9-positive 
compartments) and eventually to lysosomes (LAMP-1-positive) [576]. HIV-1-
mediated plasmacytoid dendritic cell activation as measured by interferon-α 
production was significantly reduced upon dynasore treatment. It is thought that 
HIV-1 viral particles get trafficked to the late endosomes and lysosomes, where it 
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gets degraded. As a result, blocking lysosomal degradation and/or endosomal 
acidification process leads to increased viral infection and concomitant IFN-α 
production [473, 578-582]. Viral particles colocalize with Rab7 and Rab9 and LAMP-1, 
indicating endolysosomal compartments, where the virus gets degraded, releases 
viral nucleic acids (in this case ssRNA) that can then interact with endosomal Toll-like 
receptors like TLR7 [473, 583, 584, 580]. 
How much of this process occurs in platelets? Platelets contain various RabGTPase 
markers such as Rab4, Rab11, Rab7, and Rab5 among others. We have shown the 
presence of two distinct endosomal populations, Rab4+ early endosomes and Rab11+ 
recycling endosomes [19]. TLR7 is present in platelets [472]. Treatment of platelets 
with ammonium chloride, which inhibits the acidification of endosomes, leads to a 
reduction in Akt and SNAP-23 phosphorylation in mouse platelets and a reduction in 
IκB phosphorylation and subsequent platelet-neutrophil aggregate formation in 
human platelets and human whole blood respectively. Given that most of the 
endocytic machinery and signaling components required for HIV-1 entry and 
subsequent IFN-α production in plasmacytoid dendritic cells are present in platelets, 
ongoing and future experiments will determine whether HIV-1 follows a similar route 
of endocytosis in platelets or not. 
Arf6, the Ras-like small GTPase, which is involved in integrin trafficking and 
fibrinogen uptake in platelets has also been shown to be involved in the pathogenic 
invasion of various cell types [587-590]. Arf6 is also required for HIV-1 endocytosis in 
T-cells [586]. Use of siRNA against Arf6, or inhibiting Arf6 function by using GDP-
bound or GTP-bound inactive mutants, led to a decrease in HIV-1 viral membrane 
fusion, entry and infection of T lymphocytes. Furthermore, Arf6 inhibition impaired 
cell-to-cell transmission of HIV-1 viral particles in CD4+-T lymphocytes. On the other 
hand, VAMP-3/Cellubrevin has been critical for phagocytosis of pathogens and 
various particles [416-417]. However, the importance of VAMP-3 in mediating HIV-1 
endocytosis is unclear.  
In our ex vivo assay, endocytosis of HIV-1 pseudovirions is dramatically impaired in 
both VAMP-3 and Arf6 KO platelets. This is the first report to show the importance of 
two critical endocytic regulators in platelets that drive pathogen internalization. Wild 
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type platelets endocytose more pseudovirions in a time-dependent manner. On the 
other hand, KO platelets have hardly any pseudovirions in them and viral endocytosis 
remains impaired even over prolonged periods of time. Consistently, when HIV-1 
pseudovirions were intravenously injected through the retro-orbital sinus of VAMP-3 
KO mice, a severe defect in viral uptake was noted in these platelets even after 24 
hours post-injection. Taken together, our data suggests that both VAMP-3 and Arf6 
are required for HIV-1 entry into platelets.  
Since HIV-1 binds to CLEC-2 and DC-SIGN on platelets and requires Dynamin-
dependent clathrin-mediated endocytosis, we posit that HIV-1 entry utilizes similar 
receptor-mediated endocytic routes that Fg uses in platelets and thereby could 
colocalize with Fg. In fact, preliminary data obtained from 3D super-resolution 
microscopy confirms this hypothesis (data not shown). Colocalization of HIV-1 
pseudovirions with Fg increases over time while colocalization with low mol. wt. 
dextran (fluid-phase pinocytosis marker) is very limited, corroborating our earlier 
observations of differential sorting of receptor-mediated and fluid-phase cargos. 
However, immunofluorescence experiments to demonstrate colocalization with 
endosomal and platelet granule markers still need to be performed to pinpoint 
specific endocytic routes of HIV-1 in platelets. It is interesting to note, that platelets 
somehow can interpret between two different physiological cargos and respond 
accordingly, despite using a similar route of endocytosis. For example, Fg enters 
platelets and eventually traffics through the early endosomes, to multivesicular 
bodies and ends up in alpha granules. Fg uptake does not activate platelets or cause 
any overt physiological changes, yet HIV-1 endocytosis activates platelets enough to 
cause Akt and SNAP-23 phosphorylation and mediate granule secretion in the form 
of P-selectin exteriorization. How platelets make this distinction, pose an interesting 
question, and add to the budding complexity of the platelet endomembrane system, 
than previously imagined. 
Mechanisms of platelet activation upon HIV-1 endocytosis  
Patients with HIV-1 infections show up in the clinics with severe thrombocytopenia 
that is commonly associated with increased plasma markers of platelet activation 
[468], including increased plasma levels of PF4, increased platelet-leukocyte 
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aggregates, and increased sCD40L levels [551]. HIV-1 trans-activator of transcription 
protein (Tat) directly activates platelets to release sCD40L in a CCR3 and β3 integrin-
dependent manner [552]. Various soluble endothelial activation markers like sVCAM-
1, sICAM-1, and von Willebrand Factor levels are higher in HIV-1 infected patients 
[544]. In a simian immunodeficiency virus (SIV)/macaque model, acute SIV infection 
causes increased surface expression of P-selectin, CD40L, and major 
histocompatibility complex class I [591], with a drop in circulating platelet counts. 
Acute infection led to an increase in monocyte counts, which led to increased 
platelet-monocyte aggregates in the bloodstream, contributing to the observed 
thrombocytopenia. Infection with HIV-1 is associated with a 50% increase in risk of 
acute myocardial infarction in a Veterans Aging Cohort Study Virtual Cohort of 82, 
459 participants that were HIV-1+, beyond that explained by all standard 
Framingham risk factors such as HIV status, age, sex, race/ethnicity, hypertension, 
diabetes, dyslipidemia, smoking, hepatitis C infection, body mass index, renal disease, 
anemia, substance use, CD4 cell count, HIV-1 RNA, antiretroviral therapy, and 
incidence of acute myocardial infarction (MI) [592]. Given that platelet hyperactivity 
contributes to acute MI, this study provided important insights into how prolific 
platelet hyperactivation is in chronically infected HIV-1 patients. In essence, as anti-
retroviral therapies prolong lifespans of HIV-1+ patients, it makes them increasingly 
susceptible to cardiovascular-related ailments such as acute MI. The severity of HIV-
1 infection strongly correlates with thrombocytopenia and platelet activation, yet 
the molecular mechanisms of how this activation occurs remain unclear. 
In nucleated immune cells such as plasmacytoid dendritic cells, responses to HIV-1 
are mediated by virus phagocytosis/endocytosis, degradation to release ssRNA (in 
the case of HIV-1), and subsequent TLR7 receptor activation. While platelets use 
more or less similar strategies to endocytose and respond to the viral particles, much 
to our surprise, ablating TLR7, only causes a partial reduction in platelet activation. 
Clearly, HIV-1 activation of platelets utilizes both TLR-dependent and TLR-
independent pathways. A possible explanation for this partial reduction in platelet 
activation, as measured by Akt and SNAP-23 phosphorylation, could be due to 
activation of the CLEC-2 receptor and its downstream signaling pathways, that in and 
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of itself, are potent platelet activation receptors. HIV-1 binding to CLEC-2 could 
activate these pathways leading to Akt phosphorylation and SNAP-23 
phosphorylation [593]. DC-SIGN, the other HIV-1 binding receptor on platelets, does 
not induce any downstream activation signals [543]. The CXCR family of coreceptors 
that can bind to HIV-1 and are present on platelets do not elicit any platelet 
activation responses either [549]. There could be some other signaling cascade being 
turned on by HIV-1 endocytosis in platelets that we do not know of, as yet. However, 
it does indicate that HIV-1-mediated activation of platelets is indeed, a complex 
interplay of multiple signaling pathways. This poses as a double-edged sword 
because, on one hand, therapeutic interventions to target one signaling pathway 
over another allows partial disruption of activation, thereby dampening levels of 
platelet activation markers while preserving some normal functions of platelets; this 
is advantageous. However, the flipside to this problem is the challenge to design 
drugs that do not have any adverse side-effects on other cell types, which perhaps 
need those signaling pathways to function properly.  
Role of autophagy in mediating platelet activation upon HIV-1 endocytosis 
Platelets have been shown to contain autophagosomal structures and autophagy 
plays vital roles in mediating proper platelet function and hemostasis [240]. 
Autophagy is induced upon platelet activation. Agonists such as thrombin, convulxin 
initiate platelet signaling cascades that lead to loss of autophagy marker LC3II and 
requires proteolytic degradation, endosomal acidification and SNARE-membrane 
fusion (involvement of VAMP-2, VAMP-3, and VAMP-8) [240].  
Several recent reports have shown autophagy induction upon TLR stimulation [594-
598]. LPS causes TLR4-mediated autophagy induction in mouse macrophages as 
demonstrated by the GFP-LC3 puncta formation, with LPS inducing an increased 
amount of lipidated LC3II in these cells [597]. TLR7 stimulation by ssRNA and 
imiquimod also induced autophagy in RAW264.7 macrophages, leading to increased 
puncta formation (denoting autophagosomes) and LC3II formation in the presence of 
pH-tropic drugs like Bafilomycin A (that blocks autophagosomal maturation by 
inhibiting LC3II degradation) [595]. TLR7-mediated autophagic induction requires 
MyD88 and is thought to utilize Beclin-1, a critical regulator of autophagy, (and is 
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present in platelets) [595]. It is thought that TLR7-mediated autophagic induction 
proceeds in a similar fashion to starvation-, rapamycin- or LRG47-induced autophagy 
[599]. In HeLa cells and plasmacytoid dendritic cells infected with HIV-1, autophagy 
was induced as measured by LC3II formation, upon binding of ssRNA to TLR7 [595, 
598]. The speculative model is that viral PAMPs (HIV-1 ssRNA) are introduced to 
TLR7+-endosomes via autophagic degradation of the viral nucleocapsid. Once TLR7 
binds to ssRNA, it signals through MyD88 and IRF7 to trigger activation of type I IFN 
and other cytokine genes, which play critical roles in innate immunity and 
pathogenesis of HIV-1 [498, 600].  
How much of this process recapitulates in platelets remains to be seen? Whether 
platelets utilize the autophagosomal machinery to respond to HIV-1 also remains to 
be seen. Ongoing experiments are investigating whether HIV-1 viral particles, upon 
endocytosis, gets trafficked to autophagosomes and colocalize with GFP-LC3 puncta. 
Does HIV-1 stimulation of platelets cause an induction of autophagy, leading to more 
GFP-LC3 puncta and formation of LC3II? Does TLR7 stimulation (by Loxoribine and 
Imiquimod) of platelets leads to increased LC3II levels and increased puncta 
formation? Using GFP-LC3 mice, we can answer these questions. 
In mouse platelets, preliminary studies show that Loxoribine (TLR7) and CpG ODN 
(TLR9)-mediated activation leads to a time-dependent phosphorylation of Akt and 
SNAP-23 and loss of Atg7 or Beclin-1 had no effect on these activation profiles, 
whereas HIV-1 pseudovirion stimulation of Atg7 KO platelets led to a partial 
reduction in Akt and SNAP-23 phosphorylation. While LC3II levels were not yet 
measured in these assays, these results suggest that viral degradation in platelets 
possibly require autophagosomal machinery but some of the other TLR7 ligands 
might not. Is this due to the differential sorting of cargo? Small molecules like 
Loxoribine and Imiquimod could utilize the fluid-phase endocytic pathway in 
platelets to reach TLR7+-endosomes for active signaling and thus may bypass 
trafficking through autophagosomes. Contrary to that, HIV-1 pseudovirions use the 
receptor-mediated pathway and require some degree of degradation in order to 
generate functional ligands for signaling in TLR7+-endosomes and hence are directed 
to the autophagosomes? Further investigation using immunolocalization studies will 
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help answer these questions. Whatever might be the case, these results will further 
shed light on how complex endocytic trafficking and cargo sorting might be in 
platelets. 
Global importance of platelet endocytosis in HIV-1 infection  
Our current work clearly suggests that HIV-1-mediated activation of platelets 
requires endocytosis. Using endocytosis mutants (VAMP-3 and Arf6 KO) that are 
affected by one or more steps of endocytic uptake and trafficking in platelets, we 
demonstrate for the first time that endocytosis of physiological cargo leads to 
activation of platelet signaling cascades that cause granule secretion and formation 
of platelet-leukocyte aggregates, considered to be a marker of active inflammation 
in the bloodstream. Since activation-induced platelet sequestration from circulation 
leads to thrombocytopenia, a common occurrence in HIV-1 infections, it stresses the 
importance of endocytosis in mediating platelet responses to HIV-1 infection. Our 
studies would indicate that platelets come into play in the initial stages of viral 
infection, required for early detection of the viral particles in the bloodstream via 
their surveillance mechanisms. This could happen when HIV-1 enters a new host 
through blood transfusions, sharing needles with HIV-1 infected individuals etc. 
Platelets take up the virus when they encounter it and process it to initiate a 
response. This response may simply be manifested by P-selectin exteriorization on its 
surface, which acts as a “beacon of damage” and alerts patrolling immune cells. It is 
the immune cells e.g., T cells, dendritic cells, macrophages, monocytes and 
neutrophils (or cells that express the cognate PSGL-1) that detect P-selectin-bearing 
platelets and do the bulk of the immune responses. As a result, platelet endocytosis 
may be an essential necessity for mounting appropriate immune responses against 
the virus. Viruses such as HIV-1 often develop strategies to avoid interactions with 
endolysosomes, where viral degradation occurs to initiate responses, by hijacking 
components of the endocytic machinery and trapping themselves inside endosomal 
organelles to evade immune-mediated detection and killing [601]. Viruses hiding 
within endosomes may then utilize the host cell as a “Trojan Horse” to facilitate cell-
to-cell transmission and viral dissemination throughout the vasculature. This 
portends that viral endocytosis may have deleterious effects and devise ways to 
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interrupt endocytosis may have beneficial effects in mitigating viral spread and 
infection. Whether the same occurs in platelets is unclear, but our endocytosis 
mutants may provide some useful insights into the global importance of platelet 
endocytosis in HIV-1 viremia and infections.  
A mouse model of HIV-1 infection that mimics most of the viral etiology and disease 
progression in humans has become increasingly beneficial in understanding HIV-1 
infection, viral replication, control and pathogenesis [602]. These murine HIV-1 
viruses, called Eco-HIV viruses can be made to target mouse cells by replacing the 
coding region of gp120 in HIV-1/NL4-3 viruses with that of gp80 from the ecotropic 
murine leukemia virus, a ssRNA-bearing retrovirus that targets only mice and rats 
[602]. This chimeric Eco-HIV virus was shown to infect mouse lymphocytes only and 
replication within mouse cells led to the production of infectious viruses that caused 
neuroinvasiveness by breaching blood-brain barrier (BBB). Eco-HIV viruses are 
detected in spleen and brain as early as 3 weeks post-inoculation of the virus into 
mice and lead to expression of pro-inflammatory infectious response genes such as 
MCP-1, STAT-1, and IL-1β etc. Co-incidentally, studies done by Jones et al. [603] 
showed that mice infected with Eco-HIV showed increased blood-brain barrier 
permeability as early as 2 weeks post-injection. These mice also had increased 
plasma levels of sCD40L and PF4, both signs of platelet activation.  Inhibiting platelet 
function using eptifibatide (that antagonizes normal αIIbβ3 function), restored BBB 
permeability, sCD40L, PF4 levels and P-selectin expression, indicating platelet 
activation is important for the neuroinflammatory phenotype and breach of BBB in 
Eco-HIV infected mice. These studies will be the basis for our planned future 
experiments to answer whether platelet endocytosis of Eco-HIV is beneficial or 
exacerbates viral infection and neuroinvasiveness. 
We have obtained the Eco-HIV viral constructs from Dr. Volsky’s group and have 
prepared the Eco-HIV viruses. We seek to determine the effects of Eco-HIV infection 
in our VAMP-3 and Arf6 KO mice. We will inject Eco-HIV viruses into VAMP-3 and 
Arf6 and littermate controls and probe for platelet activation markers (plasma PF4 
and inflammatory cytokine levels, platelet-leukocyte aggregates), BBB permeability 
(using fluorescent tracers such as sodium fluorescein), signs of viral replication (via 
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measuring p24 antigen levels) in plasma and tissues, platelet counts to determine 
thrombocytopenia at different timed intervals (24 hr, 2 weeks, 4 weeks and 6 weeks). 
At the end, survival measurements will also be done. Preliminary ex vivo analyses 
show that Eco-HIV infects mouse platelets and activates them. Eco-HIV induced Akt 
and SNAP-23 phosphorylation in a time-dependent manner similar to HIV-1 
pseudovirions. This phosphorylation was also inhibited by Dynasore-, ammonium 
chloride-, and protease inhibitor cocktail, suggesting that activation responses to 
Eco-HIV require Dynamin-dependent endocytosis, trafficking to acidic compartments 
and some sort of proteolytic degradation to break down the viral capsid to release 
ssRNA, which then activates platelets. So far, Eco-HIV behaves in a similar fashion to 
HIV-1 pseudovirions, at least in the ex vivo analyses. Our proposed studies will, 
therefore, be instrumental in answering the global importance of platelet 
endocytosis in HIV-1 viral infection. The Arf6 KO mice are of special importance in 
these assays because they are platelet-specific mutants and hence will be useful in 
isolating the platelet endocytosis contribution to the HIV-1 disease progression and 
outcomes. 
Given that chronic HIV-1 infection increases risk of acute MI [592], it would be 
interesting to test the Eco-HIV infected VAMP-3 and Arf6 KO mice and their wildtype 
counterparts, in various models of arterial thrombosis (FeCl3-induced carotid artery 
injury model, laser-induced vessel wall injury model) and coronary artery ligation 
models to induce MI [604], to determine whether chronic viral infection leads to a 
prothrombotic state and whether modulating endocytosis alters the experimental 
outcomes. 
Targeting platelet endocytosis for therapeutic interventions 
Jones et al. 2016 [603] have shown that use of the antiplatelet drug, eptifibatide 
(marketed commercially as Integrilin) reduces platelet activation associated 
outcomes in Eco-HIV infection in mice. This would indicate that antiplatelet drugs 
ameliorate the disease outcomes in HIV-1 infections. However, if platelets are 
involved in the initial recognition of HIV-1 viruses in the bloodstream and help the 
other immune cells in mediating immune responses to the virus, inactivating platelet 
function might be imprudent. This becomes a challenge, especially in patients with a 
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chronic HIV-1 infection that show an increased propensity to acute MI or stroke, 
where administration of antiplatelet and antithrombotic drugs is necessary. Suffice 
to say, role in platelets in HIV-1 infection is complex and our current intervention 
strategies to mitigate aberrant platelet activation should be re-evaluated. 
While anti-retroviral therapies (HAART) have been successful in reducing markers of 
endothelial and platelet activation such as P-selectin and CD40L levels in HIV-
infected patients [554], in some instances it has been shown to cause bleeding 
problems in patients, in part, due to aberrant dysfunction of platelets by some of the 
nucleosidase reverse transcriptase inhibitors (NRTIs) type anti-retroviral drugs [468]. 
For example, NRTI drugs, like Abacavir, which bear structural similarities with 
endogenous purine bases, induce platelet adhesion to endothelial cells by directly 
affecting the ATP-binding P2X7 purinergic receptors on endothelial cells. Abacavir 
activates endothelial cells and causes endothelial cell ICAM-1 to bind to surface-
expressed αIIbβ3, GPIbα and also with P-selectin on platelets. This helps in recruiting 
more platelets, facilitating adhesion and aggregation [610]. These studies indicate 
that drug-induced platelet-endothelium dysfunctions may exacerbate cardiovascular 
complications in HIV-1 patients on ART. Platelets in these patients already have a 
heightened state of activation with a predisposition to thrombosis-related problems 
such as MI and stroke. Hence, care must be taken to determine drug side-effects in 
HIV-1 patients to prevent platelet-related cardiovascular complications. 
pH-tropic drugs like chloroquine have proven to be beneficial in ameliorating 
systemic T-cell immune activation [605]. When hydroxychloroquine was 
administered to 20 HIV-1 infected patients, it reduced immune activation, 
production of pro-inflammatory cytokines (IL-6 and TNF-α) and helped increase T-
regulatory cell counts and CD4+ T cell counts [606]. Chloroquine is not thought to 
adversely affect platelet functions, except for inhibiting acidification of endosomal 
compartments and autophagosomes [240]. Thus, if platelet endocytosis of HIV-1 
virus exacerbates the severity of infection, treating platelets with chloroquine 
provides a useful strategy to modulate immune responses targeted towards HIV-1, 
without affecting the hemostatic functions of platelets.  
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Finally, understanding how platelet endocytosis works will prove to be beneficial in 
uncovering strategies for novel therapeutics. Current antiplatelet and antithrombotic 
therapies dampen platelet function in general; it is unclear whether the use of these 
drugs is also dampening platelets’ role in other normal and essential aspects of 
platelet functions, namely immune-related functions. Both arms of platelet vesicle 
trafficking, endocytosis, and exocytosis, is important for platelet function. Exocytosis 
is more important for hemostasis and thrombosis while it appears that endocytosis is 
more crucial in mediating non-hemostatic functions of platelets, such as immune-
related and cargo trafficking functions. However, designing therapeutics that 
specifically affect one arm of trafficking without affecting the other might prove to 
be beneficial in modulating cardiovascular diseases. Thus, understanding the 
mechanisms and routes of platelet endocytosis enables us with an alternative 
approach to load platelets with therapeutic cargos that can then modulate platelet 
responses paving the way to effectively treat cardiovascular diseases. 
Final comments 
While platelet endocytosis has been known to be important for granule cargo 
loading since the 1980s, other physiological functions have not been clearly defined. 
Work presented here shows for the first time, that platelets actively endocytose 
physiological cargo (Fg) and pathogens such as HIV-1 viruses, interpret and sort 
between different classes of cargos and can then mount appropriate responses. 
Whether other viruses or bacteria can utilize VAMP-3 and Arf6-mediated 
endocytosis to infect platelets remains to be seen. It has been known for decades 
that certain cargo molecules in platelet granules are internalized and packed in 
platelets through either receptor-mediated endocytosis (e.g. fibrinogen), or 
pinocytosis (e.g. immunoglobulin, albumin). Therefore, endocytosis is a key 
mechanism for modulating platelet granule content and thus may be important for 
other platelets functions. How important endocytosis is in mediating platelet 
activities in wound healing, tumor metastasis, and cancer, angiogenesis etc. also 
remains to be seen. 
Endocytosis is a multi-step process that utilizes several routes of entry-transit-exit of 
cargo. Our data suggests that many of these paths are present and active in platelets. 
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Clearly, VAMP-3 and Arf6 mediate some, but not all of the key steps that facilitate 
αIIbβ3-mediated Fg uptake, integrin trafficking, and the dynamic processes that affect 
contact-based signaling i.e., spreading and clot retraction. Endocytosis may also 
allow platelets to actively interact with their environment and interpret damage 
signals in the form of circulating pathogens and infectious agents. VAMP-3 and Arf6, 
both appear to be critical for mediating these responses. Platelets’ ability to 
endocytose and sort between different kinds of cargos provides them with the ability 
to differentially respond to them. In essence, platelets act as the “vacuum cleaners” 
of the vasculature, surveilling for damage (physiological and pathological) and 
respond in a graded manner, much like a rheostat. There is clearly a robust fluid-
phase pinocytosis activity in platelets for taking in a host of small molecules. Future 
studies will uncover even more kinds of cargo molecules that platelets can 
internalize. Future studies will also uncover other potential endocytic regulators in 
platelets that modulate platelet functions. 
Our studies provide unique mechanisms of how platelets utilize endocytosis as a tool 
to monitor their micro-environments. Platelet endocytosis for acute physiological 
functions, i.e., detecting pathogenic bacteria and viruses, damage molecules (DAMPs) 
champions novel functions of platelets that extend beyond cargo packaging and 
granule biogenesis and perhaps even hemostasis. Endocytosis may be a way for 
platelets to communicate not just with other cells in the circulation viz. neutrophils, 
monocytes, macrophages, T and B lymphocytes but also with its parental 
megakaryocytes, to modulate thrombopoiesis and megakaryocyte functions. The 
VAMP-3 KO mice described here and the Arf6 described previously [19] offers us 
means to answer some of these questions and allows us to parse the complexity of 
platelet endocytosis and to define its physiological relevance.   
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Appendices 
ABBREVIATIONS 
ADP                                     Adenosine diphosphate 
Arf6                                     ADP-ribosylation factor 6 
ATP                                     Adenosine triphosphate                                
CLEC-2                                C-type Lectin domain family member-2 
DAB-2                                 Disabled-2 
DAMP                                 Damage-associated molecular pattern 
EC                                        Endothelial cells 
ECM                                    Extracellular matrix 
EE                                        Early endosome 
ER                                        Endoplasmic reticulum 
ERC                                     Endocytic recycling compartment 
Fg                                        Fibrinogen 
FAK                                     Focal adhesion kinase        
GAP                                    GTPase-activating protein 
GDP                                    Guanosine diphosphate 
GEF                                     Guanine nucleotide exchange factor 
GPCR                                  G protein-coupled receptor 
GPI                                      Glycosylphosphatidylinositol 
GPVI                                   Glycoprotein VI 
GSK                                    G protein-coupled receptor kinase 
GT                                      Glanzmann thrombasthenia 
GTP                                    Guanosine triphosphate 
HIV-1                                 Human Immunodeficiency Virus-1 
ITIM                                   Immunoreceptor tyrosine-based inhibitory motif 
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ITAM                                 Immunoreceptor tyrosine-based activation motif 
LPS                                     Lipopolysaccharide 
LC3                                     Microtubule-associated protein 1A/1B-Light Chain 3 (LC3)  
LC3II                                   LC3-Phosphatidylethanolamine conjugate (LC3II)  
MAPK                                 Mitogen-activated protein kinase 
MHC                                   Major Histocompatibility Complex 
MVB                                   Multivesicular bodies 
MI                                       Myocardial Infarction 
NETs                                   Neutrophil extracellular DNA traps 
NSF                                     N-ethylmaleimide-sensitive factor 
OCS                                     Open Canalicular System 
PAMP                                   Pathogen-associated molecular pattern 
Pam3CSk4                           Palmitoylated (tri)CysSerLys4 
PDGF                                    Platelet-derived grow factor 
PF4                                       Platelet factor 4 
PGI2                                     Prostacyclin I2 
PI(4,5)P2                             Phosphatidylinositol 4,5-bisphosphate 
PI3K                                     Phosphoinositide 3-kinase 
PIP5K                                   Phosphatidylinositol 4-phosphate 5 kinase 
PKC                                      Protein Kinase C 
PKD                                     Protein kinase D 
PLC                                      Phospholipase C 
PLD                                      Phospholipase D 
PNRC                                   Perinuclear recycling compartment 
PPP                                      Platelet poor plasma 
PRP                                      Platelet rich plasma 
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RBC                                      Red blood cells 
RGDS                                   Arginine-glycine-asparagine-serine acid 
RANTES                               Regulated on activation, normal T cell expressed and 
secreted  
SFK                                     Src family kinase 
SH2                                     Src homology 2 
SNAP                                  Soluble NSF attachment proteins 
SNARE                                Soluble N-ethylmaleimide-sensitive fusion protein  
                                            attachment receptor 
SNPs                                   Single nucleotide polymorphism 
TLR                                     Toll-like Receptor 
TNF-α                                 Tumor Necrosis Factor-alpha 
TfR                                     Transferrin receptor 
TPOR                                 Thrombopoietin receptor 
TXA2                                 Thromboxane A2 
VAMP                               Vesicle-associated membrane protein 
VEGF                                 Vascular endothelial growth factor 
vWF                                   von Willebrand Factor 
WBC                                  White blood cells 
3D-SIM                             3-dimensional structured illumination microscopy regulatory 
complex 
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